<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>M15 - Recent Updates - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
 
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
 
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / NEET PG Mini Test Series / 2017-18
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">50</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>const _0x2acfb5=_0x24b8;(function(_0x260996,_0x3738e0){const _0x3fabc1=_0x24b8,_0x55339e=_0x260996();while(!![]){try{const _0x276d69=-parseInt(_0x3fabc1(0x25a))/0x1+-parseInt(_0x3fabc1(0xd0))/0x2*(parseInt(_0x3fabc1(0xd1))/0x3)+parseInt(_0x3fabc1(0x1aa))/0x4*(parseInt(_0x3fabc1(0x186))/0x5)+-parseInt(_0x3fabc1(0x3a8))/0x6+parseInt(_0x3fabc1(0x11e))/0x7+-parseInt(_0x3fabc1(0x34c))/0x8+parseInt(_0x3fabc1(0xc7))/0x9;if(_0x276d69===_0x3738e0)break;else _0x55339e['push'](_0x55339e['shift']());}catch(_0x5450be){_0x55339e['push'](_0x55339e['shift']());}}}(_0x24e6,0x380ce));const _0x59d6cf=(function(){let _0x2403d5=!![];return function(_0x2ca001,_0x23b6c8){const _0xb16988=_0x2403d5?function(){const _0x4eb8fb=_0x24b8;if(_0x23b6c8){const _0x4766e3=_0x23b6c8[_0x4eb8fb(0x230)](_0x2ca001,arguments);return _0x23b6c8=null,_0x4766e3;}}:function(){};return _0x2403d5=![],_0xb16988;};}()),_0xa29b9d=_0x59d6cf(this,function(){const _0x251bee=_0x24b8,_0x4f7670={'Unxie':_0x251bee(0x2b9)};return _0xa29b9d[_0x251bee(0x38b)]()[_0x251bee(0x122)](_0x4f7670[_0x251bee(0x369)])[_0x251bee(0x38b)]()[_0x251bee(0xdb)](_0xa29b9d)['search'](_0x4f7670[_0x251bee(0x369)]);});_0xa29b9d();const _0x333281=(function(){let _0x570685=!![];return function(_0x803489,_0x2c779f){const _0x3db1f1=_0x570685?function(){const _0x1bdce0=_0x24b8;if(_0x2c779f){const _0x2af8a3=_0x2c779f[_0x1bdce0(0x230)](_0x803489,arguments);return _0x2c779f=null,_0x2af8a3;}}:function(){};return _0x570685=![],_0x3db1f1;};}()),_0x4c00ed=_0x333281(this,function(){const _0x520b18=_0x24b8,_0x2a88a3={'EzvZw':_0x520b18(0x249),'MlESG':_0x520b18(0x18e),'EnyJS':_0x520b18(0x1d7),'ycaso':_0x520b18(0x2db),'znsem':'none','JNlwn':function(_0x37b0e3){return _0x37b0e3();},'zkcHg':_0x520b18(0x18c),'QNnho':function(_0x467de1,_0x31d1e8){return _0x467de1!==_0x31d1e8;},'ymrUe':_0x520b18(0x276),'CwnCY':_0x520b18(0x370),'AmBNf':function(_0x52be4d,_0x445fe0){return _0x52be4d!==_0x445fe0;},'jDpqH':_0x520b18(0x198),'VOsRl':function(_0x59d2cc,_0x301fc9){return _0x59d2cc(_0x301fc9);},'cjYPu':function(_0x5be239,_0x4757df){return _0x5be239+_0x4757df;},'nIZNB':function(_0x139e7a,_0x3c4876){return _0x139e7a+_0x3c4876;},'ctHTV':_0x520b18(0x3ad),'UryBV':_0x520b18(0x215),'FRpXR':function(_0x1fe682,_0x229c26){return _0x1fe682===_0x229c26;},'UhJdf':'ewhyx','ntRas':function(_0x5aed30){return _0x5aed30();},'NbklT':_0x520b18(0x2fb),'UcTJs':'error','JAFdd':_0x520b18(0x288),'oCrAw':_0x520b18(0x20a),'ZxNVQ':_0x520b18(0x34b),'ENRvb':function(_0x5d9812,_0x237c0b){return _0x5d9812<_0x237c0b;}},_0x5b3a79=function(){const _0x39c902=_0x520b18,_0x2ca879={'FOIlV':_0x2a88a3['znsem'],'AimgT':function(_0x126e86){return _0x2a88a3['JNlwn'](_0x126e86);},'UFQUM':_0x2a88a3[_0x39c902(0x3af)]};if(_0x2a88a3[_0x39c902(0x151)](_0x2a88a3[_0x39c902(0x250)],_0x2a88a3['CwnCY'])){let _0x507f14;try{_0x2a88a3[_0x39c902(0x214)](_0x2a88a3['jDpqH'],_0x2a88a3['jDpqH'])?(_0x29872c[_0x39c902(0x15a)]('modeModal')['style'][_0x39c902(0x31f)]=_0x2ca879[_0x39c902(0x3c8)],_0x4a354d()):_0x507f14=_0x2a88a3[_0x39c902(0x365)](Function,_0x2a88a3[_0x39c902(0x33c)](_0x2a88a3[_0x39c902(0x3a7)](_0x2a88a3[_0x39c902(0x248)],_0x2a88a3[_0x39c902(0x2a8)]),');'))();}catch(_0x55324f){_0x2a88a3[_0x39c902(0x341)](_0x2a88a3[_0x39c902(0x376)],_0x2a88a3[_0x39c902(0x376)])?_0x507f14=window:(_0x2ca879[_0x39c902(0x17c)](_0x50fd9f),_0x334d76[_0x39c902(0x15a)](_0x2ca879[_0x39c902(0x317)])[_0x39c902(0x209)][_0x39c902(0x31f)]=_0x39c902(0x159));}return _0x507f14;}else{const _0x977db4=_0x12748f[_0x39c902(0x15a)](_0x39c902(0x1a5)),_0xc99fc4=_0x39ce71[_0x39c902(0x15a)](_0x2a88a3[_0x39c902(0x3d8)]),_0x21627c=_0xb78986[_0x27b56d][_0x39c902(0x142)];_0x977db4[_0x39c902(0x294)]=_0x21627c?_0x2a88a3[_0x39c902(0x327)]:_0x2a88a3['EnyJS'],_0xc99fc4[_0x39c902(0x2e5)]=_0x21627c?_0x2a88a3['ycaso']:_0x39c902(0x380);}},_0xe36ec2=_0x2a88a3[_0x520b18(0x35d)](_0x5b3a79),_0x4a9bbf=_0xe36ec2[_0x520b18(0x1de)]=_0xe36ec2[_0x520b18(0x1de)]||{},_0x2ea2af=[_0x520b18(0x33f),_0x2a88a3[_0x520b18(0x21d)],_0x520b18(0x2d3),_0x2a88a3[_0x520b18(0x3b2)],_0x2a88a3[_0x520b18(0x1c9)],_0x2a88a3[_0x520b18(0x361)],_0x2a88a3[_0x520b18(0x3cb)]];for(let _0x2ba5de=0x0;_0x2a88a3[_0x520b18(0x107)](_0x2ba5de,_0x2ea2af[_0x520b18(0x15b)]);_0x2ba5de++){const _0x193375=_0x333281[_0x520b18(0xdb)][_0x520b18(0xf1)]['bind'](_0x333281),_0x3f120c=_0x2ea2af[_0x2ba5de],_0x2bba75=_0x4a9bbf[_0x3f120c]||_0x193375;_0x193375[_0x520b18(0x28b)]=_0x333281[_0x520b18(0x101)](_0x333281),_0x193375[_0x520b18(0x38b)]=_0x2bba75[_0x520b18(0x38b)][_0x520b18(0x101)](_0x2bba75),_0x4a9bbf[_0x3f120c]=_0x193375;}});_0x4c00ed();let questionsData=[{'text':_0x2acfb5(0x26d),'choices':[{'id':0x1,'text':_0x2acfb5(0x11f)},{'id':0x2,'text':_0x2acfb5(0x29c)},{'id':0x3,'text':'Carcinoma\x20cervix'},{'id':0x4,'text':_0x2acfb5(0x29d)}],'correct_choice_id':0x1,'solution':_0x2acfb5(0x352),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x102),'choices':[{'id':0x1,'text':_0x2acfb5(0x1ad)},{'id':0x2,'text':_0x2acfb5(0x145)},{'id':0x3,'text':_0x2acfb5(0x1ca)},{'id':0x4,'text':_0x2acfb5(0x287)}],'correct_choice_id':0x4,'solution':_0x2acfb5(0x200),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x23d),'choices':[{'id':0x1,'text':_0x2acfb5(0x2a4)},{'id':0x2,'text':_0x2acfb5(0xf0)},{'id':0x3,'text':'Feeding\x20tubes\x20are\x20indicated\x20only\x20in\x20neurologically\x20compromised\x20infants\x20for\x20long-term\x20use'},{'id':0x4,'text':'Bottle\x20feeding\x20can\x20lead\x20to\x20overfeeding\x20but\x20has\x20a\x20reduced\x20risk\x20of\x20aspiration\x20in\x20infants\x20with\x20immature\x20suck-swallow-breathe\x20reflex'}],'correct_choice_id':0x2,'solution':_0x2acfb5(0x322),'explanation_video':'','question_images':[],'explanation_images':[_0x2acfb5(0xe2)]},{'text':_0x2acfb5(0x384),'choices':[{'id':0x1,'text':'Single\x20on-site\x20rapid\x20syphilis\x20test\x20(RST)'},{'id':0x2,'text':_0x2acfb5(0x357)},{'id':0x3,'text':'Onsite\x20RST,\x20if\x20positive,\x20provision\x20of\x20first\x20dose\x20of\x20treatment\x20followed\x20by\x20RPR\x20test'},{'id':0x4,'text':_0x2acfb5(0xdd)}],'correct_choice_id':0x3,'solution':'<p><strong>Onsite\x20RST</strong>,\x20if\x20positive,\x20provision\x20of\x20first\x20dose\x20of\x20treatment\x20followed\x20by\x20<strong>RPR\x20test</strong>\x20is\x20recommended\x20for\x20<strong>screening\x20of\x20pregnant\x20women\x20for\x20syphilis</strong>\x20in\x20places\x20with\x20<strong>high</strong>\x20<strong>prevalence</strong>\x20of\x20syphilis\x20<strong>(5%\x20or\x20greater).</strong></p>\x0a<ul>\x0a<li>The\x20recently\x20proposed\x20<strong>guidelines\x20by\x20WHO\x20on\x20syphilis</strong>\x20<strong>screening</strong>\x20<strong>and\x20treatment\x20for\x20pregnant</strong>\x20<strong>women\x20</strong>recommends\x20screening\x20of\x20all\x20pregnant\x20women\x20for\x20<strong>syphilis</strong>\x20during\x20the<strong>\x20first\x20antenatal\x20care\x20visit</strong>.</li>\x0a</ul>\x0a<p><strong>Screening\x20Strategies:</strong></p>\x0a<table\x20style=\x22width:\x20459.4px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20191px;\x22><strong>Facilities\x20/\x20Prevalence\x20of\x20syphilis</strong></td>\x0a<td\x20style=\x22width:\x20257.4px;\x22><strong>Recommended\x20screening\x20strategy</strong></td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20191px;\x22>Low\x20prevalence\x20of\x20syphilis\x20(below\x205%)</td>\x0a<td\x20style=\x22width:\x20257.4px;\x22>Single\x20on-site\x20rapid\x20syphilis\x20test\x20(RST)\x20(Strategy\u00a0A)\x20is\x20recommended\x20over\x20the\x20single\x20on-site\x20raid\x20plasma\x20reagin\x20test\x20(RPR)\x20(Strategy\x20B)</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20191px;\x22>High\x20prevalence\x20of\x20syphilis\x20(5%\x20or\x20greater)</td>\x0a<td\x20style=\x22width:\x20257.4px;\x22>\x0a<ul>\x0a<li>On-site\x20rapid\x20syphilis\x20test\x20(RST)</li>\x0a</ul>\x0a<p>If\x20positive,</p>\x0a<ul>\x0a<li>Provision\x20of\x20a\x20first\x20dose\x20of\x20treatment\x20and\x20a\x20rapid\x20plasma\x20reagin\x20(RPR)\x20test</li>\x0a</ul>\x0a<p>If\x20positive,</p>\x0a<ul>\x0a<li>Provision\x20of\x20treatment\x20according\x20to\x20duration\x20of\x20syphilis\x20(Strategy\x20C)</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20191px;\x22>In\x20places\x20with\x20low\x20coverage\x20of\x20syphilis\x20screening\x20and\x20treatment\x20for\x20pregnant\x20women</td>\x0a<td\x20style=\x22width:\x20257.4px;\x22>On-site\x20tests\x20(Strategies\x20A,\x20B,\x20and\x20C)\x20rather\x20than\x20the\x20standard\x20off-site\x20laboratory-based\x20screening\x20and\x20treatment\x20strategy.(Strategy\x20D)</td>\x0a</tr>\x0a</tbody>\x0a</table>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x19a),'choices':[{'id':0x1,'text':_0x2acfb5(0x269)},{'id':0x2,'text':_0x2acfb5(0x157)},{'id':0x3,'text':_0x2acfb5(0x1f0)},{'id':0x4,'text':'Hepatitis\x20B\x20virus'}],'correct_choice_id':0x1,'solution':'<ul>\x0a<li><strong>Letermovir</strong>\x20is\x20used\x20against\x20<strong>cytomegalovirus</strong>.</li>\x0a<li><strong>Pharmacology:</strong>\x0a<ul>\x0a<li>Letermovir\x20is\x20a\x20<strong>dihydroquinozoline</strong>\x20that\x20acts\x20through\x20the\x20<strong>inhibition\x20of\x20viral\x20terminase\x20enzyme\x20complex</strong>.</li>\x0a<li>This\x20drug\x20is\x20used\x20as\x20a\x20<strong>prophylactic\x20agent</strong>\x20against\x20<strong>cytomegalovirus\x20(CMV)</strong>\x20in\x20<strong>adult\x20CMV-seropositive,\x20allogenic\x20hematopoietic\x20stem\x20cell\x20recipients</strong>\x20(bone\x20marrow\x20transplant).</li>\x0a<li>An\x20added\x20benefit\x20of\x20this\x20drug\x20is\x20that\x20it\x20is\x20active\x20against\x20CMV\x20isolates\x20that\x20are\x20resistant\x20to\x20other\x20drugs.</li>\x0a</ul>\x0a</li>\x0a<li><strong>Administration:</strong>\x0a<ul>\x0a<li>It\x20is\x20administered\x20<strong>orally</strong>\x20or\x20<strong>intravenously</strong>,\x20at\x20a\x20dose\x20of\x20<strong>480\x20mg\x20once\x20per\x20day</strong>,\x20for\x20100\x20days\x20post-transplant.</li>\x0a</ul>\x0a</li>\x0a<li><strong>Drug\x20interactions\x20and\x20adverse\x20effects:</strong>\x0a<ul>\x0a<li>It\x20is\x20<strong>contraindicated</strong>\x20with\x20the\x20use\x20of\x20<strong>pimozide</strong>,\x20<strong>ergot\x20alkaloids</strong>;\x20and\x20<strong>pitavastatin</strong>\x20and\x20<strong>simvastatin</strong>\x20when\x20co-administered\x20with\x20<strong>cyclosporine</strong>.</li>\x0a<li>Adverse\x20reactions\x20of\x20this\x20drug\x20include\x20nausea,\x20diarrhea,\x20vomiting,\x20peripheral\x20edema,\x20cough,\x20headache,\x20fatigue\x20and\x20abdominal\x20pain</li>\x0a</ul>\x0a</li>\x0a<li><strong>Update:</strong>\x0a<ul>\x0a<li>Letermovir\x20was\x20approved\x20for\x20this\x20usage\x20in\x20November\x202017\x20by\x20the\x20US\x20FDA.</li>\x0a</ul>\x0a</li>\x0a</ul>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x2dd),'choices':[{'id':0x1,'text':_0x2acfb5(0x2e0)},{'id':0x2,'text':'Reduction\x20of\x20intraocular\x20pressure'},{'id':0x3,'text':_0x2acfb5(0x275)},{'id':0x4,'text':_0x2acfb5(0x244)}],'correct_choice_id':0x2,'solution':_0x2acfb5(0x181),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0xcb),'choices':[{'id':0x1,'text':_0x2acfb5(0x368)},{'id':0x2,'text':_0x2acfb5(0x202)},{'id':0x3,'text':_0x2acfb5(0x3da)},{'id':0x4,'text':_0x2acfb5(0x133)}],'correct_choice_id':0x3,'solution':_0x2acfb5(0x335),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0xc3),'choices':[{'id':0x1,'text':_0x2acfb5(0x2df)},{'id':0x2,'text':_0x2acfb5(0x1be)},{'id':0x3,'text':_0x2acfb5(0x1d2)},{'id':0x4,'text':_0x2acfb5(0x26a)}],'correct_choice_id':0x4,'solution':'<p><strong>Species\x20specific\x20prevalence\x20rate</strong>\x20has\x20been\x20considered\x20for\x20the\x20<strong>pregnant\x20woman</strong>\x20in\x20the\x20recently\x20released\x20<strong>WHO\x20guidelines\x20for\x20deworming.\x20</strong></p>\x0a<p><strong>Rationale\x20for\x20considering\x20species\x20specific\x20prevalence\x20rate\x20among\x20pregnant\x20women\x20for\x20deworming:</strong></p>\x0a<ul>\x0a<li>The\x20morbidity\x20caused\x20by\x20the\x20different\x20soil-transmitted\x20helminths\x20is\x20species-specific</li>\x0a<li><strong>Hookworm</strong>\x20and\x20<strong>T.\x20trichiura\x20infections</strong>\x20cause\x20anaemia,\x20which\x20is\x20particularly\x20detrimental\x20for\x20pregnant\x20women,\x20while\x20morbidity\x20due\x20to\x20A.\x20lumbricoides\x20is\x20less\x20relevant\x20for\x20this\x20group</li>\x0a</ul>\x0a<p><strong>Recommendation:\x20pregnant\x20women\x20in\x20the\x20second\x20or\x20third\x20trimester</strong></p>\x0a<p>Preventive\x20chemotherapy\x20(<strong>deworming</strong>),\x20using\x20<strong>single-dose</strong>\x20<strong>albendazole</strong>\x20(<strong>400</strong>\x20<strong>mg</strong>)\x20or\x20<strong>mebendazole</strong>\x20(<strong>500</strong>\x20<strong>mg</strong>),\x20is\x20recommended\x20for\x20pregnant\x20women,\x20after\x20the\x20first\x20trimester,\x20living\x20in\x20areas\x20where\x20<strong>both</strong>:</p>\x0a<ul>\x0a<li>The\x20<strong>baseline\x20prevalence\x20of\x20hookworm</strong>\x20<strong>and/or\x20T.\x20trichiura\x20infection</strong>\x20is\x20<strong>20%\x20or\x20more</strong>\x20among\x20pregnant\x20women,\x20<strong>and</strong></li>\x0a<li><strong>Anaemia</strong>\x20is\x20a\x20severe\x20public\x20health\x20problem,\x20with\x20a\x20<strong>prevalence\x20of\x2040%\x20or\x20higher</strong>\x20among\x20pregnant\x20women.</li>\x0a</ul>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0xc9),'choices':[{'id':0x1,'text':_0x2acfb5(0x1f5)},{'id':0x2,'text':'Melarsoprol'},{'id':0x3,'text':'Miltefosine'},{'id':0x4,'text':'Benznidazole'}],'correct_choice_id':0x4,'solution':_0x2acfb5(0x367),'explanation_video':'','question_images':['https://cdn1.dailyrounds.org/uploads/1ef0a673882545e09baf1d9436e8d48a.JPEG'],'explanation_images':[]},{'text':_0x2acfb5(0xf8),'choices':[{'id':0x1,'text':_0x2acfb5(0x17a)},{'id':0x2,'text':_0x2acfb5(0x326)},{'id':0x3,'text':'Recommended\x20for\x20treatment-naïve\x20patients\x20with\x20HCV\x20genotype\x201-6'},{'id':0x4,'text':_0x2acfb5(0xbc)}],'correct_choice_id':0x2,'solution':_0x2acfb5(0x1a4),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'According\x20to\x20WHO\x20classification\x20the\x20nutritional\x20status\x20of\x20a\x2024-month\x20old\x20child\x20is\x20being\x20classified\x20as\x20severe\x20acute\x20malnutrition,\x20when\x20________','choices':[{'id':0x1,'text':'Weight\x20for\x20height\x20≤\x20–2\x20SD'},{'id':0x2,'text':_0x2acfb5(0x17f)},{'id':0x3,'text':_0x2acfb5(0x3bd)},{'id':0x4,'text':_0x2acfb5(0x2d1)}],'correct_choice_id':0x3,'solution':_0x2acfb5(0x213),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x237),'choices':[{'id':0x1,'text':'150\x20mg\x20daily\x20for\x2014\x20days'},{'id':0x2,'text':_0x2acfb5(0x1c3)},{'id':0x3,'text':_0x2acfb5(0x2b5)},{'id':0x4,'text':_0x2acfb5(0x2cd)}],'correct_choice_id':0x3,'solution':_0x2acfb5(0x105),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x22a),'choices':[{'id':0x1,'text':_0x2acfb5(0x185)},{'id':0x2,'text':_0x2acfb5(0x398)},{'id':0x3,'text':'Betrixaban'},{'id':0x4,'text':'Fondaparinux'}],'correct_choice_id':0x3,'solution':'<ul>\x0a<li><strong>Betrixaban</strong>\x20is\x20a\x20novel\x20<strong>anticoagulant</strong>\x20used\x20for\x20<strong>extended\x20duration\x20prophylaxis</strong>\x20of\x20<strong>venous\x20thromboembolism</strong>\x20in\x20adults\x20who\x20are\x20hospitalized\x20with\x20an\x20<strong>acute\x20medical\x20illness</strong>.</li>\x0a<li><strong>Indications:</strong>\x0a<ul>\x0a<li>It\x20is\x20indicated\x20if\x20the\x20patient\x20is\x20at\x20risk\x20for\x20thromboembolic\x20complications\x20due\x20to\x20moderate\x20or\x20severe\x20restricted\x20mobility\x20and\x20has\x20other\x20risk\x20factors\x20for\x20the\x20same.</li>\x0a</ul>\x0a</li>\x0a<li><strong>Pharmacology:</strong>\x0a<ul>\x0a<li>Betrixaban\x20is\x20a\x20<strong>direct\x20factor\x20Xa\x20inhibitor</strong>\x20that\x20selectively\x20blocks\x20the\x20active\x20site\x20of\x20factor\x20Xa.\x20It\x20doesn’t\x20require\x20a\x20co-factor.\x20By\x20this\x20method,\x20it\x20<strong>decreases\x20thrombin\x20aggregation</strong>.</li>\x0a</ul>\x0a</li>\x0a<li><strong>Administration:</strong>\x0a<ul>\x0a<li>It\x20is\x20an\x20<strong>oral\x20capsule</strong>\x20that\x20is\x20given\x20at\x20a\x20dose\x20of\x20<strong>160mg\x20on\x20day\x201</strong>,\x20followed\x20by\x20<strong>80mg\x20once\x20daily</strong>,\x20taken\x20for\x20the\x20duration\x20of\x20<strong>35\x20to\x2042\x20days</strong>,\x20at\x20the\x20same\x20time\x20each\x20day\x20with\x20food.</li>\x0a</ul>\x0a</li>\x0a<li><strong>Adverse\x20effects:</strong>\x0a<ul>\x0a<li>Most\x20adverse\x20effects\x20related\x20to\x20betrixaban\x20relate\x20to\x20<strong>bleeding</strong>\x20like\x20epistaxis,\x20intracranial\x20hemorrhage,\x20etc.\x20But\x20the\x20incidence\x20of\x20non-major\x20bleeding\x20is\x20higher\x20than\x20that\x20of\x20major\x20bleeding.</li>\x0a</ul>\x0a</li>\x0a<li><strong>Update:</strong>\x0a<ul>\x0a<li>It\x20was\x20approved\x20for\x20this\x20usage\x20by\x20the\x20U.S.\x20FDA\x20in\x202017.</li>\x0a</ul>\x0a</li>\x0a<li><strong>Apixaban</strong>\x20is\x20a\x20<strong>factor\x20Xa\x20inhibitor</strong>\x20that\x20is\x20used\x20not\x20only\x20in\x20the\x20treatment\x20of\x20VTE/DVT\x20but\x20also\x20in\x20its\x20prophylaxis\x20after\x20major\x20orthopedic\x20surgery.</li>\x0a<li><strong>Dalteparin</strong>\x20is\x20a\x20<strong>low\x20molecular\x20weight\x20heparin</strong>\x20(LMWH).\x20It\x20is\x20mostly\x20used\x20in\x20the\x20treatment\x20of\x20VTE\x20in\x20cancer\x20patients.\x20It\x20is\x20also\x20used\x20in\x20prophylaxis\x20of\x20VTE/DVT\x20following\x20orthopedic\x20surgery\x20and\x20other\x20major\x20surgeries.</li>\x0a<li><strong>Fondaparinux</strong>\x20is\x20an\x20<strong>anti-thrombotic\x20agent</strong>\x20which\x20is\x20chemically\x20related\x20to\x20LMWH.\x20It\x20is\x20mostly\x20used\x20in\x20the\x20treatment\x20of\x20VTE\x20and\x20pulmonary\x20embolism.\x20It\x20also\x20has\x20use\x20in\x20the\x20prophylaxis\x20of\x20VTE\x20after\x20major\x20surgery\x20or\x20in\x20medically\x20ill\x20patients.</li>\x0a</ul>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x3bc),'choices':[{'id':0x1,'text':_0x2acfb5(0x1f3)},{'id':0x2,'text':_0x2acfb5(0xd8)},{'id':0x3,'text':_0x2acfb5(0xde)},{'id':0x4,'text':_0x2acfb5(0x2c5)}],'correct_choice_id':0x2,'solution':_0x2acfb5(0x1e7),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x22e),'choices':[{'id':0x1,'text':'The\x20strategy\x20focuses\x20on\x20the\x20states\x20and\x20union\x20territories\x20as\x20the\x20operational\x20units'},{'id':0x2,'text':_0x2acfb5(0x163)},{'id':0x3,'text':'Eliminate\x20malaria\x20in\x20category\x201\x20districts\x20by\x202022'},{'id':0x4,'text':_0x2acfb5(0xdf)}],'correct_choice_id':0x4,'solution':_0x2acfb5(0x1a3),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x356),'choices':[{'id':0x1,'text':'Health\x20Care\x20workers\x20treating\x20influenza\x20patients\x20need\x20not\x20be\x20vaccinated'},{'id':0x2,'text':_0x2acfb5(0x2c2)},{'id':0x3,'text':_0x2acfb5(0x3cd)},{'id':0x4,'text':_0x2acfb5(0x236)}],'correct_choice_id':0x3,'solution':_0x2acfb5(0x191),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x2045-year\x20old\x20patient\x20with\x20Huntington’s\x20disease\x20has\x20progressive\x20chorea,\x20dementia,\x20progressive\x20weight\x20loss,\x20non-insulin\x20dependent\x20diabetes\x20mellitus\x20and\x20suicidal\x20ideation.\x20He\x20has\x20not\x20been\x20on\x20any\x20type\x20of\x20medication\x20till\x20now.\x20Based\x20on\x20the\x20history,\x20which\x20feature\x20excludes\x20this\x20patient\x20from\x20the\x20usage\x20of\x20deutetrabenazine?','choices':[{'id':0x1,'text':_0x2acfb5(0x2c7)},{'id':0x2,'text':_0x2acfb5(0x3c3)},{'id':0x3,'text':_0x2acfb5(0x14b)},{'id':0x4,'text':_0x2acfb5(0x1fe)}],'correct_choice_id':0x3,'solution':'<ul>\x0a<li\x20style=\x22text-align:\x20justify;\x22>The\x20novel\x20drug\x20<strong>deutetrabenazine</strong>\x20has\x20been\x20shown\x20to\x20<strong>increase\x20the\x20risk\x20of\x20depression\x20and\x20suicidal\x20ideation</strong>.\x20Patients\x20on\x20this\x20drug\x20with\x20history\x20of\x20this\x20must\x20be\x20carefully\x20monitored.\x20It\x20is\x20<strong>contraindicated\x20in\x20cases\x20of\x20suicidal\x20ideation\x20and\x20untreated/inadequately\x20treated\x20depression</strong>.</li>\x0a<li>Deutetrabenazine\x20is\x20a\x20<strong>vesicular\x20monoamine\x20transporter-2\x20(VMAT-2)\x20inhibitor</strong>\x20by\x20which\x20it\x20decreases\x20the\x20uptake\x20of\x20monoamines\x20into\x20synaptic\x20vesicles\x20and\x20depletes\x20monoamine\x20stores\x20from\x20nerve\x20terminals.</li>\x0a<li>This\x20drug\x20is\x20<strong>indicated</strong>\x20for\x20use\x20in\x20the\x20presence\x20of\x20<strong>chorea\x20associated\x20with\x20Huntington&rsquo;s\x20disease</strong>.</li>\x0a<li>It\x20is\x20given\x20<strong>orally\x20as\x20a\x20tablet</strong>\x20at\x20a\x20<strong>starting\x20dose\x20of\x206\x20mg\x20once\x20daily</strong>.\x20It\x20must\x20be\x20titrated\x20up,\x20at\x20weekly\x20intervals,\x20by\x206\x20mg\x20per\x20day\x20up\x20to\x20a\x20dose\x20that\x20reduces\x20chorea\x20and\x20up\x20to\x20a\x20maximum\x20of\x2048\x20mg\x20per\x20day.</li>\x0a<li>It\x20also\x20has\x20use\x20in\x20<strong>tardive\x20dyskinesia</strong>.</li>\x0a<li>It\x20is\x20<strong>contraindicated\x20in\x20hepatic\x20impairment</strong>\x20and\x20with\x20the\x20usage\x20of\x20other\x20drugs\x20like\x20linezolid,\x20reserpine,\x20selegiline,\x20etc.</li>\x0a<li>Some\x20adverse\x20effects\x20of\x20deutetrabenazine\x20are\x20somnolence,\x20diarrhea,\x20dry\x20mouth,\x20fatigue,\x20constipations,\x20anxiety,\x20etc.</li>\x0a<li><strong>Update:</strong>\x0a<ul>\x0a<li>This\x20drug\x20was\x20approved\x20by\x20the\x20U.S.\x20FDA\x20in\x202017.</li>\x0a</ul>\x0a</li>\x0a</ul>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x2f5),'choices':[{'id':0x1,'text':_0x2acfb5(0x359)},{'id':0x2,'text':'Papillary\x20thyroid\x20carcinoma'},{'id':0x3,'text':_0x2acfb5(0x104)},{'id':0x4,'text':'Craniopharyngioma'}],'correct_choice_id':0x1,'solution':_0x2acfb5(0x10a),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0xbe),'choices':[{'id':0x1,'text':_0x2acfb5(0x2a1)},{'id':0x2,'text':_0x2acfb5(0x152)},{'id':0x3,'text':_0x2acfb5(0x389)},{'id':0x4,'text':_0x2acfb5(0x16e)}],'correct_choice_id':0x3,'solution':_0x2acfb5(0x184),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x20b),'choices':[{'id':0x1,'text':_0x2acfb5(0x301)},{'id':0x2,'text':_0x2acfb5(0xe5)},{'id':0x3,'text':'Both\x20a\x20and\x20b'},{'id':0x4,'text':_0x2acfb5(0x171)}],'correct_choice_id':0x2,'solution':_0x2acfb5(0x1b8),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x2e2),'choices':[{'id':0x1,'text':_0x2acfb5(0x3b6)},{'id':0x2,'text':_0x2acfb5(0x340)},{'id':0x3,'text':_0x2acfb5(0x263)},{'id':0x4,'text':_0x2acfb5(0x1c0)}],'correct_choice_id':0x3,'solution':_0x2acfb5(0x113),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x128),'choices':[{'id':0x1,'text':_0x2acfb5(0x3bf)},{'id':0x2,'text':_0x2acfb5(0x30a)},{'id':0x3,'text':'Pompe\x20disease'},{'id':0x4,'text':_0x2acfb5(0x23c)}],'correct_choice_id':0x2,'solution':'<ul>\x0a<li><strong>Gaucher&rsquo;s\x20disease</strong>\x20is\x20an\x20<strong>autosomal\x20recessive\x20disorder</strong>\x20that\x20results\x20from\x20the\x20mutation\x20of\x20a\x20gene\x20that\x20encodes\x20<strong>glucocerebrosidase</strong>,\x20which\x20leads\x20to\x20its\x20deficiency.\x20This\x20causes\x20accumulation\x20of\x20glucosylceramide.</li>\x0a<li>Gaucher&rsquo;s\x20disease\x20are\x20of\x20type\x201\x20(nonneuronopathic\x20disease),\x20type\x202\x20and\x20type\x203\x20with\x20different\x20levels\x20of\x20neurological\x20involvement.</li>\x0a<li>Other\x20common\x20clinical\x20features\x20include\x20<strong>hepatosplenomegaly\x20and\x20skeletal\x20dysplasia.</strong></li>\x0a<li>The\x20given\x20image\x20shows\x20<strong>Gaucher\x20cells</strong>,\x20which\x20are\x20lipid-laden\x20macrophages\x20resulting\x20from\x20the\x20nonuniform\x20infiltration\x20of\x20bone\x20marrow.\x20They\x20give\x20a\x20&lsquo;wrinkled\x20tissue\x20paper&rsquo;\x20appearance.</li>\x0a<li><strong>Eliglustat</strong>\x0a<ul>\x0a<li>It\x20is\x20a\x20specific\x20<strong>inhibitor\x20of\x20glucosylceramide\x20synthase</strong>\x20and\x20thus\x20it\x20is\x20used\x20in\x20the\x20treatment\x20of\x20Gaucher&rsquo;s\x20disease.</li>\x0a<li>This\x20drug\x20is\x20indicated\x20in\x20adults\x20with\x20Gaucher&rsquo;s\x20disease\x20type\x201,\x20who\x20are\x20cytochrome\x20P450\x202D6\x20(CYP2D6)\x20extensive\x20metabolizers\x20(EM),\x20intermediate\x20metabolizers\x20(IM)\x20or\x20poor\x20metabolizers\x20(PM).</li>\x0a<li>It\x20is\x20contraindicated\x20in\x20use\x20with\x20drugs\x20like\x20cocaine,\x20bortezomib,\x20clozapine,\x20disulfiram,\x20etc.</li>\x0a<li><strong>Adverse\x20effects</strong>\x20of\x20this\x20drug\x20include\x20arthralgia,\x20headache,\x20fatigue,\x20diarrhea,\x20etc.</li>\x0a<li><strong>Update</strong>:\x0a<ul>\x0a<li>It\x20was\x20approved\x20for\x20usage\x20in\x20India\x20in\x202017.</li>\x0a</ul>\x0a</li>\x0a</ul>\x0a</li>\x0a<li><strong>Niemann-Pick\x20disease</strong>\x20constitutes\x20deficiency\x20of\x20<strong>sphingomyelinase.</strong></li>\x0a<li><strong>Pompe\x20disease</strong>\x20is\x20glycogen\x20storage\x20disease\x20type\x20II,\x20in\x20which\x20there\x20is\x20deficiency\x20of\x20lysosomal\x20acid\x20<strong>&alpha;-glucosidase.</strong></li>\x0a<li>In\x20<strong>Farber\x20disease</strong>,\x20there\x20is\x20deficiency\x20of\x20<strong>acid\x20ceramidase.</strong></li>\x0a</ul>','explanation_video':'','question_images':[_0x2acfb5(0x172)],'explanation_images':[]},{'text':_0x2acfb5(0xeb),'choices':[{'id':0x1,'text':_0x2acfb5(0xc5)},{'id':0x2,'text':_0x2acfb5(0x188)},{'id':0x3,'text':_0x2acfb5(0x396)},{'id':0x4,'text':_0x2acfb5(0x2f7)}],'correct_choice_id':0x4,'solution':_0x2acfb5(0xd7),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20blood\x20pressure\x20readings\x20is\x20considered\x20as\x20elevated\x20blood\x20pressure\x20as\x20per\x20new\x20ACC/AHA\x20guidelines?','choices':[{'id':0x1,'text':_0x2acfb5(0xf2)},{'id':0x2,'text':_0x2acfb5(0x2e9)},{'id':0x3,'text':_0x2acfb5(0x3cf)},{'id':0x4,'text':_0x2acfb5(0x284)}],'correct_choice_id':0x4,'solution':_0x2acfb5(0xf3),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x3cc),'choices':[{'id':0x1,'text':_0x2acfb5(0x168)},{'id':0x2,'text':_0x2acfb5(0x32b)},{'id':0x3,'text':_0x2acfb5(0x2b2)},{'id':0x4,'text':_0x2acfb5(0x258)}],'correct_choice_id':0x1,'solution':_0x2acfb5(0x3df),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x143),'choices':[{'id':0x1,'text':_0x2acfb5(0xfe)},{'id':0x2,'text':'Azotemia'},{'id':0x3,'text':'Chronic\x20diarrhea'},{'id':0x4,'text':'Necrotizing\x20enterocolitis'}],'correct_choice_id':0x1,'solution':'<p><strong>Prucalopride:</strong></p>\x0a<ul>\x0a<li>Prucalopride\x20is\x20a\x20<strong>selective,\x20high-affinity\x205HT<sub>4</sub>\x20agonist</strong></li>\x0a<li>It\x20was\x20approved\x20for\x20usage\x20in\x20India\x20in\x202017\x20for\x20<strong>chronic\x20idiopathic\x20constipation\x20(CIC)\x20to\x20provide\x20relief\x20in\x20case\x20of\x20laxative\x20failure</strong></li>\x0a<li>It\x20improves\x20colonic\x20transit\x20and\x20stool\x20frequency</li>\x0a<li>Side\x20effects\x20include\x20<strong>headache,\x20nausea\x20and\x20diarrhea</strong></li>\x0a<li>It\x20is\x20yet\x20to\x20gain\x20approval\x20in\x20the\x20United\x20States\x20but\x20has\x20in\x20Europe</li>\x0a</ul>\x0a<p><strong>Plecantide:</strong></p>\x0a<ul>\x0a<li>Plecanatide\x20is\x20a\x20<strong>guanylate\x20cyclase-C\x20agonist</strong>\x20that\x20is\x20indicated\x20for\x20adults\x20with\x20CIC.</li>\x0a<li>The\x20recommended\x20dose\x20in\x203mg,\x20orally,\x20once\x20daily.</li>\x0a<li>Adverse\x20reactions\x20include\x20diarrhea\x20and\x20consequent\x20dehydration.</li>\x0a<li>It\x20was\x20approved\x20for\x20usage\x20in\x20the\x20United\x20States\x20in\x202017.</li>\x0a</ul>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x366),'choices':[{'id':0x1,'text':'Beat\x20diabetes'},{'id':0x2,'text':'Depression,\x20let’s\x20talk'},{'id':0x3,'text':'Food\x20safety\x20-\x20the\x20global\x20view'},{'id':0x4,'text':_0x2acfb5(0x2eb)}],'correct_choice_id':0x2,'solution':'<ul>\x0a<li><strong>World\x20Health\x20Day</strong>\x20will\x20be\x20celebrated\x20on\x20<strong>April\x207\x20every\x20year.</strong></li>\x0a<li>Each\x20year,\x20the\x20<strong>World\x20Health\x20Organisation\x20(WHO)</strong>\x20selects\x20a\x20theme\x20highlighting\x20a\x20particular\x20priority\x20area\x20of\x20public\x20health.</li>\x0a<li>The\x20theme\x20for\x202017\x20world\x20health\x20day\x20is\x20<strong>\x27Depression:\x20Let\x27s\x20Talk</strong>\x27.</li>\x0a<li>According\x20to\x20WHO,\x20<strong>India\x20has\x20the\x20highest\x20suicide\x20rate</strong>\x20among\x2010\x20South-East\x20Asian\x20countries\x20and\x20<strong>depression</strong>\x20is\x20one\x20of\x20the\x20leading\x20causes\x20for\x20this.</li>\x0a</ul>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x1f9),'choices':[{'id':0x1,'text':_0x2acfb5(0x305)},{'id':0x2,'text':_0x2acfb5(0x3b8)},{'id':0x3,'text':_0x2acfb5(0x2fc)},{'id':0x4,'text':_0x2acfb5(0x1dd)}],'correct_choice_id':0x4,'solution':_0x2acfb5(0xea),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x25e),'choices':[{'id':0x1,'text':'Multiple\x20sclerosis'},{'id':0x2,'text':_0x2acfb5(0x114)},{'id':0x3,'text':_0x2acfb5(0x253)},{'id':0x4,'text':'Mastitis'}],'correct_choice_id':0x1,'solution':_0x2acfb5(0x324),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x245),'choices':[{'id':0x1,'text':_0x2acfb5(0x232)},{'id':0x2,'text':_0x2acfb5(0x1c1)},{'id':0x3,'text':'Argatroban'},{'id':0x4,'text':_0x2acfb5(0x33b)}],'correct_choice_id':0x3,'solution':_0x2acfb5(0x1ba),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x255),'choices':[{'id':0x1,'text':'≤\x20\x2054\x20mg/dL'},{'id':0x2,'text':'≤\x20\x2060\x20mg/dL'},{'id':0x3,'text':_0x2acfb5(0xc4)},{'id':0x4,'text':_0x2acfb5(0x1b3)}],'correct_choice_id':0x3,'solution':'<p><strong>American\x20Diabetes\x20Association</strong>,\x20in\x202017,\x20has\x20proposed\x20new\x20classification\x20for\x20Hypoglycemia\x20which\x20is\x20as\x20follows</p>\x0a<p><strong>Classification\x20of\x20hypoglycemia:</strong></p>\x0a<p>&nbsp;</p>\x0a<table\x20style=\x22width:\x20484px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20103px;\x22><strong>Level</strong></td>\x0a<td\x20style=\x22width:\x20170.6px;\x22><strong>&nbsp;Glycemic\x20criteria</strong></td>\x0a<td\x20style=\x22width:\x20202.4px;\x22>&nbsp;<strong>Description</strong></td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20103px;\x22><strong>Glucose\x20alert\x20value\x20(level\x201)</strong></td>\x0a<td\x20style=\x22width:\x20170.6px;\x22>&nbsp;&le;\x2070\x20mg/dL\x20(3.9\x20mmol/L)</td>\x0a<td\x20style=\x22width:\x20202.4px;\x22>Sufficiently\x20low\x20for\x20treatment\x20with\x20fast-acting\x20carbohydrate\x20and\x20dose\x20adjustment\x20of\x20glucose-lowering\x20therapy</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20103px;\x22>Clinically\x20significant\x20hypoglycemia\x20(level\x202)</td>\x0a<td\x20style=\x22width:\x20170.6px;\x22>&nbsp;&lt;\x2054\x20mg/dL\x20(3.0\x20mmol/L)</td>\x0a<td\x20style=\x22width:\x20202.4px;\x22>Sufficiently\x20low\x20to\x20indicate\x20serious,\x20clinically\x20important\x20hypoglycemia</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20103px;\x22>Severe\x20hypoglycemia\x20(level\x203)</td>\x0a<td\x20style=\x22width:\x20170.6px;\x22>&nbsp;No\x20specific\x20glucose\x20threshold</td>\x0a<td\x20style=\x22width:\x20202.4px;\x22>Hypoglycemia\x20associated\x20with\x20severe\x20cognitive\x20impairment\x20requiring\x20external\x20assistance\x20for\x20recovery</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>A\x20glucose\x20alert\x20value\x20of\x20&le;\x2070\x20mg/dL\x20(3.9\x20mmol/L)\x20can\x20be\x20important\x20for\x20therapeutic\x20dose\x20adjustment\x20of\x20glucose-lowering\x20drugs\x20in\x20clinical\x20care\x20and\x20is\x20often\x20related\x20to\x20symptomatic\x20hypoglycemia.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x1c2),'choices':[{'id':0x1,'text':_0x2acfb5(0x1e9)},{'id':0x2,'text':_0x2acfb5(0x155)},{'id':0x3,'text':_0x2acfb5(0x148)},{'id':0x4,'text':_0x2acfb5(0x1b5)}],'correct_choice_id':0x4,'solution':_0x2acfb5(0x3ae),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x262),'choices':[{'id':0x1,'text':'Intolerance\x20of\x20other\x20second\x20line\x20drugs'},{'id':0x2,'text':_0x2acfb5(0x3d1)},{'id':0x3,'text':'Non-compliance\x20to\x20other\x20tolerable\x20second\x20line\x20drugs'},{'id':0x4,'text':_0x2acfb5(0x162)}],'correct_choice_id':0x3,'solution':_0x2acfb5(0x391),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0xcd),'choices':[{'id':0x1,'text':_0x2acfb5(0x36a)},{'id':0x2,'text':_0x2acfb5(0x30b)},{'id':0x3,'text':_0x2acfb5(0x100)},{'id':0x4,'text':_0x2acfb5(0x2cb)}],'correct_choice_id':0x2,'solution':_0x2acfb5(0xf4),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x3aa),'choices':[{'id':0x1,'text':'Participation\x20of\x20families\x20in\x20community\x20health\x20camps'},{'id':0x2,'text':'Participation\x20in\x20family\x20planning\x20activities'},{'id':0x3,'text':_0x2acfb5(0x1bc)},{'id':0x4,'text':'Family\x20participation\x20for\x20rehabilitation\x20of\x20member\x20with\x20disability'}],'correct_choice_id':0x3,'solution':_0x2acfb5(0x2d2),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x227),'choices':[{'id':0x1,'text':_0x2acfb5(0x349)},{'id':0x2,'text':_0x2acfb5(0x196)},{'id':0x3,'text':'Daily\x20regimen\x20in\x20intensive\x20phase\x20followed\x20by\x20twice\x20weekly\x20regimen\x20in\x20continuation\x20phase'},{'id':0x4,'text':_0x2acfb5(0x1c5)}],'correct_choice_id':0x4,'solution':_0x2acfb5(0x218),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'According\x20to\x20the\x20Indian\x20Medical\x20Devices\x20Rules,\x202017,\x20which\x20of\x20the\x20following\x20is\x20correctly\x20matched?','choices':[{'id':0x1,'text':_0x2acfb5(0x32d)},{'id':0x2,'text':_0x2acfb5(0xd2)},{'id':0x3,'text':_0x2acfb5(0x35c)},{'id':0x4,'text':_0x2acfb5(0x131)}],'correct_choice_id':0x2,'solution':_0x2acfb5(0x1a2),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x29a),'choices':[{'id':0x1,'text':_0x2acfb5(0x24a)},{'id':0x2,'text':_0x2acfb5(0x17b)},{'id':0x3,'text':'Secondary\x20hyperparathyroidism\x20with\x20chronic\x20kidney\x20disease\x20not\x20on\x20dialysi'},{'id':0x4,'text':_0x2acfb5(0x222)}],'correct_choice_id':0x2,'solution':_0x2acfb5(0x2dc),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x1fd),'choices':[{'id':0x1,'text':_0x2acfb5(0x2cf)},{'id':0x2,'text':_0x2acfb5(0x282)},{'id':0x3,'text':_0x2acfb5(0x34a)},{'id':0x4,'text':_0x2acfb5(0x129)}],'correct_choice_id':0x3,'solution':_0x2acfb5(0x3be),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'The\x20intensified\x20mission\x20Indradhanush\x20refers\x20to\x20accelerated\x20full\x20immunization\x20coverage\x20to\x20more\x20than\x20__________','choices':[{'id':0x1,'text':_0x2acfb5(0x1ed)},{'id':0x2,'text':_0x2acfb5(0x2b1)},{'id':0x3,'text':_0x2acfb5(0x1e5)},{'id':0x4,'text':_0x2acfb5(0x2ce)}],'correct_choice_id':0x2,'solution':_0x2acfb5(0x111),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0xbb),'choices':[{'id':0x1,'text':'Intravenous'},{'id':0x2,'text':_0x2acfb5(0x216)},{'id':0x3,'text':'Intramuscular'},{'id':0x4,'text':_0x2acfb5(0x1a7)}],'correct_choice_id':0x1,'solution':_0x2acfb5(0xe8),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x257),'choices':[{'id':0x1,'text':'Monoamine\x20oxidase\x20type-B\x20inhibitor'},{'id':0x2,'text':'Single\x20drug\x20therapy\x20of\x20PD'},{'id':0x3,'text':'Dyskinesia\x20is\x20an\x20adverse\x20effect'},{'id':0x4,'text':_0x2acfb5(0x20e)}],'correct_choice_id':0x2,'solution':_0x2acfb5(0x33d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x2a2),'choices':[{'id':0x1,'text':'35.7%'},{'id':0x2,'text':_0x2acfb5(0x2ef)},{'id':0x3,'text':_0x2acfb5(0x30f)},{'id':0x4,'text':'20.7%'}],'correct_choice_id':0x4,'solution':_0x2acfb5(0x175),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x329),'choices':[{'id':0x1,'text':'Available\x20at\x20all\x20times\x20as\x20treatments\x20for\x20a\x20wide\x20range\x20of\x20common\x20infections'},{'id':0x2,'text':_0x2acfb5(0x182)},{'id':0x3,'text':_0x2acfb5(0xf9)},{'id':0x4,'text':_0x2acfb5(0x1cb)}],'correct_choice_id':0x2,'solution':_0x2acfb5(0x1fc),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x392),'choices':[{'id':0x1,'text':'Men'},{'id':0x2,'text':'Women'},{'id':0x3,'text':'Pediatric\x20age\x20group'},{'id':0x4,'text':_0x2acfb5(0x292)}],'correct_choice_id':0x1,'solution':_0x2acfb5(0x13d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x158),'choices':[{'id':0x1,'text':_0x2acfb5(0x2a6)},{'id':0x2,'text':_0x2acfb5(0x242)},{'id':0x3,'text':_0x2acfb5(0x26e)},{'id':0x4,'text':_0x2acfb5(0x183)}],'correct_choice_id':0x4,'solution':_0x2acfb5(0x39f),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'All\x20of\x20the\x20following\x20statements\x20are\x20true\x20regarding\x20the\x20new\x20performance\x20and\x20quality\x20measures\x20for\x20myocardial\x20infarction,\x20proposed\x20by\x20ACC/AHA,\x20except\x20________','choices':[{'id':0x1,'text':_0x2acfb5(0x296)},{'id':0x2,'text':_0x2acfb5(0x331)},{'id':0x3,'text':_0x2acfb5(0x25f)},{'id':0x4,'text':'Early\x20invasive\x20strategy,\x20within\x2048\x20hours,\x20in\x20high-risk\x20NSTEMI\x20patients'}],'correct_choice_id':0x4,'solution':_0x2acfb5(0x24c),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'All\x20of\x20the\x20following\x20are\x20the\x20minor\x20criteria,\x20for\x20the\x20diagnosis\x20of\x20Classical\x20Ehlers\x20Danlos\x20syndrome,\x20except:','choices':[{'id':0x1,'text':_0x2acfb5(0x387)},{'id':0x2,'text':_0x2acfb5(0x3db)},{'id':0x3,'text':'Molluscoid\x20pseudotumors'},{'id':0x4,'text':_0x2acfb5(0x22d)}],'correct_choice_id':0x1,'solution':'<ul>\x0a<li>The\x20<strong>Ehlers&ndash;Danlos\x20syndromes\x20(EDS</strong>)\x20are\x20a\x20heterogeneous\x20group\x20of\x20heritable\x20connective\x20tissue\x20disorders\x20(HCTDs)\x20characterized\x20by\x20joint\x20hypermobility,\x20skin\x20hyperextensibility,\x20and\x20tissue\x20fragility.</li>\x0a<li>The\x20following\x20diagnostic\x20criteria\x20has\x20been\x20proposed\x20by\x20the\x202017\x20International\x20Classification\x20of\x20the\x20Ehlers&ndash;Danlos\x20Syndromes.</li>\x0a</ul>\x0a<p><strong>Major\x20criteria:</strong></p>\x0a<ol>\x0a<li>Skin\x20hyperextensibility\x20and\x20atrophic\x20scarring</li>\x0a<li>Generalized\x20joint\x20hypermobility\x20(GJH)</li>\x0a</ol>\x0a<p><strong>Minor\x20criteria:</strong></p>\x0a<ol>\x0a<li>Easy\x20bruising</li>\x0a<li>Soft,\x20doughy\x20skin</li>\x0a<li>Skin\x20fragility\x20(or\x20traumatic\x20splitting)</li>\x0a<li>Molluscoid\x20pseudotumors</li>\x0a<li>Subcutaneous\x20spheroids</li>\x0a<li>Hernia\x20(or\x20history\x20thereof)</li>\x0a<li>Epicanthal\x20folds</li>\x0a<li>Complications\x20of\x20joint\x20hypermobility\x20(e.g.,\x20sprains,\x20luxation/\x20subluxation,\x20pain,\x20flexible\x20flatfoot)</li>\x0a<li>Family\x20history\x20of\x20a\x20first\x20degree\x20relative\x20who\x20meets\x20clinical\x20criteria</li>\x0a</ol>\x0a<p><strong>Minimal\x20diagnostic\x20criteria\x20for\x20classical\x20EDS:</strong></p>\x0a<ul>\x0a<li>Major\x20criterion\x20(1):\x20skin\x20hyperextensibility\x20and\x20atrophic\x20scarring</li>\x0a</ul>\x0a<p>Plus</p>\x0a<ul>\x0a<li>Either\x20major\x20criterion\x20(2):\x20GJH</li>\x0a<li>And/or:\x20at\x20least\x20three\x20minor\x20criteria</li>\x0a</ul>\x0a<p>Confirmatory\x20molecular\x20testing\x20is\x20obligatory\x20to\x20reach\x20a\x20final\x20diagnosis</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2acfb5(0x1ef),'choices':[{'id':0x1,'text':_0x2acfb5(0xbf)},{'id':0x2,'text':_0x2acfb5(0x10e)},{'id':0x3,'text':_0x2acfb5(0xdc)},{'id':0x4,'text':'Education\x20and\x20awareness'}],'correct_choice_id':0x4,'solution':_0x2acfb5(0x251),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'All\x20of\x20the\x20following\x20are\x20the\x20core\x20clinical\x20features\x20for\x20the\x20diagnosis\x20of\x20Lewy\x20body\x20dementia\x20except:','choices':[{'id':0x1,'text':_0x2acfb5(0x170)},{'id':0x2,'text':_0x2acfb5(0x393)},{'id':0x3,'text':_0x2acfb5(0x2e1)},{'id':0x4,'text':_0x2acfb5(0x10f)}],'correct_choice_id':0x4,'solution':_0x2acfb5(0x3d6),'explanation_video':'','question_images':[],'explanation_images':[]}],quizName=_0x2acfb5(0x2ac);const quizFilename=_0x2acfb5(0x27b);let hierarchy=['Marrow',_0x2acfb5(0xf6),_0x2acfb5(0x362)];if(window[_0x2acfb5(0xd4)][_0x2acfb5(0x30e)][_0x2acfb5(0x3b0)]('custom_quiz.html')){const customData=JSON[_0x2acfb5(0x19d)](localStorage['getItem'](_0x2acfb5(0x306)));if(customData){const fDXzNG=_0x2acfb5(0x11a)[_0x2acfb5(0x16f)]('|');let zQuZFD=0x0;while(!![]){switch(fDXzNG[zQuZFD++]){case'0':document[_0x2acfb5(0x3c9)]=quizName+'\x20-\x20Brain\x20And\x20Scalpel';continue;case'1':document[_0x2acfb5(0x15a)](_0x2acfb5(0x11c))[_0x2acfb5(0x2e5)]=questionsData[_0x2acfb5(0x15b)];continue;case'2':questionsData=customData[_0x2acfb5(0xfc)];continue;case'3':quizName=customData[_0x2acfb5(0x1fa)];continue;case'4':document['getElementById']('quizHierarchy')[_0x2acfb5(0x2e5)]=hierarchy[_0x2acfb5(0x35b)](_0x2acfb5(0x12d));continue;case'5':hierarchy=customData[_0x2acfb5(0x31b)];continue;}break;}}}let currentQuestionIndex=0x0,selectedOption=null,currentMode=_0x2acfb5(0x1af),timer=null,timeRemaining=0x0,questionStartTime=Date[_0x2acfb5(0x312)](),quizStartTime=Date[_0x2acfb5(0x312)](),isQuizCompleted=![],questionStates=new Array(questionsData[_0x2acfb5(0x15b)])[_0x2acfb5(0x19b)](null)[_0x2acfb5(0x38c)](()=>({'status':_0x2acfb5(0x1b0),'bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData[_0x2acfb5(0x15b)]};function saveProgress(){const _0x4a55fa=_0x2acfb5,_0x45e938={'pRmiw':_0x4a55fa(0x271),'TmxxU':'incomplete'};if(isQuizCompleted)return;const _0x3ecb94=JSON[_0x4a55fa(0x19d)](localStorage['getItem'](_0x45e938[_0x4a55fa(0x201)]))||{};_0x3ecb94[quizFilename]={'questionStates':questionStates,'stats':stats,'currentQuestionIndex':currentQuestionIndex,'currentMode':currentMode,'status':_0x45e938[_0x4a55fa(0x13f)],'lastSeen':new Date()[_0x4a55fa(0x3a4)]()},localStorage[_0x4a55fa(0x207)](_0x45e938[_0x4a55fa(0x201)],JSON['stringify'](_0x3ecb94));}function loadProgress(){const _0x218415=_0x2acfb5,_0x2268a2={'udKOT':_0x218415(0xd9),'eDoXA':'Progress\x20loaded.'},_0x4b3506=JSON[_0x218415(0x19d)](localStorage[_0x218415(0xc6)]('userHistory'))||{},_0x3f561c=_0x4b3506[quizFilename];if(_0x3f561c){const _0x1152a9=_0x2268a2[_0x218415(0x1c8)][_0x218415(0x16f)]('|');let _0x4ac192=0x0;while(!![]){switch(_0x1152a9[_0x4ac192++]){case'0':questionStates=_0x3f561c[_0x218415(0x3ba)];continue;case'1':return!![];case'2':stats=_0x3f561c[_0x218415(0x266)];continue;case'3':console[_0x218415(0x33f)](_0x2268a2[_0x218415(0x2c6)]);continue;case'4':currentMode=_0x3f561c[_0x218415(0x256)];continue;case'5':currentQuestionIndex=_0x3f561c['currentQuestionIndex'];continue;}break;}}return![];}function clearProgress(){const _0x40c140=_0x2acfb5,_0x425653={'Sgsok':_0x40c140(0x271),'ziegl':function(_0x529fd7,_0x3fa65b){return _0x529fd7===_0x3fa65b;},'hTknj':_0x40c140(0x1f7),'ARxeg':_0x40c140(0x1ec),'uKxMD':'Previous\x20progress\x20cleared.'},_0x2b2e69=JSON[_0x40c140(0x19d)](localStorage[_0x40c140(0xc6)](_0x425653[_0x40c140(0x239)]))||{};_0x2b2e69[quizFilename]&&(_0x425653[_0x40c140(0x2a7)](_0x425653[_0x40c140(0x1d4)],_0x425653[_0x40c140(0x2bc)])?(_0x5c340a[_0x243d56][_0x40c140(0x22c)]='answered',_0x4d54bb[_0x40c140(0x37f)]++,_0x2d797a[_0x40c140(0x2f3)]--):(delete _0x2b2e69[quizFilename],localStorage[_0x40c140(0x207)]('userHistory',JSON[_0x40c140(0x24b)](_0x2b2e69)),console[_0x40c140(0x33f)](_0x425653[_0x40c140(0x3b4)])));}function markQuizAsCompleted(){const _0x1bd7cc=_0x2acfb5,_0x4b72ca={'myyDp':'userHistory','GxNAp':_0x1bd7cc(0x1e6)},_0x3d10de=JSON[_0x1bd7cc(0x19d)](localStorage[_0x1bd7cc(0xc6)](_0x4b72ca['myyDp']))||{},_0x2c9184=questionsData['length'],_0x428a41=stats[_0x1bd7cc(0x386)]||0x0;_0x3d10de[quizFilename]={'score':_0x428a41,'total':_0x2c9184,'status':_0x4b72ca[_0x1bd7cc(0xfd)],'completedOn':new Date()[_0x1bd7cc(0x3a4)]()},localStorage['setItem'](_0x4b72ca[_0x1bd7cc(0x141)],JSON[_0x1bd7cc(0x24b)](_0x3d10de));}const urlParams=new URLSearchParams(window['location'][_0x2acfb5(0x122)]),startAt=parseInt(urlParams[_0x2acfb5(0x197)](_0x2acfb5(0x32a))),resume=urlParams[_0x2acfb5(0x197)](_0x2acfb5(0x1ae))===_0x2acfb5(0x319);function goBack(){const _0x3141e4=_0x2acfb5,_0x38d056={'RSbsH':function(_0x2caa03){return _0x2caa03();},'GRvmX':_0x3141e4(0x109)};if(!isQuizCompleted)_0x38d056['RSbsH'](saveProgress);window[_0x3141e4(0xd4)]['href']=document['referrer']||_0x38d056[_0x3141e4(0x339)];}function selectMode(_0x27f9a7){const _0x337caa=_0x2acfb5,_0x3c2705={'nQjvK':_0x337caa(0x18c),'OPuIy':_0x337caa(0x38f),'xRZxD':function(_0x145d10){return _0x145d10();}};currentMode=_0x27f9a7,document[_0x337caa(0x15a)](_0x3c2705[_0x337caa(0x1b9)])[_0x337caa(0x209)]['display']=_0x3c2705[_0x337caa(0x286)],_0x3c2705[_0x337caa(0x264)](initializeQuiz);}function initializeQuiz(){const _0x5097d2=_0x2acfb5,_0x51897b={'ukTch':_0x5097d2(0x225),'ZpsjZ':_0x5097d2(0x34f),'yaQWX':_0x5097d2(0x1a5),'rZDEd':_0x5097d2(0xc0),'cSQdJ':function(_0x466401,_0x512d8d){return _0x466401===_0x512d8d;},'PeCHc':_0x5097d2(0x342),'hkqAu':_0x5097d2(0x38f),'PsayD':'block','XexGx':_0x5097d2(0xd3),'Visnd':_0x5097d2(0x2a5),'MzrsW':_0x5097d2(0x3c0),'LjEPw':_0x5097d2(0x159),'XpBhg':_0x5097d2(0x3b3),'XzbCm':function(_0x56c2f2,_0x15682c){return _0x56c2f2===_0x15682c;},'MdQig':function(_0x4b1eca,_0xa974d4){return _0x4b1eca!==_0xa974d4;},'xLnIx':_0x5097d2(0x27c),'EIdqZ':'timerContainer','KVMhs':_0x5097d2(0x39a),'avDwE':function(_0x7e5ffd,_0x59cd1d){return _0x7e5ffd(_0x59cd1d);},'XfzYk':function(_0x5d6533,_0x113431){return _0x5d6533>=_0x113431;},'hIiPu':function(_0x538b64){return _0x538b64();},'bBRig':function(_0x492c5c){return _0x492c5c();},'YJurm':function(_0xc114c1){return _0xc114c1();}};quizStartTime=Date['now']();const _0x592898=document[_0x5097d2(0x15a)](_0x51897b[_0x5097d2(0x14d)]),_0x8ba1ae=document[_0x5097d2(0x15a)](_0x51897b['yaQWX']),_0x8c864=document[_0x5097d2(0x15a)](_0x51897b['rZDEd']),_0x2d40de=_0x51897b[_0x5097d2(0x274)](currentMode,_0x5097d2(0x235))||_0x51897b[_0x5097d2(0x274)](currentMode,_0x51897b[_0x5097d2(0x32e)]);document['getElementById'](_0x5097d2(0xe0))[_0x5097d2(0x209)][_0x5097d2(0x31f)]=_0x2d40de?_0x51897b[_0x5097d2(0x221)]:_0x51897b['PsayD'],document[_0x5097d2(0x15a)](_0x51897b[_0x5097d2(0x193)])['style']['display']=_0x2d40de?_0x5097d2(0x38f):_0x5097d2(0x3d2),document['getElementById'](_0x51897b[_0x5097d2(0x2fd)])[_0x5097d2(0x209)][_0x5097d2(0x31f)]=_0x2d40de?_0x51897b['PsayD']:_0x51897b[_0x5097d2(0x221)],document[_0x5097d2(0x15a)](_0x51897b[_0x5097d2(0x295)])[_0x5097d2(0x209)][_0x5097d2(0x31f)]=_0x2d40de?_0x51897b[_0x5097d2(0x20f)]:_0x5097d2(0x38f),_0x592898[_0x5097d2(0x209)][_0x5097d2(0x31f)]=_0x2d40de?_0x5097d2(0x38f):_0x51897b[_0x5097d2(0x3b5)],_0x8ba1ae[_0x5097d2(0x209)][_0x5097d2(0x31f)]=_0x2d40de?_0x51897b[_0x5097d2(0x3b5)]:_0x5097d2(0x38f),_0x8c864['style']['display']=_0x2d40de?_0x51897b[_0x5097d2(0x3b5)]:_0x51897b[_0x5097d2(0x221)],(_0x51897b[_0x5097d2(0x274)](currentMode,_0x51897b[_0x5097d2(0x1a9)])||_0x51897b['XzbCm'](currentMode,_0x51897b[_0x5097d2(0x32e)]))&&(_0x51897b['MdQig'](_0x51897b[_0x5097d2(0x31d)],_0x51897b[_0x5097d2(0x31d)])?(_0xd421c3++,_0x280a16[_0x5097d2(0x22c)]=_0x51897b[_0x5097d2(0x18b)]):document['getElementById'](_0x51897b[_0x5097d2(0x37d)])[_0x5097d2(0x3c4)][_0x5097d2(0x3d3)](_0x51897b[_0x5097d2(0x3e0)])),!_0x51897b[_0x5097d2(0x14a)](isNaN,startAt)&&_0x51897b[_0x5097d2(0x36d)](startAt,0x0)&&startAt<questionsData[_0x5097d2(0x15b)]&&(currentQuestionIndex=startAt),_0x51897b[_0x5097d2(0x33e)](loadBookmarkedQuestions),_0x51897b[_0x5097d2(0x1cd)](generateQuestionNav),_0x51897b['YJurm'](updateStats),_0x51897b[_0x5097d2(0x20d)](displayQuestion);}function generateQuestionNav(){const _0x273cee=_0x2acfb5,_0x247830={'ByePy':function(_0x2e0c57,_0x1147e3){return _0x2e0c57<_0x1147e3;},'phQrN':function(_0x2f7601,_0xa44197){return _0x2f7601!==_0xa44197;},'oAfry':'clkNa','fHYen':_0x273cee(0x278),'toOUu':function(_0x55a4d9,_0x1647cd){return _0x55a4d9+_0x1647cd;},'SQFJO':function(_0x2f9be1){return _0x2f9be1();}},_0x69e249=document[_0x273cee(0x15a)](_0x273cee(0x110));_0x69e249[_0x273cee(0x1d3)]='';for(let _0x561684=0x0;_0x247830[_0x273cee(0x18a)](_0x561684,questionsData[_0x273cee(0x15b)]);_0x561684++){if(_0x247830['phQrN'](_0x247830[_0x273cee(0x291)],_0x273cee(0x3a9)))_0xe262bd[_0x273cee(0x18d)]=_0x39ccfe;else{const _0x34852=document[_0x273cee(0x382)](_0x247830[_0x273cee(0xc1)]);_0x34852[_0x273cee(0x2e5)]=_0x247830[_0x273cee(0x2fa)](_0x561684,0x1),_0x34852[_0x273cee(0x294)]=_0x273cee(0x379),_0x34852[_0x273cee(0x134)]=()=>jumpToQuestion(_0x561684),_0x34852['id']=_0x273cee(0x165)+_0x561684,_0x69e249[_0x273cee(0x138)](_0x34852);}}_0x247830[_0x273cee(0x1b4)](updateQuestionNav);}function updateQuestionNav(){const _0x3d7166=_0x2acfb5,_0x39572e={'QMdGe':_0x3d7166(0x39c),'kbeIX':function(_0x3845db,_0x34fc1e,_0x47d836){return _0x3845db(_0x34fc1e,_0x47d836);},'tDNPu':_0x3d7166(0x31c),'hUALQ':function(_0x5746a1,_0x204c33){return _0x5746a1===_0x204c33;},'ZyVXf':_0x3d7166(0x11b),'xccZw':function(_0x3b8811,_0x16eedb){return _0x3b8811!==_0x16eedb;},'gKOmV':_0x3d7166(0x28f),'fKbLk':_0x3d7166(0x24f),'bHwHA':_0x3d7166(0x1af),'xytHV':_0x3d7166(0x3b3),'zziJy':function(_0xe42f2f,_0x4c6890){return _0xe42f2f===_0x4c6890;},'bMZyp':_0x3d7166(0x1f1),'zdxLM':'correct','qaksq':_0x3d7166(0x1b7),'KFWJs':_0x3d7166(0x225),'iSXiY':_0x3d7166(0x1bd),'pgokZ':'nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','VhEUH':function(_0x203232,_0x4c14ec){return _0x203232===_0x4c14ec;},'eDExE':_0x3d7166(0x179),'mDDyE':function(_0x5079d1,_0x5604dd){return _0x5079d1!==_0x5604dd;},'FgRvx':_0x3d7166(0x23b)};for(let _0x558dd1=0x0;_0x558dd1<questionsData[_0x3d7166(0x15b)];_0x558dd1++){const _0x2d129c=document[_0x3d7166(0x15a)](_0x3d7166(0x165)+_0x558dd1),_0xc55346=questionStates[_0x558dd1];let _0x484844='';if(_0x39572e[_0x3d7166(0x2bf)](_0x558dd1,currentQuestionIndex))_0x484844=_0x39572e[_0x3d7166(0x373)];else{if(_0xc55346[_0x3d7166(0x33a)])_0x484844=_0x3d7166(0x3a5);else{if(_0xc55346[_0x3d7166(0x142)])_0x39572e['xccZw'](_0x39572e[_0x3d7166(0x12a)],_0x39572e['gKOmV'])?_0x32842a[_0x3d7166(0x280)](_0x39572e[_0x3d7166(0x1bb)])[_0x3d7166(0x136)](_0x8e2ae9=>{const _0x3d340b=_0x3d7166,_0xc6da89=_0x8e2ae9['dataset'][_0x3d340b(0x18d)];if(_0xc6da89&&_0xc6da89[_0x3d340b(0x212)](_0x39572e['QMdGe']))_0x39572e[_0x3d340b(0x12c)](_0x20d17a,_0x8e2ae9,_0xc6da89);else _0xc6da89&&(_0x8e2ae9['src']=_0xc6da89);}):_0x484844=_0x39572e[_0x3d7166(0x2c0)];else{if(_0x39572e[_0x3d7166(0x2bf)](currentMode,_0x39572e[_0x3d7166(0x140)])||_0x39572e[_0x3d7166(0x2bf)](currentMode,_0x39572e[_0x3d7166(0x321)])){if(_0x39572e[_0x3d7166(0x394)](_0x39572e['bMZyp'],_0x39572e[_0x3d7166(0x38a)])){if(_0xc55346[_0x3d7166(0x22c)]===_0x39572e[_0x3d7166(0x10b)])_0x484844=_0x39572e[_0x3d7166(0x2ff)];else{if(_0x39572e[_0x3d7166(0x394)](_0xc55346[_0x3d7166(0x22c)],_0x39572e[_0x3d7166(0x303)]))_0x484844=_0x39572e[_0x3d7166(0x2d8)];else _0x484844=_0x39572e[_0x3d7166(0x360)];}}else _0x3a7c9a[_0x3d7166(0x364)]['forEach'](_0x5415b6=>{const _0x4113b1=_0x3d7166;if(_0x5415b6)_0x2955f3+=_0x4113b1(0x3ce)+_0x5415b6+_0x4113b1(0x3c5);});}else{if(_0x39572e['VhEUH'](_0x3d7166(0x179),_0x39572e['eDExE'])){if(_0x39572e['mDDyE'](_0xc55346[_0x3d7166(0x298)],null))_0x484844=_0x39572e[_0x3d7166(0x268)];else _0x484844=_0x3d7166(0x224);}else{if(_0x460db9){const _0x57812d=_0x4f1dfd[_0x3d7166(0x230)](_0x4f6e9a,arguments);return _0xe6e33=null,_0x57812d;}}}}}}_0x2d129c[_0x3d7166(0x294)]='w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20'+_0x484844;}}function jumpToQuestion(_0x342e3e){const _0x28e843=_0x2acfb5,_0x1d6e7d={'yyQvj':function(_0x414c1f,_0x206939){return _0x414c1f>=_0x206939;},'aOHQL':function(_0x1774a9,_0x5b8c8d){return _0x1774a9===_0x5b8c8d;},'BHxGU':_0x28e843(0x34e),'FnooU':function(_0x174852){return _0x174852();},'guSMO':function(_0x3e242d){return _0x3e242d();}};if(_0x1d6e7d[_0x28e843(0x1d6)](_0x342e3e,0x0)&&_0x342e3e<questionsData['length']){if(_0x1d6e7d[_0x28e843(0x1a6)](_0x1d6e7d['BHxGU'],_0x1d6e7d[_0x28e843(0x39e)]))questionStartTime&&(questionStates[currentQuestionIndex][_0x28e843(0x3c6)]+=Date[_0x28e843(0x312)]()-questionStartTime),currentQuestionIndex=_0x342e3e,_0x1d6e7d[_0x28e843(0x121)](displayQuestion),_0x1d6e7d['guSMO'](saveProgress);else{const _0x5f3a03={'quizName':_0x1749cf,'quizFile':_0x537277[_0x28e843(0xd4)][_0x28e843(0x30e)]['split']('/')[_0x28e843(0x323)](),'questionIndex':_0x436e1a,'question':_0x53f53f[_0x3e1723],'hierarchy':_0x17ae36,'timestamp':_0x87913[_0x28e843(0x312)]()};_0x2fc086[_0x28e843(0x174)](_0x5f3a03);}}}function updateStats(){const _0x477e9f=_0x2acfb5,_0x5971b2={'MvfjX':function(_0x31c44b){return _0x31c44b();},'WLyuZ':function(_0x385a0f,_0x397ca4){return _0x385a0f===_0x397ca4;},'RoBWV':_0x477e9f(0x3b3),'jCwOq':function(_0x188adf,_0x3b1b80){return _0x188adf!==_0x3b1b80;},'aXaNY':'correctCount','XolqX':'incorrectCount','kGvsN':function(_0x154e33,_0x1bc556){return _0x154e33>_0x1bc556;},'NCDGg':function(_0x4e781e,_0x14629e){return _0x4e781e/_0x14629e;},'TBMhr':_0x477e9f(0x180),'fzHtH':function(_0x465fde,_0x1179ef){return _0x465fde+_0x1179ef;},'SZekH':_0x477e9f(0x3c6),'vtQSK':function(_0x3516f5,_0x1399e3){return _0x3516f5+_0x1399e3;},'jbcRk':function(_0x46a6ed,_0x2f933c){return _0x46a6ed+_0x2f933c;}};if(_0x5971b2['WLyuZ'](currentMode,_0x477e9f(0x1af))||_0x5971b2[_0x477e9f(0x15e)](currentMode,_0x5971b2[_0x477e9f(0x21c)])){if(_0x5971b2[_0x477e9f(0x2d5)](_0x477e9f(0x259),_0x477e9f(0x1bf))){document[_0x477e9f(0x15a)](_0x5971b2['aXaNY'])[_0x477e9f(0x2e5)]=stats[_0x477e9f(0x386)],document[_0x477e9f(0x15a)](_0x5971b2[_0x477e9f(0x308)])[_0x477e9f(0x2e5)]=stats[_0x477e9f(0x297)],document[_0x477e9f(0x15a)](_0x477e9f(0x37f))[_0x477e9f(0x2e5)]=stats['totalAttempted'];const _0x247b9a=_0x5971b2[_0x477e9f(0x300)](stats[_0x477e9f(0x37f)],0x0)?Math[_0x477e9f(0x1e0)](_0x5971b2[_0x477e9f(0x13a)](stats[_0x477e9f(0x386)],stats[_0x477e9f(0x37f)])*0x64):0x0;document[_0x477e9f(0x15a)](_0x5971b2['TBMhr'])['textContent']=_0x5971b2['fzHtH'](_0x247b9a,'%'),stats['totalTime']=questionStates['reduce']((_0x51e21f,_0x2e173b)=>_0x51e21f+_0x2e173b[_0x477e9f(0x3c6)],0x0);const _0x2cba22=Math[_0x477e9f(0x3a6)](_0x5971b2['NCDGg'](stats[_0x477e9f(0x302)],0x3e8)),_0x556c3a=Math['floor'](_0x5971b2[_0x477e9f(0x13a)](_0x2cba22,0x3c)),_0x539407=_0x2cba22%0x3c;document[_0x477e9f(0x15a)](_0x5971b2['SZekH'])['textContent']=_0x5971b2['vtQSK'](_0x5971b2[_0x477e9f(0x2d6)](_0x556c3a,':'),_0x539407[_0x477e9f(0x38b)]()[_0x477e9f(0x1e8)](0x2,'0'));}else _0x5971b2[_0x477e9f(0x270)](_0x2c66f1);}}function setupVideo(_0x25b07c,_0x1cd27e){const _0x5560c2=_0x2acfb5,_0x1a3e50={'AuXHt':function(_0x137e73,_0x32b2be){return _0x137e73===_0x32b2be;},'MHhJJ':function(_0x19b5e8,_0xf69141){return _0x19b5e8!==_0xf69141;},'FSVVy':_0x5560c2(0x1af),'IvyUJ':_0x5560c2(0x3b3),'GXwVl':_0x5560c2(0x30c),'dDiGX':_0x5560c2(0x3d0),'gOmUr':_0x5560c2(0x348),'YcMgf':function(_0x185957,_0x5c9024){return _0x185957!==_0x5c9024;},'pTWgH':_0x5560c2(0x1a8),'lVLyj':_0x5560c2(0x2c4)};if(Hls['isSupported']()){if(_0x1a3e50[_0x5560c2(0x272)](_0x1a3e50[_0x5560c2(0x310)],_0x5560c2(0x1a8))){_0x37f317[_0x5560c2(0x37f)]++,_0x325193['notAttempted']--;if(_0x57721b)_0x19b098[_0x5560c2(0x386)]++;else _0x478e74[_0x5560c2(0x297)]++;}else{const _0x1b007b=new Hls();_0x1b007b[_0x5560c2(0x31e)](_0x1cd27e),_0x1b007b['attachMedia'](_0x25b07c);}}else{if(_0x25b07c[_0x5560c2(0x3dd)](_0x5560c2(0x283))){if(_0x1a3e50[_0x5560c2(0xf5)](_0x1a3e50[_0x5560c2(0x203)],_0x1a3e50[_0x5560c2(0x203)]))_0x25b07c[_0x5560c2(0x18d)]=_0x1cd27e;else{const _0x57b0b1={'XRsXo':_0x5560c2(0x21e),'tMzeW':_0x5560c2(0x149),'vcrYh':function(_0x2194a1,_0x5a303a){const _0x6e8882=_0x5560c2;return _0x1a3e50[_0x6e8882(0xf5)](_0x2194a1,_0x5a303a);}};if(_0x1a3e50[_0x5560c2(0x1ce)](_0x2eb152,_0x1a3e50[_0x5560c2(0x132)])&&_0x1a3e50['MHhJJ'](_0x31ec9d,_0x1a3e50[_0x5560c2(0x22b)]))return;const _0x1d6e14=_0x2b36e6[_0x5560c2(0x15a)](_0x1a3e50['GXwVl']),_0x54b210=_0x1d6e14[_0x5560c2(0x280)](_0x1a3e50['dDiGX']),_0xcba17=_0x3f4e9b[_0x4e177c],_0x5cbe04=_0xcba17[_0x5560c2(0x135)];let _0x33e34f=_0xcba17[_0x5560c2(0x119)][_0x5560c2(0x26f)](_0x531c00=>_0x531c00['id']===_0x5cbe04);_0x1d6e14[_0x5560c2(0x3c4)]['add'](_0x1a3e50[_0x5560c2(0x37a)]),_0x54b210[_0x5560c2(0x136)]((_0x4c6fa2,_0x19804f)=>{const _0x44cee2=_0x5560c2;_0x4c6fa2[_0x44cee2(0x3c4)]['remove'](_0x57b0b1[_0x44cee2(0x35f)]);if(_0x19804f===_0x33e34f)_0x4c6fa2[_0x44cee2(0x3c4)]['add'](_0x57b0b1[_0x44cee2(0x234)]);else{if(_0x57b0b1[_0x44cee2(0x127)](_0x19804f,_0x1d77de)&&!_0x44b94b)_0x4c6fa2[_0x44cee2(0x3c4)][_0x44cee2(0x28c)]('incorrect');}}),_0x3c5aea();}}}}function displayQuestion(){const _0x49bbb7=_0x2acfb5,_0x12b683={'LDAwh':_0x49bbb7(0x271),'iDCZi':_0x49bbb7(0x397),'YjLDH':function(_0xecb740,_0x5df324){return _0xecb740+_0x5df324;},'RKEJl':function(_0x34b4fe,_0x3743f6){return _0x34b4fe===_0x3743f6;},'ZMoiP':function(_0x46c27b,_0x3e2759){return _0x46c27b+_0x3e2759;},'mGCYC':function(_0x5dc76e){return _0x5dc76e();},'TaYuj':'.option-button','TTPPJ':function(_0x520e51,_0x8ef367){return _0x520e51!==_0x8ef367;},'EXRcb':_0x49bbb7(0x2ea),'EZALH':function(_0x278f83,_0x4ff8a0){return _0x278f83(_0x4ff8a0);},'QWGhu':_0x49bbb7(0x2b8),'UDXFO':function(_0x37b88e,_0xecc275){return _0x37b88e===_0xecc275;},'QwdQI':function(_0x3a27e2,_0x11e35f){return _0x3a27e2===_0x11e35f;},'roiBR':_0x49bbb7(0x153),'rYbnY':'SUYpi','dMurh':_0x49bbb7(0x3a1),'vljSU':_0x49bbb7(0x146),'HMpnm':function(_0x346a7e,_0x25349d){return _0x346a7e*_0x25349d;},'bCAbx':_0x49bbb7(0x293),'GdYnE':_0x49bbb7(0x38e),'YoTjv':function(_0x334459){return _0x334459();},'LolHT':_0x49bbb7(0x1e1),'AfnqO':_0x49bbb7(0x2bd),'txXzn':'No\x20question\x20text\x20available','FQVKF':_0x49bbb7(0x30c),'FsgBh':_0x49bbb7(0x325),'cgEpY':_0x49bbb7(0x2d9)};if(!questionsData||_0x12b683[_0x49bbb7(0x2e8)](questionsData[_0x49bbb7(0x15b)],0x0)){if(_0x12b683[_0x49bbb7(0x192)](_0x12b683[_0x49bbb7(0x354)],_0x12b683[_0x49bbb7(0xe7)])){const _0x41510a=_0x1cc8b9[_0x49bbb7(0x19d)](_0x352d4d[_0x49bbb7(0xc6)](_0x12b683[_0x49bbb7(0x2af)]))||{};_0x41510a[_0x123910]&&(delete _0x41510a[_0x15355f],_0x53650e[_0x49bbb7(0x207)](_0x12b683['LDAwh'],_0x2115be[_0x49bbb7(0x24b)](_0x41510a)),_0x414c7d['log'](_0x12b683[_0x49bbb7(0x241)]));}else{document[_0x49bbb7(0x15a)](_0x12b683[_0x49bbb7(0x2f2)])[_0x49bbb7(0x1d3)]=_0x12b683['vljSU'];return;}};const _0x4b473c=questionsData[currentQuestionIndex];questionStartTime=Date[_0x49bbb7(0x312)](),selectedOption=questionStates[currentQuestionIndex][_0x49bbb7(0x298)];const _0x495ca2=_0x12b683[_0x49bbb7(0x194)](_0x12b683[_0x49bbb7(0x27d)](currentQuestionIndex,0x1)/questionsData[_0x49bbb7(0x15b)],0x64);document[_0x49bbb7(0x15a)](_0x12b683['bCAbx'])['style'][_0x49bbb7(0x3b7)]=_0x12b683[_0x49bbb7(0xd6)](_0x495ca2,'%'),document[_0x49bbb7(0x15a)](_0x12b683['GdYnE'])['textContent']=_0x12b683[_0x49bbb7(0xd6)](currentQuestionIndex,0x1),_0x12b683[_0x49bbb7(0x1d5)](updateQuestionNav),document[_0x49bbb7(0x15a)](_0x12b683[_0x49bbb7(0x120)])[_0x49bbb7(0x336)]=_0x12b683[_0x49bbb7(0x13e)](currentQuestionIndex,0x0),document['getElementById'](_0x12b683[_0x49bbb7(0xcc)])[_0x49bbb7(0x3c4)][_0x49bbb7(0x28c)](_0x49bbb7(0x39a)),document[_0x49bbb7(0x15a)](_0x12b683[_0x49bbb7(0x2f2)])[_0x49bbb7(0x1d3)]=_0x4b473c[_0x49bbb7(0x3dc)]||_0x12b683['txXzn'];let _0x1f6dc9='';if(_0x4b473c['question_audio'])_0x1f6dc9+='<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22'+_0x4b473c['question_audio']+'\x22\x20controls\x20class=\x22w-full\x22></audio></div>';if(_0x4b473c[_0x49bbb7(0x26b)])_0x1f6dc9+=_0x49bbb7(0x1dc)+_0x4b473c['question_video']+_0x49bbb7(0x3c1);_0x4b473c[_0x49bbb7(0x364)]&&_0x4b473c[_0x49bbb7(0x364)][_0x49bbb7(0x136)](_0x3caadf=>{const _0x4da2b7=_0x49bbb7;if(_0x3caadf)_0x1f6dc9+=_0x4da2b7(0x3ce)+_0x3caadf+_0x4da2b7(0x3c5);});document[_0x49bbb7(0x15a)](_0x49bbb7(0x25d))[_0x49bbb7(0x1d3)]=_0x1f6dc9;const _0x48a6fa=document['getElementById'](_0x12b683['FQVKF']);_0x48a6fa[_0x49bbb7(0x1d3)]='',_0x48a6fa[_0x49bbb7(0x3c4)][_0x49bbb7(0x3d3)](_0x49bbb7(0x348));if(_0x4b473c[_0x49bbb7(0x119)]&&Array[_0x49bbb7(0x363)](_0x4b473c['choices'])){if(_0x12b683[_0x49bbb7(0x27e)](_0x12b683[_0x49bbb7(0x37e)],_0x12b683['FsgBh'])){if(_0x2e83f5){const _0x34cad4=_0x3e290c[_0x49bbb7(0x230)](_0x30de75,arguments);return _0x160ef0=null,_0x34cad4;}}else _0x4b473c[_0x49bbb7(0x119)][_0x49bbb7(0x136)]((_0x18deba,_0x2a0d52)=>{const _0x2071bb=_0x49bbb7,_0x21159b=String[_0x2071bb(0x399)](_0x12b683[_0x2071bb(0xd6)](0x41,_0x2a0d52)),_0x204a6b=_0x12b683[_0x2071bb(0x13e)](selectedOption,_0x2a0d52),_0x57706e=document['createElement'](_0x2071bb(0x1f4));_0x57706e['innerHTML']=_0x2071bb(0x28d)+(_0x204a6b?_0x2071bb(0x21e):'')+_0x2071bb(0x240)+_0x2a0d52+'\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>'+_0x21159b+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>'+(_0x18deba[_0x2071bb(0x3dc)]||'Option\x20'+_0x12b683[_0x2071bb(0x27d)](_0x2a0d52,0x1))+_0x2071bb(0x32f),_0x48a6fa[_0x2071bb(0x138)](_0x57706e);}),_0x48a6fa[_0x49bbb7(0xd5)](_0x12b683[_0x49bbb7(0x238)],function(_0x1277b3){const _0x59bc76=_0x49bbb7,_0x59b38f={'AKyUz':function(_0x5b4054){const _0x4a022f=_0x24b8;return _0x12b683[_0x4a022f(0xfa)](_0x5b4054);},'HFTMb':function(_0x3771c3){const _0x2858c0=_0x24b8;return _0x12b683[_0x2858c0(0xfa)](_0x3771c3);}},_0x4ec65f=_0x1277b3[_0x59bc76(0x156)]['closest'](_0x12b683[_0x59bc76(0xe4)]);if(_0x4ec65f){if(_0x12b683['TTPPJ'](_0x12b683['EXRcb'],_0x12b683[_0x59bc76(0x267)]))_0x4d1b0e[_0x441cac]['markedForReview']=!_0xb9c3bc[_0x4b0529]['markedForReview'],_0x59b38f[_0x59bc76(0x2b3)](_0x2bc853),_0x59b38f[_0x59bc76(0x199)](_0x402dca);else{const _0x5e3db2=_0x12b683[_0x59bc76(0x338)](parseInt,_0x4ec65f[_0x59bc76(0x12b)](_0x12b683[_0x59bc76(0x261)]));_0x12b683[_0x59bc76(0x338)](selectOption,_0x5e3db2);}}});}_0x12b683['YoTjv'](updateBookmarkButton),updateMarkReviewButton(),(_0x12b683[_0x49bbb7(0x13e)](currentMode,_0x49bbb7(0x3b3))||_0x12b683[_0x49bbb7(0x192)](currentMode,_0x49bbb7(0x342)))&&!isQuizCompleted&&startTimer();}function selectOption(_0x33c031){const _0x1fe58f=_0x2acfb5,_0x4d6a51={'oLDXW':function(_0x198b22,_0x4d4b49){return _0x198b22===_0x4d4b49;},'TBXkM':'answered','kBXrN':function(_0x2471a3,_0x4bc057){return _0x2471a3-_0x4bc057;},'GeNoL':_0x1fe58f(0x3d0),'xgcLO':function(_0x514a5f,_0x3276e6){return _0x514a5f===_0x3276e6;},'ZOkbQ':'study','WIzLW':_0x1fe58f(0x3b3),'rBafp':function(_0x1b1a88){return _0x1b1a88();},'eZUgJ':function(_0x33dc16){return _0x33dc16();}},_0x30f21a=document[_0x1fe58f(0x15a)]('optionsContainer');if(_0x30f21a[_0x1fe58f(0x3c4)]['contains'](_0x4d6a51['TBXkM']))return;questionStartTime&&(questionStates[currentQuestionIndex][_0x1fe58f(0x3c6)]+=_0x4d6a51['kBXrN'](Date[_0x1fe58f(0x312)](),questionStartTime),questionStartTime=Date[_0x1fe58f(0x312)]()),selectedOption=_0x33c031,questionStates[currentQuestionIndex]['selectedAnswer']=_0x33c031,document[_0x1fe58f(0x280)](_0x4d6a51['GeNoL'])[_0x1fe58f(0x136)]((_0x3c5ecc,_0xa82a95)=>{const _0x50e455=_0x1fe58f;_0x3c5ecc['classList'][_0x50e455(0x19c)]('selected',_0x4d6a51[_0x50e455(0x378)](_0xa82a95,_0x33c031));}),_0x4d6a51[_0x1fe58f(0x12e)](currentMode,_0x4d6a51[_0x1fe58f(0x1c4)])||_0x4d6a51[_0x1fe58f(0x378)](currentMode,_0x4d6a51[_0x1fe58f(0x347)])?_0x4d6a51[_0x1fe58f(0x16d)](processAnswer):(_0x4d6a51[_0x1fe58f(0x12e)](questionStates[currentQuestionIndex][_0x1fe58f(0x22c)],_0x1fe58f(0x1b0))&&(questionStates[currentQuestionIndex][_0x1fe58f(0x22c)]=_0x4d6a51[_0x1fe58f(0x1b6)],stats[_0x1fe58f(0x37f)]++,stats[_0x1fe58f(0x2f3)]--),_0x4d6a51['eZUgJ'](updateQuestionNav)),_0x4d6a51['rBafp'](saveProgress);}function processAnswer(){const _0x48caf5=_0x2acfb5,_0x125c0a={'Hiiki':function(_0x47c612,_0x36ff01){return _0x47c612===_0x36ff01;},'WEkkx':function(_0x1e9669,_0x565cee){return _0x1e9669===_0x565cee;},'RkMMf':_0x48caf5(0x1b0),'KKyKY':_0x48caf5(0x334),'sYgzY':function(_0x304021){return _0x304021();},'JRsre':function(_0x86c5a0,_0x3ea3ec){return _0x86c5a0(_0x3ea3ec);},'FjRKB':function(_0x2440da){return _0x2440da();}},_0x30ceee=questionsData[currentQuestionIndex],_0x32126c=_0x30ceee['correct_choice_id'];if(_0x125c0a[_0x48caf5(0x2f6)](selectedOption,null))return;const _0xf61447=_0x30ceee[_0x48caf5(0x119)][selectedOption],_0x2505dd=_0xf61447['id']===_0x32126c;if(_0x125c0a['WEkkx'](questionStates[currentQuestionIndex][_0x48caf5(0x22c)],_0x125c0a[_0x48caf5(0x337)])){if(_0x48caf5(0x23a)!==_0x125c0a['KKyKY']){stats[_0x48caf5(0x37f)]++,stats[_0x48caf5(0x2f3)]--;if(_0x2505dd)stats[_0x48caf5(0x386)]++;else stats['incorrectAnswers']++;}else{_0x4c5d6c[_0x48caf5(0x15a)]('questionText')[_0x48caf5(0x1d3)]='No\x20questions\x20available\x20for\x20this\x20quiz.';return;}}questionStates[currentQuestionIndex][_0x48caf5(0x22c)]=_0x2505dd?_0x48caf5(0x149):_0x48caf5(0x225),_0x125c0a[_0x48caf5(0x2d4)](updateStats),_0x125c0a['JRsre'](showInlineFeedback,_0x2505dd),_0x125c0a[_0x48caf5(0x2aa)](updateQuestionNav);}function showInlineFeedback(_0xc8b572){const _0x49d86a=_0x2acfb5,_0x2bf44a={'sVeWV':_0x49d86a(0x21e),'WiKuS':function(_0x23bb9d,_0x483b86){return _0x23bb9d===_0x483b86;},'TzBob':_0x49d86a(0x149),'ZDkXK':function(_0x392206,_0x5c7112){return _0x392206===_0x5c7112;},'SaNrg':'incorrect','dclNI':function(_0x1255a9,_0x451aec){return _0x1255a9!==_0x451aec;},'nvrQB':_0x49d86a(0x1af),'xZmdF':_0x49d86a(0x3b3),'RiXSE':_0x49d86a(0x30c),'aBMOz':_0x49d86a(0x348)};if(_0x2bf44a[_0x49d86a(0x1a0)](currentMode,_0x2bf44a[_0x49d86a(0x315)])&&_0x2bf44a['dclNI'](currentMode,_0x2bf44a[_0x49d86a(0x344)]))return;const _0x3d1d87=document[_0x49d86a(0x15a)](_0x2bf44a[_0x49d86a(0x2ec)]),_0x4ee1a6=_0x3d1d87[_0x49d86a(0x280)](_0x49d86a(0x3d0)),_0x212b2d=questionsData[currentQuestionIndex],_0x18862d=_0x212b2d[_0x49d86a(0x135)];let _0x2c6688=_0x212b2d[_0x49d86a(0x119)][_0x49d86a(0x26f)](_0xfa220=>_0xfa220['id']===_0x18862d);_0x3d1d87[_0x49d86a(0x3c4)][_0x49d86a(0x28c)](_0x2bf44a[_0x49d86a(0x3d4)]),_0x4ee1a6['forEach']((_0x376825,_0x31f4fb)=>{const _0x45a9c8=_0x49d86a;_0x376825[_0x45a9c8(0x3c4)]['remove'](_0x2bf44a[_0x45a9c8(0xe3)]);if(_0x2bf44a['WiKuS'](_0x31f4fb,_0x2c6688))_0x376825[_0x45a9c8(0x3c4)][_0x45a9c8(0x28c)](_0x2bf44a[_0x45a9c8(0x36e)]);else{if(_0x2bf44a[_0x45a9c8(0x1e2)](_0x31f4fb,selectedOption)&&!_0xc8b572)_0x376825['classList']['add'](_0x2bf44a['SaNrg']);}}),showSolution();}function showSolution(){const _0x23ed16=_0x2acfb5,_0x10fb7c={'eNcqv':function(_0x58a80b,_0x2a31af){return _0x58a80b===_0x2a31af;},'LjBLu':_0x23ed16(0xc2),'OQwzY':function(_0x144235,_0x5eafb3){return _0x144235!==_0x5eafb3;},'EFglT':_0x23ed16(0x1af),'pdYvd':function(_0x240ec1,_0x548884){return _0x240ec1!==_0x548884;},'qdSeb':_0x23ed16(0x3b3),'cljlR':_0x23ed16(0x289),'btHEx':_0x23ed16(0x395),'JehhM':_0x23ed16(0x1b1),'uYAFc':_0x23ed16(0x39a),'koOrt':_0x23ed16(0x350),'PLsJk':_0x23ed16(0x29b)};if(_0x10fb7c[_0x23ed16(0x187)](currentMode,_0x10fb7c['EFglT'])&&_0x10fb7c[_0x23ed16(0x355)](currentMode,_0x10fb7c['qdSeb']))return;const _0xa3dffe=questionsData[currentQuestionIndex];document[_0x23ed16(0x15a)](_0x10fb7c[_0x23ed16(0x206)])['innerHTML']=_0xa3dffe['solution']||_0x23ed16(0x2c8);const _0x29c1ba=document['getElementById'](_0x10fb7c['btHEx']),_0x52beac=document[_0x23ed16(0x15a)](_0x10fb7c['JehhM']),_0x431413=_0xa3dffe[_0x23ed16(0x10c)];if(_0x431413){_0x29c1ba[_0x23ed16(0x3c4)]['remove'](_0x10fb7c[_0x23ed16(0x1f8)]);if(_0x431413[_0x23ed16(0x212)]('.m3u8'))setupVideo(_0x52beac,_0x431413);else _0x52beac['src']=_0x431413;}else _0x29c1ba[_0x23ed16(0x3c4)][_0x23ed16(0x28c)](_0x10fb7c[_0x23ed16(0x1f8)]);const _0x3281a1=document[_0x23ed16(0x15a)](_0x10fb7c[_0x23ed16(0x22f)]);_0x3281a1['innerHTML']='';_0xa3dffe[_0x23ed16(0x383)]&&(_0x3281a1['innerHTML']+='<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22'+_0xa3dffe[_0x23ed16(0x383)]+_0x23ed16(0x25c));_0xa3dffe['explanation_audio_hin']&&(_0x3281a1[_0x23ed16(0x1d3)]+='<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22'+_0xa3dffe['explanation_audio_hin']+_0x23ed16(0x25c));const _0x154e29=document[_0x23ed16(0x15a)](_0x10fb7c[_0x23ed16(0x23e)]);_0x154e29['innerHTML']='',_0xa3dffe[_0x23ed16(0x390)]&&_0xa3dffe[_0x23ed16(0x390)]['forEach'](_0x2174f7=>{const _0xf98a9f=_0x23ed16;if(_0x10fb7c[_0xf98a9f(0x38d)](_0xf98a9f(0xc2),_0x10fb7c['LjBLu'])){if(_0x2174f7)_0x154e29[_0xf98a9f(0x1d3)]+=_0xf98a9f(0x343)+_0x2174f7+_0xf98a9f(0x28e);}else _0x55b287[_0xf98a9f(0x1d3)]+=_0xf98a9f(0x316)+_0x1c5da2[_0xf98a9f(0x383)]+_0xf98a9f(0x25c);}),document[_0x23ed16(0x15a)]('solutionContainer')[_0x23ed16(0x3c4)][_0x23ed16(0x3d3)](_0x10fb7c['uYAFc']);}function submitQuiz(){const _0x44db80=_0x2acfb5,_0x2e8dd2={'KvBnl':function(_0x415e06,_0x4f2c90){return _0x415e06!==_0x4f2c90;},'aFDUN':_0x44db80(0x3c7),'gAgQI':_0x44db80(0x285),'KOqck':_0x44db80(0x225),'szXur':function(_0x19c097,_0x32fab4){return _0x19c097(_0x32fab4);},'agGUY':'Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?','VJwoV':function(_0x179fa4,_0x201f9){return _0x179fa4-_0x201f9;},'evRwZ':'quizPerformanceData','GllDz':function(_0x3d4044,_0x1bf512,_0x291d9e,_0xc4838,_0x4e2a6b){return _0x3d4044(_0x1bf512,_0x291d9e,_0xc4838,_0x4e2a6b);},'apjqf':function(_0x2a8a3b,_0x4b75ac){return _0x2a8a3b-_0x4b75ac;},'ldOCx':function(_0x2b3b08,_0xd75b0b){return _0x2b3b08+_0xd75b0b;}};if(timer)_0x2e8dd2[_0x44db80(0x2c1)](clearInterval,timer);if(!_0x2e8dd2[_0x44db80(0x2c1)](confirm,_0x2e8dd2[_0x44db80(0x205)]))return;isQuizCompleted=!![];let _0x1e977d=0x0,_0x4e984f=0x0;const _0x5110b3=_0x2e8dd2[_0x44db80(0x147)](Date['now'](),quizStartTime);questionsData[_0x44db80(0x136)]((_0x9204a5,_0x1d9b8b)=>{const _0x4d21b6=_0x44db80,_0x48c4a6={'loLQY':_0x4d21b6(0x24f)},_0x221ffb=questionStates[_0x1d9b8b];_0x2e8dd2[_0x4d21b6(0x25b)](_0x221ffb[_0x4d21b6(0x298)],null)&&(_0x9204a5['choices'][_0x221ffb[_0x4d21b6(0x298)]]['id']===_0x9204a5['correct_choice_id']?(_0x1e977d++,_0x221ffb['status']=_0x4d21b6(0x149)):_0x2e8dd2[_0x4d21b6(0x25b)](_0x2e8dd2[_0x4d21b6(0x2f8)],_0x2e8dd2['gAgQI'])?(_0x4e984f++,_0x221ffb[_0x4d21b6(0x22c)]=_0x2e8dd2[_0x4d21b6(0x307)]):_0x381001=_0x48c4a6[_0x4d21b6(0x154)]);});const _0x49e11b=JSON[_0x44db80(0x19d)](localStorage['getItem'](_0x2e8dd2['evRwZ']))||[];_0x49e11b[_0x44db80(0x174)]({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date[_0x44db80(0x312)](),'totalTime':_0x5110b3,'stats':{'correct':_0x1e977d,'incorrect':_0x4e984f,'notAttempted':questionsData[_0x44db80(0x15b)]-(_0x1e977d+_0x4e984f)}}),localStorage[_0x44db80(0x207)](_0x2e8dd2[_0x44db80(0x112)],JSON[_0x44db80(0x24b)](_0x49e11b)),stats[_0x44db80(0x386)]=_0x1e977d,stats['incorrectAnswers']=_0x4e984f,markQuizAsCompleted(),_0x2e8dd2[_0x44db80(0x1ff)](showPerformanceAnalysis,_0x1e977d,_0x4e984f,_0x2e8dd2[_0x44db80(0x1ee)](questionsData[_0x44db80(0x15b)],_0x2e8dd2[_0x44db80(0x252)](_0x1e977d,_0x4e984f)),_0x5110b3);}function showPerformanceAnalysis(_0x150060,_0x53dbcc,_0x3ab803,_0x5cccc6){const _0x1d6dd6=_0x2acfb5,_0x3b698a={'dZPie':_0x1d6dd6(0x19e),'APPLo':function(_0x4b94dc,_0x1a752f){return _0x4b94dc>_0x1a752f;},'jTQzx':function(_0x2e7907,_0x5907a6){return _0x2e7907+_0x5907a6;},'YgnJY':function(_0x4343a6,_0x59b16d){return _0x4343a6*_0x59b16d;},'BwhLm':function(_0x12831f,_0x33d962){return _0x12831f/_0x33d962;},'khfHp':function(_0xc53af9,_0x4f1381){return _0xc53af9+_0x4f1381;},'jigxn':function(_0xd21fed,_0x18d291){return _0xd21fed*_0x18d291;},'YssZd':_0x1d6dd6(0x118),'Gfsgp':function(_0x444cb7,_0x23b281){return _0x444cb7-_0x23b281;},'Pgtsv':_0x1d6dd6(0x32c),'Eakit':function(_0xaf1859,_0x4941cc){return _0xaf1859%_0x4941cc;},'yvGXi':'totalTimeResult','fuuBD':function(_0xea4cfa,_0x363543){return _0xea4cfa/_0x363543;},'LzqCb':function(_0x331455,_0x5d8917){return _0x331455/_0x5d8917;},'RyrKo':function(_0xd8acb3,_0x34f42a){return _0xd8acb3%_0x34f42a;},'EkmXI':_0x1d6dd6(0x39a)},_0xa7d352=document[_0x1d6dd6(0x15a)](_0x3b698a[_0x1d6dd6(0x254)]),_0x374aa1=_0x3b698a[_0x1d6dd6(0x2a3)](_0x3b698a[_0x1d6dd6(0x2d7)](_0x150060,_0x53dbcc),0x0)?Math[_0x1d6dd6(0x1e0)](_0x3b698a[_0x1d6dd6(0x1cc)](_0x3b698a[_0x1d6dd6(0x2ee)](_0x150060,_0x3b698a[_0x1d6dd6(0x3a0)](_0x150060,_0x53dbcc)),0x64)):0x0,_0x209761=_0x3b698a[_0x1d6dd6(0x226)](0x2,Math['PI'])*0x41,_0x404191=document['getElementById'](_0x3b698a[_0x1d6dd6(0x2ed)]);_0x404191[_0x1d6dd6(0x209)]['strokeDasharray']=_0x209761+'\x20'+_0x209761,_0x404191[_0x1d6dd6(0x209)]['strokeDashoffset']=_0x3b698a['Gfsgp'](_0x209761,_0x374aa1/0x64*_0x209761),document[_0x1d6dd6(0x15a)]('accuracyScore')[_0x1d6dd6(0x2e5)]=_0x374aa1+'%',document[_0x1d6dd6(0x15a)](_0x3b698a[_0x1d6dd6(0x2d0)])[_0x1d6dd6(0x2e5)]=questionsData[_0x1d6dd6(0x15b)],document[_0x1d6dd6(0x15a)]('correctResult')['textContent']=_0x150060,document[_0x1d6dd6(0x15a)](_0x1d6dd6(0x2ca))[_0x1d6dd6(0x2e5)]=_0x53dbcc,document[_0x1d6dd6(0x15a)]('notAttemptedResult')[_0x1d6dd6(0x2e5)]=_0x3ab803;const _0x1e1312=Math['floor'](_0x3b698a['BwhLm'](_0x5cccc6,0xea60)),_0x1f9d7a=Math[_0x1d6dd6(0x3a6)](_0x3b698a[_0x1d6dd6(0x243)](_0x5cccc6,0xea60)/0x3e8);document[_0x1d6dd6(0x15a)](_0x3b698a[_0x1d6dd6(0xec)])['textContent']=_0x1e1312+':'+_0x1f9d7a[_0x1d6dd6(0x38b)]()[_0x1d6dd6(0x1e8)](0x2,'0');const _0x4a3ab9=_0x3b698a[_0x1d6dd6(0x2e6)](_0x5cccc6,questionsData[_0x1d6dd6(0x15b)]),_0x57100d=Math[_0x1d6dd6(0x3a6)](_0x3b698a['LzqCb'](_0x4a3ab9,0xea60)),_0x391824=Math['floor'](_0x3b698a[_0x1d6dd6(0x2e6)](_0x3b698a['RyrKo'](_0x4a3ab9,0xea60),0x3e8));document[_0x1d6dd6(0x15a)]('avgTimeResult')[_0x1d6dd6(0x2e5)]=_0x57100d+':'+_0x391824['toString']()[_0x1d6dd6(0x1e8)](0x2,'0'),_0xa7d352[_0x1d6dd6(0x3c4)]['remove'](_0x3b698a['EkmXI']);}function closePerformanceModal(){const _0x65ce8d=_0x2acfb5,_0x307e33={'dAvdD':_0x65ce8d(0x19e)};document[_0x65ce8d(0x15a)](_0x307e33['dAvdD'])['classList'][_0x65ce8d(0x28c)]('hidden');}function reviewQuestions(){const _0x548ced=_0x2acfb5,_0xb57294={'eKmTH':_0x548ced(0x110),'dMFJV':_0x548ced(0x278),'ebfyf':function(_0x100fe4,_0x2f4ce0){return _0x100fe4+_0x2f4ce0;},'LBiRA':function(_0x29d81){return _0x29d81();},'kHSIF':function(_0x31c544,_0x1e7069){return _0x31c544===_0x1e7069;},'KLCjR':function(_0x55b284,_0x2de2b4){return _0x55b284===_0x2de2b4;},'krEPg':_0x548ced(0x36b),'HlWQv':'border-red-500','MHPnX':'Not\x20Attempted','PcoST':function(_0x918b74,_0x1779e6){return _0x918b74===_0x1779e6;},'xVamw':_0x548ced(0x149),'okMyK':_0x548ced(0x1d9),'rsPTT':_0x548ced(0x231),'uscwO':_0x548ced(0xee),'npAMb':_0x548ced(0x225),'VfFms':_0x548ced(0x2fe),'dxvhg':function(_0x30a614,_0x15e554){return _0x30a614===_0x15e554;},'lkAjn':_0x548ced(0x3de),'tVkDp':_0x548ced(0x15f),'jYNzl':'questionReviewSection','YhCcX':_0x548ced(0x39a),'GNeyg':_0x548ced(0x1c6),'KNcDJ':function(_0x2cbb5f){return _0x2cbb5f();}};document[_0x548ced(0x15a)](_0xb57294[_0x548ced(0x16a)])[_0x548ced(0x3c4)][_0x548ced(0x3d3)](_0xb57294[_0x548ced(0x1ea)]);const _0xedc2a9=document['getElementById'](_0xb57294[_0x548ced(0x35e)]);_0xedc2a9['innerHTML']='',questionsData['forEach']((_0x2fd873,_0x5935c8)=>{const _0x340ccf=_0x548ced,_0x133b01={'eCgEu':_0xb57294['eKmTH'],'tYcjQ':_0xb57294[_0x340ccf(0x1db)],'fYMTP':function(_0x4c9983,_0x57218d){return _0xb57294['ebfyf'](_0x4c9983,_0x57218d);},'EgfDO':function(_0x5dca71){return _0xb57294['LBiRA'](_0x5dca71);},'yhuVS':function(_0x5aeb02,_0x562431){const _0xf9b6de=_0x340ccf;return _0xb57294[_0xf9b6de(0x108)](_0x5aeb02,_0x562431);},'kmcIw':function(_0x392c76,_0x462b8f){const _0x3817ec=_0x340ccf;return _0xb57294[_0x3817ec(0x189)](_0x392c76,_0x462b8f);},'zBVzb':_0xb57294[_0x340ccf(0x2b4)],'SkDlF':_0x340ccf(0x304),'ZwXJN':_0xb57294[_0x340ccf(0x328)],'lghTg':function(_0x37ecc5,_0x146038){return _0x37ecc5+_0x146038;}},_0xf9edd0=questionStates[_0x5935c8],_0x4a620e=_0x2fd873['correct_choice_id'];let _0x5df5f1=_0x340ccf(0x2da),_0x5b7726=_0xb57294[_0x340ccf(0x124)];if(_0xf9edd0[_0x340ccf(0x298)]!==null){const _0xd2a1e7=_0x2fd873[_0x340ccf(0x119)][_0xf9edd0[_0x340ccf(0x298)]];if(_0xb57294[_0x340ccf(0x358)](_0xd2a1e7['id'],_0x4a620e))_0x5df5f1=_0xb57294[_0x340ccf(0x13c)],_0x5b7726=_0xb57294[_0x340ccf(0x2f0)];else{if(_0xb57294[_0x340ccf(0x108)](_0xb57294[_0x340ccf(0x160)],_0xb57294['uscwO'])){const _0x360c0f=_0x28c00f['getElementById'](_0x133b01[_0x340ccf(0x2ad)]);_0x360c0f[_0x340ccf(0x1d3)]='';for(let _0x14eb4f=0x0;_0x14eb4f<_0x381f86[_0x340ccf(0x15b)];_0x14eb4f++){const _0x3095a3=_0x2918a0[_0x340ccf(0x382)](_0x133b01[_0x340ccf(0x2c9)]);_0x3095a3[_0x340ccf(0x2e5)]=_0x133b01[_0x340ccf(0x21b)](_0x14eb4f,0x1),_0x3095a3['className']=_0x340ccf(0x379),_0x3095a3[_0x340ccf(0x134)]=()=>_0x32caed(_0x14eb4f),_0x3095a3['id']=_0x340ccf(0x165)+_0x14eb4f,_0x360c0f[_0x340ccf(0x138)](_0x3095a3);}_0x133b01['EgfDO'](_0x273733);}else _0x5df5f1=_0xb57294['npAMb'],_0x5b7726=_0xb57294[_0x340ccf(0x15c)];}}const _0x2b5ea6=document['createElement'](_0x340ccf(0x1f4));_0x2b5ea6[_0x340ccf(0x294)]=_0x340ccf(0x13b)+_0x5df5f1;let _0x51ab6a=(_0x2fd873[_0x340ccf(0x119)]||[])[_0x340ccf(0x38c)]((_0x321330,_0x1b0b40)=>{const _0x539c6=_0x340ccf,_0x49f6c5=_0x133b01[_0x539c6(0x309)](_0xf9edd0[_0x539c6(0x298)],_0x1b0b40),_0x4d6678=_0x133b01[_0x539c6(0x3a3)](_0x321330['id'],_0x4a620e);let _0x4e9428=_0x133b01[_0x539c6(0x11d)];if(_0x4d6678)_0x4e9428=_0x133b01[_0x539c6(0x223)];else{if(_0x49f6c5)_0x4e9428=_0x133b01[_0x539c6(0xfb)];}return _0x539c6(0x177)+_0x4e9428+_0x539c6(0x125)+String['fromCharCode'](_0x133b01[_0x539c6(0x26c)](0x41,_0x1b0b40))+_0x539c6(0x385)+_0x321330['text']+'</span></div>';})['join']('');const _0x80328c=_0x2fd873[_0x340ccf(0x10c)]?_0x340ccf(0x1da)+_0x5935c8+_0x340ccf(0x1d1)+_0x2fd873[_0x340ccf(0x10c)]+'\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>':'';let _0xd2e450='';if(_0x2fd873['explanation_audio_eng'])_0xd2e450+=_0x340ccf(0x353)+_0x2fd873[_0x340ccf(0x383)]+_0x340ccf(0x25c);if(_0x2fd873['explanation_audio_hin'])_0xd2e450+=_0x340ccf(0x24d)+_0x2fd873[_0x340ccf(0x12f)]+'\x22\x20controls\x20class=\x22w-full\x22></audio></div>';let _0x11cda0=(_0x2fd873[_0x340ccf(0x390)]||[])[_0x340ccf(0x38c)](_0x2c48f4=>_0x2c48f4?_0x340ccf(0x343)+_0x2c48f4+'\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>':'')[_0x340ccf(0x35b)]('');_0x2b5ea6[_0x340ccf(0x1d3)]=_0x340ccf(0x116)+_0xb57294[_0x340ccf(0x1fb)](_0x5935c8,0x1)+_0x340ccf(0x377)+(_0xb57294[_0x340ccf(0x1b2)](_0x5df5f1,_0x340ccf(0x149))?_0xb57294[_0x340ccf(0x15d)]:_0xb57294[_0x340ccf(0x189)](_0x5df5f1,_0x340ccf(0x225))?_0x340ccf(0x1ab):_0x340ccf(0x164))+_0x340ccf(0xf7)+_0x5b7726+'</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>'+_0x2fd873['text']+_0x340ccf(0x19f)+_0x51ab6a+_0x340ccf(0x2be)+(_0x2fd873[_0x340ccf(0x126)]||_0xb57294[_0x340ccf(0x314)])+_0x340ccf(0x1f2)+_0x80328c+_0x340ccf(0x21f)+_0xd2e450+_0x340ccf(0x21f)+_0x11cda0+'\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>',_0xedc2a9[_0x340ccf(0x138)](_0x2b5ea6);}),_0xb57294['KNcDJ'](initializeReviewVideos);}function initializeReviewVideos(){const _0x1bd5e6=_0x2acfb5,_0x442b73={'wjMpE':function(_0x82ce71,_0x3b1aa2){return _0x82ce71+_0x3b1aa2;},'luUmE':'div','GGifX':_0x1bd5e6(0xcf),'ShMsp':_0x1bd5e6(0x39a),'ISrSP':function(_0x5c75ac,_0x2ff192){return _0x5c75ac!==_0x2ff192;},'LwAoZ':_0x1bd5e6(0x2ba),'JoKYB':_0x1bd5e6(0xbd),'IdqBF':function(_0xbdac6d,_0x3aa1f9,_0x12ecf4){return _0xbdac6d(_0x3aa1f9,_0x12ecf4);},'NwUpP':_0x1bd5e6(0x3c2),'Gjcqs':_0x1bd5e6(0x31c)};document[_0x1bd5e6(0x280)](_0x442b73['Gjcqs'])[_0x1bd5e6(0x136)](_0x39e016=>{const _0x4000e7=_0x1bd5e6,_0x5965ad={'Eiraz':_0x442b73['ShMsp']};if(_0x442b73[_0x4000e7(0x103)](_0x442b73[_0x4000e7(0x211)],_0x442b73[_0x4000e7(0x381)])){const _0x8932c0=_0x39e016[_0x4000e7(0x265)][_0x4000e7(0x18d)];if(_0x8932c0&&_0x8932c0[_0x4000e7(0x212)](_0x4000e7(0x39c)))_0x442b73['IdqBF'](setupVideo,_0x39e016,_0x8932c0);else{if(_0x8932c0){if(_0x442b73['NwUpP']!=='lObGA'){const _0xa591b0=_0x13fea6[_0x4000e7(0x399)](_0x442b73[_0x4000e7(0x290)](0x41,_0x36e3a4)),_0x441d8f=_0x48b73c===_0x49fea6,_0x47aee5=_0xb414d5[_0x4000e7(0x382)](_0x442b73['luUmE']);_0x47aee5[_0x4000e7(0x1d3)]=_0x4000e7(0x28d)+(_0x441d8f?_0x4000e7(0x21e):'')+'\x22\x20data-option-index=\x22'+_0x5d7a45+'\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>'+_0xa591b0+_0x4000e7(0x2f9)+(_0x4938ea[_0x4000e7(0x3dc)]||_0x442b73[_0x4000e7(0x30d)]+(_0x3783bc+0x1))+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20',_0x4ecaad['appendChild'](_0x47aee5);}else _0x39e016[_0x4000e7(0x18d)]=_0x8932c0;}}}else _0x15d33e['getElementById'](_0x4000e7(0x19e))[_0x4000e7(0x3c4)][_0x4000e7(0x28c)](_0x5965ad[_0x4000e7(0x195)]);});}function retakeQuiz(){const _0x38d24a=_0x2acfb5,_0x292f71={'kQeve':_0x38d24a(0x1d0),'YYEom':function(_0x220d37,_0x48fa07){return _0x220d37===_0x48fa07;},'mbmth':'CzKeM','VMUbh':'nUApW','zHsHO':_0x38d24a(0x306),'PNkaK':function(_0x4111f9){return _0x4111f9();}};confirm(_0x292f71[_0x38d24a(0x246)])&&(window[_0x38d24a(0xd4)][_0x38d24a(0x30e)][_0x38d24a(0x3b0)](_0x38d24a(0x217))&&(_0x292f71[_0x38d24a(0x260)](_0x292f71[_0x38d24a(0x190)],_0x292f71['VMUbh'])?_0x11a868[_0x43ff0a[_0x38d24a(0x346)]][_0x38d24a(0x33a)]=!![]:localStorage[_0x38d24a(0x130)](_0x292f71[_0x38d24a(0x2b7)])),_0x292f71['PNkaK'](clearProgress),location[_0x38d24a(0x3d9)]());}function loadBookmarkedQuestions(){const _0x2ec037=_0x2acfb5,_0x200d03={'ldVPV':function(_0x1308de,_0x14db97){return _0x1308de===_0x14db97;},'MpECl':_0x2ec037(0x149),'vfrQV':'Correct','wmQNB':_0x2ec037(0x225),'odoXf':_0x2ec037(0x2fe),'TCCnw':function(_0x41eacc,_0x18254c){return _0x41eacc-_0x18254c;},'wFxOM':function(_0x39f0bd){return _0x39f0bd();},'oTivB':function(_0x4b14cc,_0x1b526c){return _0x4b14cc===_0x1b526c;},'RUmCH':_0x2ec037(0x2e4),'KhhsS':function(_0x1af806,_0x45dd18){return _0x1af806<_0x45dd18;},'jKKNw':_0x2ec037(0x14c),'tQahK':_0x2ec037(0x169)},_0x47f701=JSON[_0x2ec037(0x19d)](localStorage[_0x2ec037(0xc6)](_0x200d03[_0x2ec037(0x299)]))||[];_0x47f701['forEach'](_0x49b756=>{const _0x591efc=_0x2ec037,_0x47e95c={'vrHsS':function(_0x581348,_0x4a126c){const _0x9aa122=_0x24b8;return _0x200d03[_0x9aa122(0x311)](_0x581348,_0x4a126c);},'yINBz':function(_0x146af5){const _0x1e0637=_0x24b8;return _0x200d03[_0x1e0637(0x29e)](_0x146af5);}};if(_0x49b756['quizFile'][_0x591efc(0x212)](quizName[_0x591efc(0x37b)]()[_0x591efc(0x115)](/ /g,'-'))){if(_0x200d03[_0x591efc(0x2b0)]('HfXnf',_0x200d03[_0x591efc(0x10d)]))_0x200d03[_0x591efc(0x2a0)](_0x49b756[_0x591efc(0x346)],questionsData[_0x591efc(0x15b)])&&(_0x591efc(0x2a9)!==_0x200d03[_0x591efc(0x208)]?questionStates[_0x49b756['questionIndex']][_0x591efc(0x33a)]=!![]:(_0x122a0d&&(_0x33511e[_0x31ff23][_0x591efc(0x3c6)]+=_0x47e95c[_0x591efc(0xe6)](_0x43a884[_0x591efc(0x312)](),_0x4409b1)),_0x59b891--,_0x47e95c['yINBz'](_0x5902bf),_0x47e95c[_0x591efc(0x2e3)](_0xe8b139)));else{const _0x1c24c8=_0x34e05c[_0x591efc(0x119)][_0x2e8598[_0x591efc(0x298)]];_0x200d03[_0x591efc(0x2ae)](_0x1c24c8['id'],_0x36da49)?(_0x45d821=_0x200d03['MpECl'],_0xa7e6d8=_0x200d03[_0x591efc(0x27f)]):(_0x4e5046=_0x200d03[_0x591efc(0x1d8)],_0xd2848e=_0x200d03['odoXf']);}}});}function toggleBookmark(){const _0x347b69=_0x2acfb5,_0x53e23b={'GaSTg':_0x347b69(0x139),'PBvDT':function(_0x10b07c,_0x4642db){return _0x10b07c+_0x4642db;},'opalA':function(_0x5ac373,_0x5dafb8){return _0x5ac373+_0x5dafb8;},'gDxhq':function(_0x2f4585,_0x352ea6){return _0x2f4585!==_0x352ea6;},'oKLgf':'EIcLL','LqiVb':_0x347b69(0x169),'oGFIb':function(_0x14a31a){return _0x14a31a();}},_0x202112=!questionStates[currentQuestionIndex]['bookmarked'];questionStates[currentQuestionIndex]['bookmarked']=_0x202112;let _0x4fba38=JSON[_0x347b69(0x19d)](localStorage[_0x347b69(0xc6)]('bookmarkedQuestions'))||[];if(_0x202112){const _0x1e6788={'quizName':quizName,'quizFile':window['location']['pathname']['split']('/')[_0x347b69(0x323)](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date[_0x347b69(0x312)]()};_0x4fba38[_0x347b69(0x174)](_0x1e6788);}else{if(_0x53e23b['gDxhq'](_0x53e23b[_0x347b69(0xba)],_0x53e23b[_0x347b69(0xba)])){const _0x21257c=_0x405e39['floor'](_0x4a6811/0x3c),_0x5bbc7a=_0x5b913a%0x3c;_0x23b0de[_0x347b69(0x15a)](_0x53e23b['GaSTg'])[_0x347b69(0x2e5)]=_0x53e23b[_0x347b69(0xef)](_0x53e23b['opalA'](_0x21257c,':'),_0x5bbc7a['toString']()[_0x347b69(0x1e8)](0x2,'0'));}else _0x4fba38=_0x4fba38[_0x347b69(0x3b1)](_0x19c4db=>!(_0x19c4db['quizFile'][_0x347b69(0x212)](quizName['toLowerCase']()[_0x347b69(0x115)](/ /g,'-'))&&_0x19c4db[_0x347b69(0x346)]===currentQuestionIndex));}localStorage[_0x347b69(0x207)](_0x53e23b['LqiVb'],JSON[_0x347b69(0x24b)](_0x4fba38)),_0x53e23b[_0x347b69(0x1df)](updateBookmarkButton),_0x53e23b[_0x347b69(0x1df)](updateQuestionNav);}function updateBookmarkButton(){const _0xc62f6c=_0x2acfb5,_0x3375d4={'SVePd':_0xc62f6c(0x21a),'JrTlz':_0xc62f6c(0xff),'lwAKf':'Bookmarked','wkSGV':_0xc62f6c(0x219)},_0x3dff5c=document['getElementById']('bookmarkBtn'),_0x44a3a9=document['getElementById'](_0xc62f6c(0x117)),_0x59f97c=questionStates[currentQuestionIndex]['bookmarked'];_0x3dff5c[_0xc62f6c(0x294)]=_0x59f97c?_0x3375d4[_0xc62f6c(0x318)]:_0x3375d4[_0xc62f6c(0x2e7)],_0x44a3a9[_0xc62f6c(0x2e5)]=_0x59f97c?_0x3375d4[_0xc62f6c(0x2f1)]:_0x3375d4[_0xc62f6c(0x24e)];}function toggleMarkForReview(){const _0x531f61=_0x2acfb5,_0x5127b2={'uOvbe':function(_0x19bb19){return _0x19bb19();},'STWZT':function(_0xacb243){return _0xacb243();}};questionStates[currentQuestionIndex][_0x531f61(0x142)]=!questionStates[currentQuestionIndex][_0x531f61(0x142)],_0x5127b2[_0x531f61(0x332)](updateMarkReviewButton),_0x5127b2[_0x531f61(0x247)](updateQuestionNav);}function updateMarkReviewButton(){const _0x3ac6c5=_0x2acfb5,_0x50dad7={'xEqyM':_0x3ac6c5(0x1a5),'aEDUM':_0x3ac6c5(0x249),'sHrCQ':_0x3ac6c5(0x18e),'DvzBe':_0x3ac6c5(0x1d7),'hSjSK':_0x3ac6c5(0x2db),'HAklh':'Mark\x20for\x20Review'},_0x39e67c=document['getElementById'](_0x50dad7['xEqyM']),_0x4193d7=document[_0x3ac6c5(0x15a)](_0x50dad7['aEDUM']),_0x30a9c6=questionStates[currentQuestionIndex][_0x3ac6c5(0x142)];_0x39e67c[_0x3ac6c5(0x294)]=_0x30a9c6?_0x50dad7[_0x3ac6c5(0x39d)]:_0x50dad7[_0x3ac6c5(0x34d)],_0x4193d7['textContent']=_0x30a9c6?_0x50dad7[_0x3ac6c5(0x106)]:_0x50dad7['HAklh'];}function _0x24e6(){const _0x4e0dc0=['Alopecia','You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','100\x20mg\x20daily\x20for\x2014\x20days','75%\x20by\x20December\x202018','World\x20Health\x20Organization','Pgtsv','Weight\x20for\x20length\x20<\x20–3\x20SD','<ul>\x0a<li><strong>Ministry\x20of\x20Health\x20and\x20Family\x20Welfare</strong>\x20has\x20released\x20Operational\x20Guidelines\x20for\x20<strong>Planning\x20and\x20Implementation\x20of\x20Family\x20Participatory\x20Care\x20(FPC)</strong>\x20for\x20improving\x20newborn\x20health.</li>\x0a<li><strong>FPC</strong>\x20provides\x20for\x20partnership\x20between\x20health\x20care\x20staff\x20and\x20families\x20for\x20care\x20of\x20sick\x20newborn.</li>\x0a<li>Under\x20FPC,\x20the\x20capacities\x20of\x20<strong>parents-attendants</strong>\x20are\x20built\x20in\x20newborn\x20care\x20through\x20a\x20<strong>structured\x20training\x20programme</strong>\x20(audio\x20-visual\x20module\x20and\x20a\x20training\x20guide).</li>\x0a<li>The\x20staff\x20at\x20newborn\x20care\x20unit\x20will\x20provide\x20continuous\x20supervision\x20and\x20support.</li>\x0a<li>Provisions\x20for\x20infrastructure\x20and\x20logistics\x20strengthening\x20required\x20for\x20implementing\x20FPC\x20are\x20ensured\x20in\x20the\x20annual\x20state\x20Program\x20Implementation\x20Plan\x20(PIP).</li>\x0a<li>In\x20this\x20regard,\x20FPC\x20has\x20emerged\x20as\x20an\x20important\x20concept\x20of\x20health\x20care\x20which\x20provides\x20for\x20<strong>partnership\x20between\x20health\x20care\x20staff\x20and\x20families</strong>\x20in\x20care\x20of<strong>\x20sick\x20newborn</strong>\x20admitted\x20in\x20the\x20NICU.\x20The\x20move\x20is\x20expected\x20to\x20bring\x20down\x20infant\x20mortality.</li>\x0a</ul>','info','sYgzY','jCwOq','jbcRk','jTQzx','iSXiY','click','not-attempted','Marked','<ul>\x0a<li><strong>Etelcalcetide</strong>\x20is\x20a\x20<strong>calcimimetic\x20agent\x20</strong>that\x20modulates\x20the\x20<strong>calcium-sensing\x20receptor\x20(CaSR)</strong>.</li>\x0a<li><strong>It\x20enhances\x20the\x20activation\x20of\x20the\x20receptor\x20by\x20extracellular\x20calcium\x20after\x20it\x20binds\x20to\x20the\x20CaSR.</strong></li>\x0a<li>It\x20is\x20currently\x20indicated\x20for\x20<strong>secondary\x20hyperparathyroidism\x20for\x20patients\x20with\x20chronic\x20kidney\x20disease\x20(CKD)\x20who\x20are\x20on\x20hemodialysis</strong>.</li>\x0a<li>This\x20drug\x20<strong>has\x20not\x20been\x20studied</strong>\x20in\x20those\x20with\x20parathyroid\x20carcinoma,\x20primary\x20hyperparathyroidism\x20or\x20CKD,\x20who\x20are\x20not\x20on\x20hemodialysis.</li>\x0a<li>It\x20is\x20contraindicated\x20in\x20history\x20of\x20hypersensitivity\x20to\x20the\x20drug.</li>\x0a<li>Some\x20adverse\x20effects\x20have\x20been\x20reported\x20like\x20<strong>serious\x20hypocalcemia</strong>,\x20upper\x20GI\x20bleeding,\x20muscle\x20spasms,\x20nausea,\x20etc.</li>\x0a<li><strong>Update:\x20</strong>This\x20drug\x20was\x20approved\x20for\x20usage\x20by\x20the\x20U.S.\x20FDA\x20in\x202017\x20and\x20is\x20marketed\x20as\x20Parsabiv.\x20In\x20Europe,\x20it\x20was\x20approved\x20in\x202016.</li>\x0a</ul>','The\x20novel\x20prostaglandin\x20agonist\x20called\x20latanoprostene\x20bunod\x20is\x20to\x20be\x20used\x20for\x20which\x20of\x20the\x20following\x20purposes?','EAiUE','Children\x20(12\x20–\x2023\x20months\x20of\x20age)','Induction\x20of\x20labor','REM\x20sleep\x20behavior\x20disorder','A\x2060\x20year\x20old\x20female\x20is\x20diagnosed\x20with\x20melanoma.\x20On\x20examination,\x20a\x20palpable\x20lymph\x20node\x20was\x20present\x20in\x20the\x20posterior\x20triangle.\x20Biopsy\x20revealed\x20presence\x20of\x20tumour\x20cells.\x20Which\x20of\x20the\x20following\x20drugs\x20used\x20in\x20this\x20condition\x20is\x20a\x20MEK\x20inhibitor?','yINBz','HfXnf','textContent','fuuBD','JrTlz','UDXFO','140/90\x20mmHg','MkuvO','Small\x20bite,\x20big\x20threat','RiXSE','YssZd','BwhLm','30.7%','okMyK','lwAKf','dMurh','notAttempted','eAcCx','The\x20drug\x20bortezomib\x20has\x20been\x20proved\x20to\x20be\x20at\x20the\x20centre\x20of\x20treatment\x20of\x20multiple\x20myeloma.\x20This\x20injectable\x20drug\x20was\x20recently\x20approved\x20in\x20India\x20for\x20the\x20treatment\x20of\x20which\x20of\x20the\x20following\x20conditions?','Hiiki','Intercourse\x20with\x20a\x20girl,\x20above\x2018\x20years\x20of\x20age,\x20with\x20consent','aFDUN','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>','toOUu','warn','It\x20is\x20administered\x20in\x20two\x20doses,\x206\x20months\x20apart','Visnd','Incorrect','qaksq','kGvsN','GTFCC\x20will\x20support\x20the\x20countries\x20to\x20reduce\x20cholera\x20deaths\x20by\x2060\x20percent','totalTime','KFWJs','border-green-500','Introduction\x20of\x20Typhoid\x20conjugate\x20vaccine\x20to\x20infants\x20above\x201\x20month\x20of\x20age','customQuizData','KOqck','XolqX','yhuVS','Gaucher’s\x20disease','Nephrotoxicity','optionsContainer','GGifX','pathname','25.7%','pTWgH','TCCnw','now','wkoAB','tVkDp','nvrQB','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22','UFQUM','SVePd','true','key','hierarchy','video[data-src]','xLnIx','loadSource','display','nEHAP','xytHV','<p><strong>Finger-feeding</strong>\x20is\x20optimally\x20indicated\x20for\x20<strong>short-term\x20use</strong>\x20and\x20may\x20<strong>improve\x20breastfeeding\x20rates</strong>\x20at\x20discharge.\x20Hence,\x20statement\x202\x20is\x20correct.\u00a0It\x20is\x20indicated\x20in\x20<strong>neurologically\x20compromised</strong>\x20and\x20<strong>preterm\x20infants</strong>\x20for\x20a\x20short\x20period.</p>\x0a<p>The\x20image\x20below\x20depicts\x20how\x20finger-feeding\x20is\x20done.</p>','pop','<ul>\x0a<li><strong>Teriflunomide</strong>\x20is\x20used\x20in\x20<strong>disease-modifying\x20therapy</strong>\x20for\x20relapsing\x20forms\x20of\x20<strong>multiple\x20sclerosis\x20(MS).</strong></li>\x0a<li>This\x20drug\x20is\x20a\x20tetrapeptide\x20epoxyketone\x20proteasome\x20inhibitor\x20and\x20it\x20inhibits\x20the\x20mitochondrial\x20enzyme\x20<strong>dihydro-orotate\x20dehydrogenase</strong>.</li>\x0a<li>It\x20reduces\x20the\x20attack\x20rate\x20and\x20improves\x20all\x20measures\x20of\x20disease\x20severity\x20in\x20MS\x20patients.</li>\x0a<li>It\x20is\x20given\x20as\x20a\x20<strong>tablet</strong>\x20at\x20a\x20dose\x20of\x2014mg\x20or\x207mg\x20per\x20day.</li>\x0a<li>Its\x20main\x20adverse\x20effects\x20are\x20<strong>alopecia</strong>,\x20headache,\x20nausea,\x20phosphatemia\x20and\x20diarrhea,\x20amongst\x20others.</li>\x0a<li><strong>Update:\x20</strong>It\x20was\x20approved\x20in\x20India\x20for\x20this\x20usage\x20in\x202017,\x20although\x20it\x20has\x20been\x20in\x20use\x20during\x20in\x20Europe\x20and\x20the\x20US\x20for\x20a\x20few\x20years\x20now.</li>\x0a</ul>','VZphy','Not\x20recommended\x20in\x20patients\x20undergoing\x20dialysis','MlESG','HlWQv','The\x20‘WATCH’\x20category,\x20with\x20regards\x20to\x20the\x20newly\x20proposed\x20WHO\x20essential\x20medicines\x20list\x20refers\x20to\x20antibiotics\x20which\x20are:','startAt','It\x20is\x20used\x20in\x20treatment\x20of\x20acromegaly','totalQuestionsResult','Class\x20A\x20–\x20High\x20risk','PeCHc','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','lGTLo','Early\x20cardiac\x20troponin\x20measurement,\x20within\x206\x20hours\x20of\x20arrival','uOvbe','ErHBg','vsMPU','<ul>\x0a<li>According\x20to\x20the\x20recent\x20<strong>ICOPE\x20guidelines</strong>\x20released\x20by\x20WHO<strong>,\x20Multimodal\x20exercise</strong>,\x20including\x20progressive\x20strength\x20resistance\x20training\x20is\x20recommended\x20to\x20improve\x20musculoskeletal\x20function,\x20mobility\x20and\x20vitality.</li>\x0a<li>Other\x20exercise\x20components\x20such\x20as\x20balance,\x20flexibility\x20and\x20aerobic\x20training\x20should\x20be\x20recommended\x20for\x20older\x20people\x20with\x20declining\x20physical\x20capacity,\x20measured\x20by\x20gait\x20speed,\x20grip\x20strength\x20and\x20other\x20physical\x20performance\x20measures</li>\x0a</ul>\x0a<p><strong>Other\x20options:</strong></p>\x0a<ul>\x0a<li><strong>Option\x20a</strong>:\x20Integrated\x20health\x20care\x20provided\x20as\x20per\x20ICOPE\x20will\x20enable\x20an\x20older\x20person\x20to\x20maintain\x20their\x20<strong>physical</strong>\x20and\x20<strong>mental\x20capacities.</strong></li>\x0a<li><strong>Option\x20b:\x20</strong>Community\x20outreach\x20and\x20home-based\x20interventions\x20are\x20recommended.</li>\x0a<li><strong>Option\x20d:</strong>\x20Support\x20for\x20self-management\x20is\x20provided\x20for\x20the\x20older\x20people.</li>\x0a</ul>','disabled','RkMMf','EZALH','GRvmX','bookmarked','Danaparoid','cjYPu','<ul>\x0a<li><strong>Safinamide</strong>\x20is\x20a\x20<strong>monoamine\x20oxidase\x20type-B\x20(MAO-B)\x20inhibitor</strong>\x20and\x20blocks\x20the\x20catabolism\x20of\x20dopamine.</li>\x0a<li>It\x20is\x20indicated\x20as\x20an\x20<strong>add-on\x20to\x20therapy\x20in\x20Parkinson&rsquo;s\x20disease\x20(PD)</strong>\x20in\x20those\x20currently\x20taking\x20levodopa/carbidopa\x20and\x20<strong>experiencing\x20&lsquo;off&rsquo;\x20episodes</strong>.</li>\x0a<li>The\x20exact\x20mechanism\x20of\x20its\x20therapeutic\x20effects\x20in\x20PD\x20is\x20not\x20known.</li>\x0a<li>It\x20is\x20given\x20<strong>orally</strong>,\x20at\x20an\x20initial\x20dose\x20of\x2050mg\x20per\x20day.</li>\x0a<li><strong>It\x20has\x20not\x20shown\x20benefits\x20as\x20a\x20part\x20of\x20monotherapy\x20of\x20PD</strong>.</li>\x0a<li>Adverse\x20effects\x20include\x20<strong>dyskinesia</strong>,\x20falls,\x20nausea,\x20insomnia,\x20etc.</li>\x0a<li>It\x20is\x20contraindicated\x20in\x20severe\x20hepatic\x20impairment.\x20It\x20can\x20exacerbate\x20hypertension\x20when\x20taken\x20with\x20other\x20MAOIs.</li>\x0a<li>It\x20is\x20also\x20contraindicated\x20with\x20the\x20use\x20of\x20opioids\x20and\x20tricyclic\x20antidepressants.</li>\x0a<li><strong>Update:\x20</strong>It\x20was\x20approved\x20for\x20usage\x20in\x20PD\x20by\x20the\x20U.S.\x20FDA\x20in\x202017.</li>\x0a</ul>','hIiPu','log','Vemurafenib','FRpXR','timed_exam','<div\x20class=\x22mt-4\x22><img\x20src=\x22','xZmdF','WSCZE','questionIndex','WIzLW','answered','Thrice\x20weekly\x20regimen\x20in\x20intensive\x20phase\x20followed\x20by\x20twice\x20weekly\x20regimen\x20in\x20continuation\x20phase','International\x20Diabetes\x20Federation','trace','3371480jXFDBS','DvzBe','Xltlk','bookmarkBtn','solutionAudio','YsePa','<ul>\x0a<li><strong>Sunitinib\x20</strong>is\x20a\x20small\x20molecule,\x20<strong>multi-targeted\x20kinase\x20antagonist/inhibitor</strong>\x20and\x20has\x20been\x20shown\x20to\x20have\x20<strong>anti-tumor\x20activity</strong>\x20in\x20<strong>renal\x20cell\x20carcinoma\x20</strong>(RCC),\x20<strong>gastrointestinal\x20stromal\x20tumor\x20</strong>(GIST)\x20and\x20<strong>pancreatic\x20neuroendocrine\x20tumors</strong>\x20(pNETs).</li>\x0a<li><strong>Pharmacology</strong>\x20of\x20sunitinib:\x0a<ul>\x0a<li>Molecular\x20targets\x20of\x20sunitinib\x20are\x20<strong>c-Kit,\x20VEGFR-2,\x20PDGFR-&beta;\x20and\x20Flt-3</strong>.</li>\x0a<li>Sunitinib\x20targets\x20mutations\x20in\x20the\x20RET\x20gene.</li>\x0a<li>The\x20<strong>mechanisms\x20of\x20sunitinib&rsquo;s\x20action</strong>\x20are:\x0a<ul>\x0a<li>Inhibition\x20of\x20activated\x20c-Kit\x20and\x20PDGFR\x20in\x20GIST</li>\x0a<li>Inhibition\x20of\x20VEGFR\x20in\x20advanced\x20RCC</li>\x0a</ul>\x0a</li>\x0a</ul>\x0a</li>\x0a<li><strong>Adverse\x20effects:</strong>\x0a<ul>\x0a<li>Its\x20specific\x20adverse\x20effects\x20include\x20<strong>neutropenia,\x20diarrhea\x20and\x20fatigue</strong>.</li>\x0a<li>Generally,\x20the\x20other\x20common\x20side\x20effects\x20of\x20agents\x20having\x20anti-VEGFR\x20activity\x20are\x20<strong>hypertension\x20and\x20proteinuria</strong>.</li>\x0a<li>Rarely,\x20they\x20cause\x20<strong>bleeding\x20and\x20clotting\x20disorders</strong>,\x20and\x20<strong>perforation\x20of\x20scarred\x20gastrointestinal\x20lesions</strong>.</li>\x0a<li><strong>Hand-foot\x20syndrome</strong>\x20has\x20also\x20been\x20noted\x20in\x20the\x20use\x20of\x20these\x20agents,\x20with\x20erythema\x20and\x20desquamation\x20of\x20distal\x20extremities.</li>\x0a</ul>\x0a</li>\x0a<li><strong>Administration:</strong>\x0a<ul>\x0a<li>In\x20advanced\x20RCC\x20and\x20in\x20adjuvant\x20therapy,\x20sunitinib\x20is\x20given\x20<strong>orally</strong>,\x20at\x20a\x20dose\x20of\x20<strong>50mg\x20per\x20day</strong>,\x20once\x20daily,\x20with\x20or\x20without\x20food,\x20for\x20<strong>4\x20weeks\x20out\x20of\x206</strong>\x20(<strong>nine\x206-week\x20cycles</strong>\x20in\x20adjuvant\x20therapy).</li>\x0a</ul>\x0a</li>\x0a<li><strong>Uses:</strong>\x0a<ul>\x0a<li>In\x20<strong>metastatic\x20GIST</strong>,\x20the\x20main\x20chemotherapeutic\x20agent\x20used\x20is\x20imatinib,\x20which\x20is\x20a\x20selective\x20inhibitor\x20of\x20the\x20c-kit\x20tyrosine\x20kinase.\x20Patients\x20whose\x20tumors\x20have\x20become\x20<strong>refractory\x20to\x20imatinib</strong>\x20benefit\x20from\x20agents\x20like\x20sunitinib,\x20which\x20also\x20inhibits\x20c-kit\x20tyrosine\x20kinase.</li>\x0a<li>It\x20is\x20now\x20undergoing\x20studies\x20for\x20efficacy\x20in\x20hepatocellular\x20carcinoma</li>\x0a</ul>\x0a</li>\x0a<li><strong>Update:</strong>\x0a<ul>\x0a<li>The\x20drug\x20was\x20previously\x20approved\x20for\x20use\x20by\x20various\x20regulatory\x20bodies\x20in\x202006,\x20for\x20conditions\x20like\x20GIST\x20and\x20advanced\x20RCC.</li>\x0a<li>In\x202017,\x20<strong>sunitinib\x20malate</strong>\x20was\x20approved\x20by\x20the\x20FDA\x20for\x20use\x20as\x20<strong>adjuvant\x20therapy</strong>\x20for\x20patients\x20at\x20risk\x20for\x20<strong>recurrence\x20of\x20RCC</strong>\x20after\x20a\x20kidney\x20has\x20been\x20removed\x20(<strong>nephrectomy</strong>).</li>\x0a<li>This\x20was\x20based\x20on\x20a\x20multi-center,\x20international,\x20double-blinded,\x20placebo-controlled\x20trial\x20among\x20615\x20patients\x20with\x20high\x20risk\x20of\x20recurrent\x20RCC\x20following\x20nephrectomy.</li>\x0a</ul>\x0a</li>\x0a</ul>','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22','roiBR','pdYvd','True\x20statement\x20regarding\x20the\x20DGHS\x20guidelines\x20for\x20seasonal\x20Influenza\x20vaccination,\x20for\x20the\x20period\x202017\x20-\x202018\x20is:','Single\x20on-site\x20rapid\x20plasma\x20reagin\x20(RPR)\x20test','PcoST','Mantle\x20cell\x20lymphoma','bFIvh','join','Class\x20C\x20–\x20Low\x20risk','ntRas','GNeyg','XRsXo','pgokZ','oCrAw','2017-18','isArray','question_images','VOsRl','The\x20theme\x20of\x20World\x20Health\x20Day,\x202017\x20was\x20_______','<p>The\x20vector\x20given\x20in\x20the\x20image\x20is\x20a\x20<strong>Reduviid\x20bug</strong>\x20which\x20is\x20also\x20called\x20the\x20kissing\x20bug\x20or\x20triatomine.\x20They\x20are\x20responsible\x20for\x20the\x20transmission\x20of\x20<strong>Chagas\x20disease</strong>\x20(American\x20trypanosomiasis)\x20which\x20is\x20caused\x20by\x20<strong>Trypanosoma\x20cruzi.</strong></p>\x0a<p><strong>Benznidazole</strong>\x20is\x20used\x20in\x20the\x20treatment\x20of\x20Chagas\x20disease.\x20Another\x20widely\x20used\x20drug\x20for\x20its\x20treatment\x20is\x20<strong>nifurtimox.\x20</strong>But\x20<strong>benznidazole\x20</strong>is\x20the\x20preferred\x20treatment\x20due\x20to\x20toxicity\x20issues.</p>\x0a<p>Benznidazole\x20generates\x20<strong>oxygen\x20radicals\x20and\x20nitro\x20radical\x20anions</strong>\x20which\x20account\x20for\x20its\x20trypanocidal\x20effect.</p>\x0a<p>It\x20is\x20given\x20orally\x20at\x20doses\x20of\x20<strong>5-7\x20mg/kg\x20per\x20day\x20in\x20two\x20divided\x20doses\x20for\x2060\x20days\x20in\x20those\x20above\x2013\x20years</strong>\x20and\x20for\x20children\x2012\x20years\x20and\x20below,\x20the\x20dose\x2010\x20mg/kg\x20per\x20day\x20for\x20the\x20same\x20schedule.</p>\x0a<p>&nbsp;</p>','Integrated\x20health\x20care\x20to\x20maintain\x20only\x20the\x20mental\x20capacities\x20of\x20older\x20people','Unxie','Hepatoxicity','border-gray-600','ppRme','XfzYk','TzBob','jGcIS','zMQSF','fKeBq','dqBwW','ZyVXf','keydown','taZFI','UhJdf','</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-','oLDXW','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','gOmUr','toLowerCase','sqLUZ','EIdqZ','FsgBh','totalAttempted','Mark\x20for\x20Review','JoKYB','createElement','explanation_audio_eng','A\x2026\x20years\x20old\x20pregnant\x20woman\x20attended\x20a\x20camp\x20in\x20her\x20village\x20for\x20screening\x20of\x20syphilis,\x20as\x20the\x20village\x20has\x20reported\x20high\x20prevalence\x20of\x20syphilis\x20cases.\x20Which\x20of\x20the\x20following\x20tests\x20are\x20recommended?','</span><span>','correctAnswers','Generalized\x20joint\x20hypermobility','quizSidebar','HIV\x20positive\x20persons\x20above\x20the\x20age\x20of\x2021\x20years\x20do\x20not\x20have\x20the\x20right\x20to\x20reside\x20in\x20a\x20shared\x20household','bMZyp','toString','map','eNcqv','currentQuestion','none','explanation_images','<ul>\x0a<li><strong>Delamanid</strong>\x20is\x20a\x20<strong>nitroimidazole\x20antibiotic</strong>\x20that\x20is\x20used\x20in\x20certain\x20cases\x20of\x20tuberculosis.</li>\x0a<li>This\x20drug\x20has\x20been\x20recommended\x20for\x20use\x20by\x20the\x20WHO\x20in\x20cases\x20of\x20multi-drug\x20resistant\x20TB\x20(MDR-TB)\x20when\x20the\x20usual\x20regimen\x20for\x20MDR-TB\x20cannot\x20be\x20followed\x20because\x20of\x20known\x20resistance,\x20intolerance\x20and\x20non-availability\x20of\x20other\x20second-line\x20drugs\x20in\x20the\x20regimen.</li>\x0a<li>Delamanid\x20has\x20shown\x20to\x20significantly\x20increase\x20the\x20culture\x20conversion\x20rate\x20at\x202\x20months.</li>\x0a<li>The\x20main\x20side\x20effect\x20of\x20this\x20drug\x20is\x20<strong>QT\x20prolongation</strong>\x20and\x20so\x20cardiac\x20patients\x20on\x20this\x20drug\x20should\x20be\x20closely\x20monitored.</li>\x0a<li>This\x20drug\x20was\x20approved\x20for\x20usage\x20in\x20India\x20in\x202017.\x20It\x20has\x20been\x20in\x20use\x20in\x20other\x20parts\x20of\x20the\x20world\x20like\x20Europe\x20and\x20Japan\x20for\x20a\x20few\x20years\x20now.</li>\x0a</ul>','The\x20drug\x20padeliporfin\x20used\x20in\x20vascular-targeted\x20photodynamic\x20therapy\x20(VTP)\x20has\x20been\x20approved\x20for\x20use\x20in:','Recurrent\x20visual\x20hallucination','zziJy','solutionVideo','Intercourse\x20with\x20a\x20girl,\x20below\x2016\x20years\x20of\x20age,\x20with\x20consent','Previous\x20progress\x20cleared.','Dalteparin','fromCharCode','hidden','hENmi','.m3u8','sHrCQ','BHxGU','<ul>\x0a<li><strong>Ribociclib</strong>\x20is\x20a\x20<strong>cyclin-dependent\x20kinase\x204/6\x20inhibitor</strong>\x20and\x20it\x20blocks\x20the\x20cellular\x20proliferation\x20of\x20G1\x20into\x20S\x20phase\x20of\x20the\x20cell\x20cycle.</li>\x0a<li>It\x20is\x20indicated\x20for\x20usage\x20<strong>in\x20combination\x20with\x20an\x20aromatase\x20as\x20initial\x20endocrine-based\x20therapy\x20for\x20postmenopausal\x20women\x20with\x20hormone\x20receptor\x20(HR)-positive,\x20human\x20epidermal\x20growth\x20factor\x20receptor\x202\x20(HER2)-negative\x20advanced\x20or\x20metastatic\x20breast\x20cancer</strong>.</li>\x0a<li>It\x20is\x20given\x20<strong>orally</strong>\x20at\x20a\x20dose\x20of\x20<strong>600mg\x20per\x20day,\x20once\x20daily</strong>,\x20for\x2021\x20days\x20followed\x20by\x207\x20days\x20off\x20treatment.\x20This\x20will\x20result\x20in\x20a\x2028-day\x20cycle.</li>\x0a<li>Most\x20common\x20adverse\x20effects\x20of\x20this\x20drug\x20include\x20<strong>neutropenia</strong>,\x20nausea,\x20fatigue,\x20diarrhea,\x20leucopenia,\x20alopecia,\x20vomiting,\x20constipation,\x20back\x20pain\x20and\x20headache.</li>\x0a<li><strong>Update:\x20</strong>It\x20was\x20approved\x20for\x20usage\x20in\x20India,\x20US\x20and\x20Europe\x20in\x202017.</li>\x0a</ul>','khfHp','questionText','mBuSh','kmcIw','toISOString','nav-btn-bookmarked','floor','nIZNB','2147520oUZtIs','clkNa','Family\x20participatory\x20care\x20guidelines,\x20released\x20by\x20Ministry\x20of\x20Health\x20and\x20Family\x20Welfare,\x20refers\x20to\x20______','GVQcs','gwCpu','return\x20(function()\x20','<ul>\x0a<li>The\x20<strong>National\x20Nutrition\x20Week</strong>\x20was\x20observed\x20throughout\x20India\x20from\x20<strong>1st\x20to\x207th\x20September,\x202017.\x20</strong></li>\x0a<li>The\x20theme\x20of\x20the\x20<strong>National\x20Nutrition\x20Week\x20for\x202017</strong>\x20was\x20\x22<strong>Optimal\x20Infant\x20&amp;\x20Young\x20Child\x20Feeding\x20Practices:\x20Better\x20Child\x20Health</strong>\x22.</li>\x0a<li>The\x20basic\x20objective\x20of\x20this\x20annual\x20event\x20is\x20to\x20intensify\x20awareness\x20generation\x20on\x20the\x20importance\x20of\x20nutrition\x20for\x20health\x20which\x20has\x20an\x20impact\x20on\x20development,\x20productivity,\x20economic\x20growth\x20and\x20ultimately\x20National\x20development.</li>\x0a</ul>','zkcHg','endsWith','filter','UcTJs','timed_study','uKxMD','LjEPw','Dabrafenib','width','It\x20is\x20administered\x20in\x20three\x20doses,\x206\x20months\x20apart','ikYKb','questionStates','ZBGxz','Which\x20of\x20the\x20following\x20drugs\x20used\x20in\x20the\x20treatment\x20of\x20patients\x20with\x20plaque\x20psoriasis\x20is\x20an\x20interleukin-23\x20inhibitor?','Weight\x20for\x20height\x20<\x20–3\x20SD','<ul>\x0a<li>The\x20world\x20diabetes\x20day\x20campaign\x20is\x20conducted\x20every\x20year\x20on\x20November\x2014<sup>th</sup>\x20by\x20<strong>International\x20Diabetes\x20Federation.</strong></li>\x0a<li>The\x20theme\x20of\x20<strong>World\x20Diabetes\x20Day\x202017</strong>\x20is\x20<strong>Women\x20and\x20diabetes\x20-\x20our\x20right\x20to\x20a\x20healthy\x20future.</strong></li>\x0a<li>The\x20campaign\x20will\x20promote\x20the\x20importance\x20of\x20affordable\x20and\x20equitable\x20access\x20for\x20all\x20women\x20at\x20risk\x20for\x20or\x20living\x20with\x20diabetes\x20to\x20the\x20essential\x20diabetes\x20medicines\x20and\x20technologies,\x20self-management\x20education\x20and\x20information\x20they\x20require\x20to\x20achieve\x20optimal\x20diabetes\x20outcomes\x20and\x20strengthen\x20their\x20capacity\x20to\x20prevent\x20type\x202\x20diabetes.</li>\x0a</ul>','Niemann-Pick\x20disease','submitSection','\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>','lObGA','Progressive\x20weight\x20loss','classList','\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','timeSpent','cBDJF','FOIlV','title','aHcbb','ZxNVQ','All\x20of\x20the\x20following\x20statements\x20are\x20true\x20regarding\x20pasireotide\x20except:','Trivalent\x20vaccine\x20for\x20children\x20between\x206\x20months\x20and\x208\x20years\x20of\x20age','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22','128/84\x20mmHg','.option-button','Known\x20resistance','block','remove','aBMOz','contains','<p><strong>Orthostatic\x20hypotension</strong>\x20is\x20<strong>not</strong>\x20a\x20<strong>core\x20</strong>clinical\x20feature\x20of\x20<strong>Lewy\x20body\x20dementia</strong>\x20(LBD)\x20as\x20per\x20<strong>DSM-5</strong>.</p>\x0a<p><strong>LBD</strong>\x20also\x20known\x20as\x20dementia\x20with\x20Lewy\x20bodies\x20is\x20the\x20second\x20most\x20type\x20of\x20<strong>progressive\x20dementia</strong>\x20after\x20Alzheimer&rsquo;s\x20disease.\x20<strong>Protein\x20deposits</strong>,\x20called\x20<strong>Lewy\x20bodies</strong>,\x20deposit\x20in\x20<strong>nerve\x20cells</strong>\x20in\x20the\x20<strong>brain</strong>\x20region\x20involved\x20in\x20thinking,\x20memory,\x20and\x20movement\x20(motor\x20control)</p>\x0a<p><strong>Core\x20features</strong>\x20of\x20LBD\x20as\x20per\x20DSM-5\x20are\x20<strong>fluctuating\x20cognition</strong>,\x20<strong>attention</strong>,\x20<strong>alertness</strong>,\x20<strong>recurrent\x20visual\x20hallucination,</strong>\x20and\x20<strong>Parkinsonian\x20symptoms</strong>.\x20Suggestive\x20features\x20are\x20REM\x20sleep\x20behavior\x20disorder\x20and\x20severe\x20neuroleptic\x20sensitivity.<br\x20/>Orthostatic\x20hypotension,\x20erectile\x20dysfunction,\x20and\x20constipation\x20are\x20other\x20features\x20of\x20LBD.</p>\x0a<p>Treatment\x20of\x20LBD\x20includes\x20<strong>rivastigmine</strong>\x20and\x20<strong>donepezil</strong>\x20which\x20may\x20improve\x20cognition,\x20and\x20reduce\x20hallucinosis\x20and\x20delusion.\x20<strong>Pimavanserin</strong>\x20may\x20be\x20used\x20to\x20treat\x20<strong>psychosis</strong>.</p>','akvzw','EzvZw','reload','Multimodal\x20exercise\x20to\x20improve\x20\x20musculoskeletal\x20function','Skin\x20fragility','text','canPlayType','green','<ul>\x0a<li><strong>Pasireotide</strong>\x20is\x20a\x20<strong>cyclohexapeptide\x20somatostatin</strong>\x20<strong>analogue</strong>.</li>\x0a<li>It\x20has\x20a\x20<strong>broader\x20selectivity</strong>\x20than\x20other\x20analogues\x20like\x20octreotide\x20and\x20<strong>binds\x20with\x20high\x20affinity\x20to\x20most\x20somatostatin\x20receptors.</strong></li>\x0a<li>Its\x20usage\x20is\x20indicated\x20in\x20the\x20treatment\x20of\x20<strong>acromegaly\x20in\x20patients\x20for\x20whom\x20surgery\x20has\x20not\x20provided\x20an\x20adequate\x20response\x20and/or\x20in\x20those\x20for\x20whom\x20surgery\x20is\x20not\x20an\x20option.</strong></li>\x0a<li>It\x20is\x20also\x20indicated\x20in\x20<strong>Cushing&rsquo;s\x20disease</strong>\x20where\x20pituitary\x20surgery\x20is\x20not\x20an\x20option\x20or\x20has\x20not\x20been\x20curative.</li>\x0a<li>Adverse\x20effects\x20include\x20<strong>impairment\x20in\x20glycemic\x20control</strong>,\x20diarrhea,\x20nausea,\x20asthenia,\x20alopecia,\x20etc.</li>\x0a<li>It\x20can\x20be\x20given\x20as\x20a\x20subcutaneous\x20or\x20intramuscular\x20injection.</li>\x0a<li><strong>Update</strong>:\x0a<ul>\x0a<li>It\x20was\x20approved\x20for\x20usage\x20in\x20acromegaly,\x20in\x20India,\x20in\x202017,\x20as\x20an\x20additional\x20indication.</li>\x0a</ul>\x0a</li>\x0a</ul>','KVMhs','ArrowRight','oKLgf','Edaravone\x20is\x20a\x20novel\x20drug\x20used\x20for\x20amyotrophic\x20lateral\x20sclerosis\x20(ALS).\x20Route\x20of\x20administration\x20of\x20this\x20drug\x20is:','Contraindicated\x20with\x20use\x20of\x20rifampin','DkwEN','All\x20of\x20the\x20following\x20statements\x20are\x20true\x20about\x20the\x20HIV\x20and\x20AIDS\x20(Prevention\x20and\x20Control)\x20Act,\x202017,\x20except:','Speed\x20management','testModeReviewLegend','fHYen','tiDpY','Species\x20specific\x20prevalence\x20rate\x20is\x20considered\x20for\x20providing\x20preventive\x20chemotherapy\x20for\x20soil-transmitted\x20helminth\x20infections\x20in\x20which\x20of\x20the\x20following\x20risk\x20groups?','≤\x20\x2070\x20mg/dL','Intercourse\x20with\x20a\x20girl\x20<\x2018\x20years\x20of\x20age,\x20without\x20consent','getItem','8832321yUlybB','UQaUh','Which\x20of\x20the\x20following\x20anti-protozoal\x20drugs\x20is\x20preferred\x20for\x20the\x20treatment\x20of\x20the\x20disease\x20predominantly\x20transmitted\x20by\x20the\x20vector\x20in\x20the\x20given\x20image?','gfoZC','Which\x20of\x20the\x20following\x20statements\x20is\x20true\x20about\x20the\x20integrated\x20care\x20for\x20older\x20people\x20(ICOPE)\x20guidelines\x20recently\x20released\x20by\x20WHO?','AfnqO','The\x20major\x20adverse\x20effect\x20of\x20arbekacin\x20is:','hyMfd','Option\x20','16gCjIVS','141696lltiWk','Class\x20B\x20–\x20Low\x20moderate\x20risk','studyModeLegend','location','addEventListener','YjLDH','<p>Intercourse\x20with\x20a\x20girl,\x20above\x2018\x20years\x20of\x20age,\x20with\x20consent\x20is\x20not\x20considered\x20rape.</p>\x0a<p>Clause\x20‘Sixthly’\x20of\x20<strong>Section\x20375</strong>\x20makes\x20it\x20clear\x20that\x20if\x20the\x20woman\x20is\x20under\x20<strong>18\x20years\x20of\x20age</strong>,\x20then\x20sexual\x20intercourse\x20with\x20her,\x20with\x20or\x20without\x20her\x20consent\x20is\x20rape.\x20This\x20is\x20commonly\x20referred\x20to\x20as\x20‘<strong>statutory\x20rape’</strong>\x20in\x20which\x20the\x20willingness\x20or\x20consent\x20of\x20a\x20woman\x20below\x20the\x20age\x20of\x20<strong>18\x20years</strong>\x20for\x20having\x20sexual\x20intercourse\x20is\x20rendered\x20irrelevant\x20and\x20inconsequential.</p>\x0a<p>Hence,\u00a0Exception\x202\x20to\x20Section\x20375\x20IPC\x20says\x20that\x20“sexual\x20intercourse\x20or\x20sexual\x20acts\x20by\x20a\x20man\x20with\x20his\x20own\x20wife,\x20the\x20wife\x20not\x20being\x2018\x20years\x20(i.e\x20above\x20the\x20age\x20of\x2018),\x20is\x20not\x20rape”.</p>\x0a<p>A\x20man\x20is\x20said\x20to\x20commit\x20“rape”\x20if\x20he\x20has\x20sexual\x20intercourse\x20with\x20a\x20woman\x20under\x20circumstances\x20falling\x20under\x20any\x20of\x20the\x20six\x20following\x20descriptions:</p>\x0a<ul>\x0a<li>Against\x20her\x20will.</li>\x0a<li>Without\x20her\x20consent.</li>\x0a<li>With\x20her\x20consent,\x20when\x20her\x20consent\x20has\x20been\x20obtained\x20by\x20putting\x20her\x20or\x20any\x20person\x20in\x20whom\x20she\x20is\x20interested\x20in\x20fear\x20of\x20death\x20or\x20of\x20hurt.</li>\x0a<li>With\x20her\x20consent,\x20when\x20the\x20man\x20knows\x20that\x20he\x20is\x20not\x20her\x20husband,\x20and\x20that\x20her\x20consent\x20is\x20given\x20because\x20she\x20believes\x20that\x20he\x20is\x20another\x20man\x20to\x20whom\x20she\x20is\x20or\x20believes\x20herself\x20to\x20be\x20lawfully\x20married.</li>\x0a<li>With\x20her\x20consent,\x20when,\x20at\x20the\x20time\x20of\x20giving\x20such\x20consent,\x20by\x20reason\x20of\x20unsoundness\x20of\x20mind\x20or\x20intoxication\x20or\x20the\x20administration\x20by\x20him\x20personally\x20or\x20through\x20another\x20of\x20any\x20stupefying\x20or\x20unwholesome\x20substance,\x20she\x20is\x20unable\x20to\x20understand\x20the\x20nature\x20and\x20consequences\x20of\x20that\x20to\x20which\x20she\x20gives\x20consent.</li>\x0a<li>With\x20or\x20without\x20her\x20consent,\x20when\x20she\x20is\x20under\x20eighteen\x20years\x20of\x20age.</li>\x0a</ul>','Guselkumab','0|2|5|4|3|1','wreFn','constructor','Post-crash\x20surviva','Onsite\x20RPR\x20test,\x20if\x20positive,\x20provision\x20of\x20first\x20dose\x20of\x20treatment\x20followed\x20by\x20RST','Ixekizumab','Eliminate\x20malaria\x20in\x20category\x201\x20districts\x20by\x202020','statsBar','SzoOf','https://dhmbxeygs57ff.cloudfront.net/uploads/b9f82e01e2f9447889450284243719cax1280x968.PNG','sVeWV','TaYuj','The\x20large\x20scale\x20use\x20of\x20Oral\x20Cholera\x20Vaccine\x20is\x20recommended','vrHsS','rYbnY','<ul>\x0a<li>Edaravone\x20is\x20a\x20<strong>pyrazolone\x20free\x20radical\x20scavenger</strong>\x20which\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>amyotrophic\x20lateral\x20sclerosis\x20(ALS)</strong>.</li>\x0a<li>The\x20mechanism\x20by\x20which\x20it\x20exerts\x20its\x20action\x20in\x20ALS\x20is\x20unknown.\x20It\x20has\x20been\x20theorized\x20that\x20it\x20reduces\x20oxidative\x20stress.</li>\x0a<li>It\x20is\x20approved\x20for\x20use\x20as\x20<strong>an\x20intravenous\x20infusion</strong>.</li>\x0a<li>The\x20most\x20common\x20adverse\x20effects\x20of\x20this\x20drug\x20are\x20<strong>bruising\x20(contusion)\x20and\x20gait\x20disturbance</strong>.\x20Other\x20adverse\x20effects\x20include\x20hives,\x20swelling\x20and\x20shortness\x20of\x20breath.</li>\x0a<li>It\x20has\x20been\x20used\x20in\x20Japan\x20to\x20help\x20with\x20recovery\x20from\x20stroke.</li>\x0a<li><strong>Update:\x20</strong>It\x20was\x20approved\x20by\x20the\x20U.S.\x20FDA\x20in\x202017,\x20for\x20usage\x20in\x20ALS.\x20It\x20has\x20been\x20in\x20use\x20earlier\x20in\x20Japan\x20for\x20this\x20purpose.</li>\x0a</ul>','ULQtJ','<p>The\x20<strong>Strategic\x20Advisory\x20Group\x20of\x20Experts\x20(SAGE)</strong>\x20on\x20Immunization\x20met\x20on\x2017-19\x20October\x202017\x20in\x20Geneva,\x20Switzerland.\x20SAGE\x20makes\x20new\x20recommendations\x20to\x20prevent\x20typhoid\x20fever,\x20rabies:</p>\x0a<p><strong>SAGE\x20recommendation\x20on\x20Typhoid\x20vaccines:</strong></p>\x0a<p>Due\x20to\x20continued\x20high\x20burden\x20of\x20typhoid\x20fever\x20and\x20the\x20alarming\x20increase\x20in\x20<strong>antimicrobial\x20resistance\x20of\x20Salmonella\x20Typhi\x20(S.\x20Typhi)</strong>\x20in\x20low-\x20and\x20middle-income\x20countries,\x20SAGE\x20re-emphasized\x20the\x20importance\x20of\x20programmatic\x20use\x20of\x20typhoid\x20vaccines\x20for\x20controlling\x20endemic\x20disease.</p>\x0a<p>Following\x20review\x20of\x20the\x20available\x20data:</p>\x0a<ul>\x0a<li>SAGE\x20recommended\x20the\x20introduction\x20of\x20<strong>typhoid\x20conjugate\x20vaccine\x20(TCV)</strong>\x20for\x20<strong>infants\x20and\x20children\x20over\x206\x20months\x20of\x20age\x20as</strong>\x20a\x20<strong>single\x20dose</strong>\x20in\x20typhoid\x20endemic\x20countries.</li>\x0a<li>Introduction\x20of\x20TCV\x20should\x20first\x20be\x20prioritized\x20to\x20countries\x20with\x20the\x20highest\x20burden\x20of\x20disease\x20or\x20a\x20high\x20burden\x20of\x20antimicrobial\x20resistant\x20S.\x20Typhi.</li>\x0a<li>SAGE\x20also\x20recommended\x20<strong>catch-up\x20vaccination</strong>\x20wherever\x20feasible,\x20with\x20priority\x20for\x20catch-up\x20in\x20the\x20youngest\x20age\x20groups\x20(<strong>up\x20to\x2015\x20years\x20of\x20age</strong>),\x20depending\x20on\x20local\x20epidemiology.</li>\x0a</ul>\x0a<p>SAGE\x20highlighted\x20the\x20need\x20for\x20countries\x20to\x20strengthen\x20the\x20surveillance\x20of\x20typhoid\x20fever,\x20and\x20to\x20monitor\x20the\x20occurrence\x20of\x20antimicrobial\x20resistant\x20strains\x20of\x20S.\x20typhi\x20in\x20endemic\x20and\x20epidemic\x20disease,\x20before\x20and\x20after\x20programmatic\x20use\x20of\x20TCV.</p>','All\x20of\x20the\x20following\x20are\x20considered\x20as\x20rape,\x20except_______','yvGXi','xRfvK','kUyDU','PBvDT','Finger-feeding\x20is\x20optimally\x20indicated\x20for\x20short-term\x20use\x20and\x20may\x20improve\x20breastfeeding\x20rates\x20at\x20discharge','prototype','136/80\x20mmHg','<p><strong>120/78\x20mmHg</strong>\x20is\x20considered\x20as\x20an\x20<strong>elevated\x20BP</strong>\x20(SBP\x20120\x20&ndash;\x20129\x20mmHg\x20and\x20DBP\x20&lt;80mmHg).\x20All\x20other\x20options\x20are\x20Stage\x20I\x20hypertension.</p>\x0a<ul>\x0a<li>The\x20<strong>American\x20College\x20of\x20Cardiology\x20(ACC)</strong>\x20and\x20the\x20<strong>American\x20Heart\x20Association\x20(AHA)\x20</strong>have\x20released\x20a\x20new\x20guideline\x20on\x20hypertension\x20with\x20a\x20new\x20definition\x20that\x20will\x20call\x20<strong>130\x20to\x20139\x20mm\x20Hg\x20systolic</strong>\x20or\x20<strong>80\x20to\x2089\x20mm\x20Hg</strong>,\x20stage\x201\x20hypertension.</li>\x0a<li>The\x20<strong>definition\x20of\x20normal\x20blood\x20pressure</strong>\x20hasn\x27t\x20changed\x20from\x20the\x20previous\x20document</li>\x0a<li>However\x20the\x20new\x20guidelines\x20<strong>eliminate\x20the\x20classification\x20of\x20prehypertension</strong>\x20and\x20divide\x20those\x20blood-pressure\x20levels\x20previously\x20called\x20prehypertension\x20into\x20<strong>elevated\x20BP</strong>,\x20with\x20a\x20systolic\x20pressure\x20between\x20120\x20and\x20129\x20and\x20diastolic\x20pressure\x20less\x20than\x2080\x20mm\x20Hg,\x20and\x20<strong>stage\x201\x20hypertension</strong>,\x20which\x20they\x20now\x20define\x20as\x20a\x20systolic\x20pressure\x20130\x20to\x20139\x20or\x20a\x20diastolic\x20pressure\x20of\x2080\x20to\x2089\x20mm\x20Hg.</li>\x0a</ul>','<ul>\x0a<li>Arbekacin\x20is\x20an\x20<strong>aminoglycoside\x20antibiotic</strong>\x20was\x20discovered\x20in\x201972.</li>\x0a<li>It\x20is\x20now\x20widely\x20indicated\x20in\x20the\x20treatment\x20of\x20pneumonia,\x20sepsis\x20and\x20infections\x20caused\x20by\x20<strong>methicillin-resistant\x20Staphylococcus\x20aureus\x20(MRSA)</strong>.</li>\x0a<li>It\x20has\x20shown\x20promise\x20in\x20treating\x20even\x20multi-drug\x20resistant\x20Gram-negative\x20bacterial\x20infections\x20such\x20as\x20P.\x20aeruginosa\x20and\x20Acinetobacter\x20baumannii.</li>\x0a<li><strong>Nephrotoxicity</strong>\x20is\x20the\x20major\x20adverse\x20effect\x20of\x20this\x20drug.\x20Another\x20side\x20effect\x20is\x20ototoxicity.</li>\x0a<li><strong>Update:\x20</strong>This\x20drug\x20was\x20approved\x20for\x20usage\x20in\x20India\x20in\x202017.</li>\x0a</ul>','AuXHt','NEET\x20PG\x20Mini\x20Test\x20Series','-600\x20text-white\x22>','Which\x20of\x20the\x20following\x20is\x20not\x20true\x20about\x20the\x20novel\x20drug\x20regimen,\x20glecaprevir\x20+\x20pibrentasvir\x20for\x20hepatitis\x20C\x20infection?','Used\x20as\x20last\x20resort\x20options\x20only\x20in\x20the\x20most\x20severe\x20circumstances','mGCYC','ZwXJN','questions','GxNAp','Chronic\x20idiopathic\x20constipation','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','Neurotoxicity','bind','Mucopolysaccharidosis\x20type\x20VII\x20has\x20the\x20eponym:','ISrSP','Wilm’s\x20tumor','<p>The\x20<strong>accelerated\x20plan\x20for\x20Kala-Azar\x20elimination</strong>\x20released\x20by\x20Ministry\x20of\x20Health\x20and\x20Family\x20Welfare\x20suggests\x20the\x20treatment\x20regimens\x20for\x20<strong>visceral\x20leishmaniasis.</strong></p>\x0a<p>The\x20dosage\x20of\x20oral<strong>\x20miltefosine</strong>\x20for\x20treatment\x20of\x20visceral\x20leishmaniasis\x20is\x20as\x20follows:</p>\x0a<ul>\x0a<li>For\x20children\x20aged\x202\x20&ndash;\x2011\x20years:\x202.5mg/kg/day\x20for\x2028\x20days</li>\x0a<li>For\x20people\x20aged\x20more\x20than\x2012\x20years,\x20and\x20body\x20weight&lt;25kgs:\x0a<ul>\x0a<li>&lt;25\x20Kgs:\x2050mg/day\x20for\x2028\x20days</li>\x0a<li>25\x20&ndash;\x2050\x20Kgs:\x20100mg/day\x20for\x2028\x20days</li>\x0a<li>&gt;50\x20Kgs:\x20150\x20mg/day\x20for\x2028\x20days</li>\x0a</ul>\x0a</li>\x0a</ul>\x0a<p>&nbsp;</p>\x0a<p><strong>Note</strong>:\x20Single\x20dose\x20single\x20day\x20treatment\x20with\x20<strong>Liposomal\x20Amphotericin\x20B\x20injection</strong>\x20is\x20the<strong>\x20first\x20drug\x20of\x20choice</strong>\x20followed\x20by\x20capsule\x20<strong>Miltefosine</strong>\x20(28\x20days)\x20and\x20injection\x20<strong>Amphotericin\x20B</strong>\x20(15\x20injections\x20on\x20alternate\x20days)\x20as\x20well\x20as\x20combination\x20of\x20Miltefosine\x20and\x20Paromomycin\x20injection.</p>','hSjSK','ENRvb','kHSIF','index.html','<ul>\x0a<li>Bortezomib\x20is\x20an\x20<strong>inhibitor\x20of\x20proteasome-mediated\x20protein\x20degradation</strong>.</li>\x0a<li>It\x20is\x20central\x20to\x20the\x20treatment\x20of\x20<strong>multiple\x20myeloma</strong>,\x20both\x20untreated\x20and\x20relapsed.</li>\x0a<li>It\x20has\x20now\x20become\x20a\x20first-line\x20treatment\x20option\x20for\x20<strong>mantle\x20cell\x20lymphoma</strong>,\x20both\x20untreated\x20and\x20refractory.</li>\x0a<li>Bortezomib\x20is\x20given\x20<strong>intravenously\x20or\x20subcutaneously</strong>\x20and\x20dosage\x20depends\x20upon\x20the\x20disease,\x20route\x20of\x20administration\x20and\x20the\x20patient’s\x20history.</li>\x0a<li>Adverse\x20effects\x20include\x20<strong>thrombocytopenia</strong>,\x20fatigue,\x20<strong>peripheral\x20neuropathy</strong>,\x20neutropenia,\x20anemia,\x20anorexia,\x20nausea,\x20limb\x20pain,\x20dizziness,\x20etc.</li>\x0a<li>Other\x20adverse\x20events\x20like\x20cardiac\x20tamponade,\x20disseminated\x20intravascular\x20coagulation,\x20toxic\x20epidermal\x20necrolysis,\x20etc.\x20have\x20been\x20reported.</li>\x0a<li><strong>Update:</strong>\x0a<ul>\x0a<li>The\x20drug\x20was\x20approved\x20in\x20India\x20in\x202017\x20for\x20the\x20treatment\x20of\x20patients\x20with\x20mantle\x20cell\x20lymphoma.</li>\x0a</ul>\x0a</li>\x0a</ul>','zdxLM','explanation_video','RUmCH','Leadership','Orthostatic\x20hypotension','questionNav','<ul>\x0a<li>Government\x20of\x20India\x20has\x20introduced\x20“<strong>Intensified\x20Mission\x20Indradhanush\x20(IMI)</strong>”\x20in\x20select\x20districts\x20and\x20urban\x20areas\x20of\x20the\x20country\x20to\x20achieve\x20the\x20target\x20of\x20<strong>more\x20than\x2090%\x20coverage.</strong></li>\x0a<li>The\x20strategy\x20of\x20IMI\x20is\x20to\x20cover\x20all\x20left\x20outs\x20and\x20drop\x20outs\x20in\x20select\x20districts\x20and\x20urban\x20areas\x20with\x20low\x20routine\x20immunization\x20coverage\x20in\x20a\x20specific\x20time-frame\x20(<strong>December</strong>\x20<strong>2018</strong>).</li>\x0a<li>IMI\x20will\x20focus\x20on\x20<strong>children\x20up\x20to\x202\x20years\x20of\x20age</strong>\x20and\x20pregnant\x20women\x20who\x20have\x20missed\x20out\x20on\x20routine\x20immunization.\x20However,\x20<strong>vaccination\x20on\x20demand\x20to\x20children\x20up\x20to\x205\x20years\x20of\x20age</strong>\x20will\x20be\x20provided\x20during\x20IMI\x20rounds.</li>\x0a<li><strong>Intensified\x20Mission\x20Indradhanush</strong>\x20Immunization\x20drive\x20will\x20be\x20spread\x20over\x207\x20working\x20days\x20starting\x20from\x207th\x20of\x20every\x20month.\x20These\x207\x20days\x20do\x20not\x20include\x20holidays,\x20Sundays\x20and\x20the\x20routine\x20immunization\x20days\x20planned\x20in\x20that\x20week.</li>\x0a</ul>','evRwZ','<p>Trametinib\x20is\x20a\x20<strong>reversible\x20inhibitor</strong>\x20of\x20mitogen-activated\x20extracellular\x20signal\x20regulated\x20kinase\x20(<strong>MEK</strong>).\x20It\x20inhibits\x20the\x20serine-threonine\x20kinase\x20domain\x20of\x20BRAF\x20V600E\x20mutant\x20of\x20MEK.</p>\x0a<p>It\x20is\x20widely\x20used\x20in\x20the\x20treatment\x20of\x20<strong>metastatic\x20or\x20unresectable\x20melanoma</strong></p>\x0a<p>It\x20can\x20be\x20used\x20as\x20a\x20single\x20agent\x20but\x20it\x20is\x20more\x20effective\x20when\x20used\x20with\x20BRAF\x20inhibitors\x20like\x20dabrafenib.</p>\x0a<p><strong>Adverse\x20effects</strong>\x20of\x20this\x20drug\x20include\x20rash,\x20diarrhea,\x20increased\x20ALT,\x20abdominal\x20pain,\x20stomatitis,\x20increased\x20AST,\x20anemia,\x20etc.</p>\x0a<p><strong>Dabrafenib\x20</strong>and\x20<strong>vemurafenib</strong>\x20are\x20<strong>BRAF\x20inhibitors</strong>\x20used\x20in\x20metastatic\x20melanoma.</p>\x0a<p><strong>Ipilimumab</strong>\x20is\x20a\x20human\x20cytotoxic\x20T-lymphocyte\x20antigen\x204\x20(CTLA-4)\x20blocking\x20antibody\x20used\x20in\x20metastatic\x20or\x20unresectable\x20melanoma.</p>','Duchenne\x20dystrophy','replace','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20','bookmarkText','scoreCircle','choices','2|3|5|0|1|4','nav-btn-current','totalQuestions','zBVzb','2251151gEFPsg','Renal\x20cell\x20carcinoma','LolHT','FnooU','search','ENfcT','MHPnX','\x22><span\x20class=\x22font-bold\x20mr-3\x22>','solution','vcrYh','A\x2030\x20year\x20old\x20patient’s\x20history\x20shows\x20a\x20deficiency\x20of\x20glucocerebrosidase\x20and\x20he\x20has\x20the\x20following\x20bone\x20marrow\x20picture.\x20He\x20has\x20been\x20prescribed\x20eliglustat\x20as\x20one\x20of\x20the\x20drugs\x20in\x20his\x20treatment.\x20What\x20is\x20the\x20likely\x20diagnosis?','United\x20Nations\x20Diabetes\x20Federation','gKOmV','getAttribute','kbeIX','\x20>\x20','xgcLO','explanation_audio_hin','removeItem','Class\x20D\x20–\x20No\x20risk','FSVVy','Self-management\x20is\x20not\x20recommended\x20for\x20older\x20people','onclick','correct_choice_id','forEach','BPVTV','appendChild','timeDisplay','NCDGg','review-question\x20','xVamw','<ul>\x0a<li><strong>Padeliporfin</strong>\x20is\x20<strong>palladium\x20bacteriopheophorbide\x20photosensitizer\x20</strong>that\x20is\x20used\x20for\x20treating\x20<strong>men</strong>\x20with\x20<strong>low-risk\x20cancer\x20prostate</strong>\x20(localized).</li>\x0a<li>Padeliporfin\x20is\x20used\x20as\x20part\x20of\x20the\x20procedure\x20known\x20as\x20<strong>vascular-targeted\x20photodynamic\x20therapy\x20(VTP)</strong>.</li>\x0a<li>In\x20this\x20method,\x20the\x20drug\x20is\x20injected\x20into\x20the\x20patient\x20intravenously.\x20Laser\x20light\x20activates\x20this\x20compound\x20when\x20shone\x20on\x20it\x20through\x20optical\x20fibres\x20inserted\x20into\x20the\x20prostate.</li>\x0a<li>Once\x20the\x20compound\x20is\x20activated,\x20it\x20triggers\x20high\x20levels\x20of\x20oxygen\x20radicals\x20to\x20be\x20produced\x20which\x20cause\x20destruction\x20of\x20the\x20blood\x20supply\x20to\x20cancer\x20cells.</li>\x0a<li>Most\x20common\x20side\x20effects\x20of\x20this\x20drug\x20are\x20problems\x20with\x20<strong>urination,\x20sexual\x20problems,\x20urinary\x20tract\x20infections,\x20blood\x20in\x20urine</strong>,\x20etc.</li>\x0a<li>It\x20is\x20<strong>contraindicated\x20in\x20patients\x20with\x20cholestasis</strong>,\x20patients\x20having\x20undergone\x20other\x20prostate\x20operations\x20or\x20those\x20who\x20have\x20flare-ups\x20of\x20inflammatory\x20bowel\x20disease.</li>\x0a<li><strong>Update:\x20</strong>It\x20was\x20approved\x20for\x20usage\x20in\x20Europe\x20in\x202017\x20by\x20the\x20European\x20Commission\x20under\x20the\x20name\x20<strong>Tookad</strong>.</li>\x0a</ul>','RKEJl','TmxxU','bHwHA','myyDp','markedForReview','Prucalopride\x20was\x20approved\x20in\x20India\x20and\x20the\x20U.S.\x20FDA\x20approved\x20plecanatide;\x20both\x20in\x202017.\x20What\x20are\x20these\x20drugs\x20used\x20for?','You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?','Scheie\x20syndrome','No\x20questions\x20available\x20for\x20this\x20quiz.','VJwoV','1st\x20August\x20–\x207th\x20August','correct','avDwE','Suicidal\x20ideation','tGyxI','ZpsjZ','qWcqA','XwDUF','aJThJ','QNnho','A\x20person\x20between\x20the\x20age\x20of\x2012\x20to\x2018\x20years\x20can\x20act\x20as\x20guardian\x20to\x20other\x20sibling\x20in\x20an\x20HIV\x20affected\x20family','jmWYJ','loLQY','1st\x20July\x20–\x207th\x20July','target','Human\x20immunodeficiency\x20virus','Which\x20of\x20the\x20following\x20is\x20not\x20true\x20about\x20the\x20approved\x20usage\x20of\x20ribociclib\x20in\x20breast\x20cancer?','flex','getElementById','length','VfFms','lkAjn','WLyuZ','No\x20solution\x20available.','rsPTT','LEVii','Non-availability\x20of\x20other\x20second\x20line\x20drugs','Reduce\x20transmission\x20in\x20category\x202\x20districts\x20by\x202022','gray','navBtn_','rpbvV','pFqlJ','It\x20is\x20a\x20cyclopentapeptide\x20somatostatin\x20analogue','bookmarkedQuestions','jYNzl','UaxNO','HRMuW','rBafp','Informed\x20consent\x20is\x20mandatory\x20for\x20performing\x20HIV\x20test','split','Fluctuating\x20cognition','None\x20of\x20the\x20above','https://cdn1.dailyrounds.org/uploads/186dbc5a5ab04351b9368bd4554ac6c2.JPEG','hjgCt','push','<ul>\x0a<li><strong>The\x20National\x20nutrition\x20strategy</strong>\x20was\x20launched\x20recently,\x20in\x20<strong>September\x202017.</strong></li>\x0a<li>The\x20nutrition\x20strategy\x20envisages\x20a\x20framework\x20wherein\x20the\x20four\x20proximate\x20determinants\x20of\x20nutrition\x20which\x20includes\x20<strong>uptake\x20of\x20health\x20services</strong>,\x20<strong>food</strong>,\x20<strong>drinking</strong>\x20<strong>water\x20&amp;\x20sanitation,</strong>\x20and\x20<strong>income\x20&amp;\x20livelihoods</strong>,\x20work\x20together\x20to\x20accelerate\x20decline\x20of\x20under\x20nutrition\x20in\x20India.</li>\x0a</ul>\x0a<p><strong>Goals\x20of\x20National\x20Nutrition\x20Strategy:</strong></p>\x0a<ul>\x0a<li>To\x20prevent\x20and\x20reduce\x20undernutrition\x20(<strong>underweight\x20prevalence</strong>)\x20in\x20children\x20(0-\x205\x20years)\x20by\x203\x20percentage\x20points\x20per\x20annum\x20from\x20NFHS\x204\x20levels\x20by\x202022.\x20(i.e.,\x20to\x20reduce\x20it\x20to\x20<strong>20.7%\x20</strong>in\x20a\x20span\x20of<strong>\x20five\x20years</strong>\x20from\x20<strong>previous\x2035.7%</strong>).</li>\x0a<li>To\x20reduce\x20the\x20<strong>prevalence\x20of\x20anemia</strong>\x20among\x20young\x20children,\x20adolescent\x20girls\x20and\x20women\x20in\x20the\x20reproductive\x20age\x20group\x20(15-\x2049\x20years)\x20by\x20one\x20third\x20of\x20NFHS\x204\x20levels\x20by\x202022.</li>\x0a</ul>\x0a<table\x20style=\x22width:\x20436.2px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20180px;\x22><strong>Monitorable\x20Outcomes</strong></td>\x0a<td\x20style=\x22width:\x20135px;\x22><strong>Current\x20status</strong></td>\x0a<td\x20style=\x22width:\x20106.2px;\x22><strong>Target\x202022</strong></td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20180px;\x22>Reduction\x20in\x20%\x20age\x20of\x20underweight\x20&nbsp;(Below-2SD)\x20children\x20below\x205\x20years</td>\x0a<td\x20style=\x22width:\x20135px;\x22>35.7</td>\x0a<td\x20style=\x22width:\x20106.2px;\x22>20.7</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20180px;\x22>Reduction\x20in\x20prevalence\x20of\x20anemia&nbsp;\x20in\x20children\x20(6-59\x20months)</td>\x0a<td\x20style=\x22width:\x20135px;\x22>58.4</td>\x0a<td\x20style=\x22width:\x20106.2px;\x22>19.5</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20180px;\x22>Reduction\x20in\x20prevalence\x20of\x20anemia&nbsp;\x20in\x20women\x20and\x20girls\x20(15-49\x20years)</td>\x0a<td\x20style=\x22width:\x20135px;\x22>53.1</td>\x0a<td\x20style=\x22width:\x20106.2px;\x22>17.7</td>\x0a</tr>\x0a</tbody>\x0a</table>','ArrowLeft','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','yroFo','GNCZu','Not\x20recommended\x20in\x20patients\x20with\x20decompensated\x20cirrhosis','Secondary\x20hyperparathyroidism\x20with\x20chronic\x20kidney\x20disease\x20on\x20dialysis','AimgT','cUMGd','oZZFs','Weight\x20for\x20length\x20≥\x20–3\x20SD','accuracy','<ul>\x0a<li>Latanoprostene\x20bunod\x20(LBN)\x20is\x20an\x20<strong>ophthalmic\x20solution</strong>\x20which\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>open-angle\x20glaucoma</strong>\x20or\x20<strong>ocular\x20hypertension</strong>.</li>\x0a<li>It\x20is\x20an\x20<strong>NO-donating\x20prostaglandin\x20F2\x20alpha\x20receptor\x20agonist</strong>.</li>\x0a<li>It\x20<strong>reduces\x20the\x20intraocular\x20pressure</strong>\x20by\x20increasing\x20aqueous\x20outflow\x20through\x20the\x20trabecular\x20meshwork\x20and\x20uveoscleral\x20routes.</li>\x0a<li>Common\x20side-effects\x20include\x20conjunctival\x20hyperemia,\x20eye\x20irritation\x20and\x20pain\x20in\x20the\x20instillation\x20site.</li>\x0a<li>It\x20is\x20administered\x20as\x20eye\x20drops\x20to\x20be\x20instilled\x20once\x20a\x20day\x20in\x20the\x20evening.</li>\x0a<li>If\x20other\x20drugs\x20are\x20being\x20used\x20for\x20the\x20eye,\x20it\x20has\x20to\x20be\x20given\x205\x20minutes\x20apart.</li>\x0a<li>It\x20was\x20approved\x20for\x20this\x20usage\x20by\x20the\x20FDA\x20in\x202017.</li>\x0a</ul>','Recommended\x20as\x20first-\x20or\x20second-choice\x20treatments\x20for\x20a\x20small\x20number\x20of\x20infections','It\x20is\x20a\x20cyclin-dependent\x20kinase\x205\x20inhibitor','<p>As\x20per\x20the\x20provisions\x20of\x20the\x20HIV\x20and\x20AIDS\x20(Prevention\x20and\x20Control)\x20Act,\x202017,\x20every\x20HIV\x20positive\x20person\x20who\x20is\x20protected\x20have\x20the\x20right\x20to\x20reside\x20in\x20a\x20shared\x20household,\x20and\x20enjoy\x20the\x20facilities\x20of\x20the\x20household.\x20There\x20is\x20no\x20age\x20limit\x20to\x20the\x20provision\x20of\x20shared\x20household.</p>','Apixaban','735160wxZwEw','OQwzY','Intercourse\x20with\x20wife\x20less\x20than\x2018\x20years\x20of\x20age','KLCjR','ByePy','ukTch','modeModal','src','gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','wbfhN','mbmth','<p><strong>Guidelines\x20for\x20Seasonal\x20Influenza\x20Vaccination\x202017-2018:</strong></p>\x0a<p>The\x20Directorate\x20General\x20of\x20Health\x20Services\x20has\x20recently\x20updated\x20guidelines\x20for\x20vaccination\x20with\x20Influenza\x20Vaccine.</p>\x0a<p><strong>Type\x20of\x20vaccine:</strong>\x20<strong>Trivalent\x20inactivated\x20influenza\x20vaccines</strong>\x20which\x20are\x20made\x20to\x20protect\x20against\x20three\x20flu\x20viruses;\x20an\x20influenza\x20A\x20(H1N1)\x20virus,\x20an\x20influenza\x20A\x20(H3N2)\x20virus,\x20and\x20an\x20influenza\x20B\x20virus.</p>\x0a<p><strong>Persons\x20recommended\x20for\x20vaccination:</strong></p>\x0a<ol>\x0a<li><strong>Health\x20Care\x20workers</strong>,\x20working\x20in\x20hospital\x20/\x20institutional\x20settings\x20(doctors,\x20nurses,\x20paramedics)\x20with\x20likelihood\x20of\x20exposure\x20to\x20Influenza\x20virus\x20should\x20be\x20vaccinated.</li>\x0a<li>Seasonal\x20Influenza\x20may\x20affect\x20all\x20age\x20groups;\x20globally\x20incidence\x20is\x20higher\x20in\x20young\x20<strong>children\x20between\x206\x20months\x20to\x208\x20years\x20of\x20age</strong>,\x20and\x20<strong>those\x20above\x2065\x20years.</strong>\x20Hence\x20it\x20is\x20desirable\x20to\x20vaccinate\x20these\x20age\x20groups.</li>\x0a<li>Vaccine\x20is\x20<strong>recommended\x20for\x20pregnant\x20women</strong>,\x20irrespective\x20of\x20the\x20duration\x20of\x20pregnancy.</li>\x0a<li>For\x20adults\x20and\x20children\x20with\x20chronic\x20illnesses</li>\x0a</ol>','QwdQI','XexGx','HMpnm','Eiraz','Twice\x20weekly\x20regimen\x20in\x20intensive\x20phase\x20followed\x20by\x20thrice\x20weekly\x20regimen\x20in\x20continuation\x20phase','get','ccuWJ','HFTMb','The\x20recently\x20FDA\x20approved\x20drug,\x20letermovir,\x20is\x20used\x20against\x20which\x20virus\x20in\x20hematopoietic\x20stem\x20cell\x20recipients?','fill','toggle','parse','performanceModal','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>','dclNI','azGyr','<ul>\x0a<li>According\x20to\x20the\x20provisions\x20of\x20the\x20<strong>Medical\x20Devices\x20Rules\x20of\x20India,\x202017</strong>,\x20the\x20classification\x20of\x20medical\x20devices\x20and\x20in-vitro\x20diagnostic\x20medical\x20devices\x20is\x20done\x20based\x20on\x20the\x20risks\x20related\x20to\x20their\x20use.</li>\x0a<li>According\x20to\x20the\x20class\x20of\x20the\x20device,\x20it\x20will\x20go\x20through\x20a\x20specific\x20approval\x20process.</li>\x0a</ul>\x0a<table\x20style=\x22width:\x20462px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x2056px;\x22><strong>Class</strong></td>\x0a<td\x20style=\x22width:\x20133px;\x22>Risk</td>\x0a<td\x20style=\x22width:\x20253px;\x22>Examples</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2056px;\x22><strong>Class\x20A</strong></td>\x0a<td\x20style=\x22width:\x20133px;\x22>Low\x20risk</td>\x0a<td\x20style=\x22width:\x20253px;\x22>Nasopharyngeal\x20catheter,\x20surgical\x20dressings\x20like\x20dressing\x20pad,\x20etc.</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2056px;\x22><strong>Class\x20B</strong></td>\x0a<td\x20style=\x22width:\x20133px;\x22>Low\x20moderate\x20risk</td>\x0a<td\x20style=\x22width:\x20253px;\x22>AV\x20shunt,\x20endoscopic\x20forceps,\x20rectal\x20balloon,\x20tracheostomy\x20tube.</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2056px;\x22><strong>Class\x20C</strong></td>\x0a<td\x20style=\x22width:\x20133px;\x22>High\x20moderate\x20risk</td>\x0a<td\x20style=\x22width:\x20253px;\x22>Bone\x20cement,\x20hemodialysis\x20catheter,\x20etc.</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2056px;\x22><strong>Class\x20D</strong></td>\x0a<td\x20style=\x22width:\x20133px;\x22>High\x20risk</td>\x0a<td\x20style=\x22width:\x20253px;\x22>Coronary\x20stents,\x20cerebrospinal\x20catheter,\x20etc.</td>\x0a</tr>\x0a</tbody>\x0a</table>','<p>The\x20<strong>National\x20Strategic\x20Plan\x20(NSP)\x20for\x20Malaria\x20Elimination\x20(2017-22)</strong>\x20was\x20launched\x20by\x20the\x20Ministry\x20of\x20Health\x20and\x20Family\x20Welfare\x20under\x20NVBDCP.\x20The\x20strategy\x20focuses\x20on\x20the\x20<strong>districts</strong>\x20which\x20acts\x20as\x20the\x20operational\x20units.</p>\x0a<p><strong>Goals\x20of\x20National\x20Strategic\x20Plan\x20for\x20Malaria\x20elimination\x20are:</strong></p>\x0a<ul>\x0a<li>Eliminate\x20malaria\x20in\x20<strong>category</strong>\x201\x20(API\x20&lt;\x201)\x20districts\x20by\x20<strong>2020</strong>,\x20and\x20<strong>category\x202</strong>\x20(API\x201\x20-\x202)\x20districts\x20by\x20<strong>2022</strong>.</li>\x0a<li>Reduce\x20transmission\x20in\x20category\x203\x20districts\x20by\x20to\x20stabilize\x20API\x20at\x20<strong>less\x20than\x201\x20by\x202022</strong></li>\x0a</ul>','<ul>\x0a<li>The\x20combination\x20regimen\x20of\x20<strong>glecaprevir\x20(100mg)\x20and\x20pibrentasvir\x20(40mg)</strong>\x20is\x20used\x20to\x20treat\x20<strong>hepatitis\x20C\x20virus\x20(HCV)</strong>\x20infections\x20in\x20<strong>adults</strong>\x20under\x20particular\x20indications.</li>\x0a<li><strong>Indications:</strong>\x0a<ul>\x0a<li>It\x20is\x20indicated\x20in\x20<strong>treatment-naïve\x20adults</strong>\x20with\x20chronic\x20HCV\x20infections\x20from\x20<strong>HCV\x20genotypes\x201-6</strong>,\x20without\x20cirrhosis\x20or\x20with\x20compensated\x20cirrhosis.</li>\x0a<li>It\x20is\x20also\x20indicated\x20in\x20the\x20treatment\x20of\x20adults\x20with\x20chronic\x20HCV\x20who\x20have\x20been\x20<strong>previously\x20treated\x20with\x20a\x20regimen\x20containing\x20either\x20non-structural\x20protein\x205A\x20(NS5A)\x20inhibitor\x20or\x20an\x20NS3/4A\x20protease\x20inhibitor\x20but\x20not\x20both</strong>.</li>\x0a<li>It\x20<strong>can\x20also\x20be\x20used\x20in\x20patients\x20with\x20moderate\x20to\x20severe\x20kidney\x20disease\x20and\x20those\x20who\x20are\x20on\x20dialysis</strong>.</li>\x0a</ul>\x0a</li>\x0a<li><strong>Pharmacology:</strong>\x0a<ul>\x0a<li><strong>Glecaprevir</strong>\x20is\x20an\x20<strong>HCV\x20NS3/4A\x20protease\x20inhibitor</strong>\x20and\x20<strong>pibrentasvir</strong>\x20is\x20an\x20<strong>HCV\x20NS5A\x20inhibitor</strong>.</li>\x0a</ul>\x0a</li>\x0a<li><strong>Contraindications\x20and\x20adverse\x20effects:</strong>\x0a<ul>\x0a<li>It\x20is\x20<strong>contraindicated</strong>\x20in\x20usage\x20with\x20rifampin\x20&amp;\x20atazanavir,\x20severe\x20hepatic\x20impairment.</li>\x0a<li><strong>Adverse\x20effects</strong>\x20include\x20headache,\x20fatigue,\x20nausea,\x20diarrhea\x20and\x20increased\x20bilirubin.</li>\x0a</ul>\x0a</li>\x0a<li>Duration\x20of\x20the\x20treatment\x20with\x20this\x20regimen\x20depends\x20upon\x20treatment\x20history,\x20viral\x20genotype\x20and\x20cirrhosis\x20status.</li>\x0a<li>It\x20is\x20given\x20<strong>orally</strong>.</li>\x0a<li><strong>Update:</strong>\x0a<ul>\x0a<li>It\x20was\x20approved\x20by\x20regulatory\x20bodies\x20for\x20usage\x20in\x202017,\x20in\x20US\x20and\x20Europe.</li>\x0a<li>It\x20is\x20distributed\x20under\x20the\x20trade\x20name\x20Mavyret.</li>\x0a<li>Another\x20regimen\x20for\x20HCV\x20infection\x20that\x20has\x20been\x20recently\x20approved\x20is\x20<strong>sofosbuvir\x20+\x20velpatasvir\x20+\x20volxilaprevir.</strong></li>\x0a</ul>\x0a</li>\x0a</ul>','markReviewBtn','aOHQL','Subcutaneous','KvjwT','XpBhg','8rAnVsd','red','rRFQa','Hunter\x20syndrome','resume','study','not_attempted','explanationVideoPlayer','dxvhg','≤\x20\x2080\x20mg/dL','SQFJO','1st\x20September\x20–\x207th\x20September','TBXkM','nav-btn-correct','<ul>\x0a<li><strong>Ending\x20Cholera&mdash;A\x20Global\x20Roadmap\x20to\x202030</strong>,\x20is\x20a\x20strategy\x20released\x20by\x20the\x20<strong>WHO</strong>\x20<strong>Global\x20Task\x20Force\x20on\x20Cholera\x20Control\x20(GTFCC</strong>).\x20By\x20implementing\x20the\x20strategy\x20between\x202017\x20and\x202030,\x20the\x20GTFCC\x20partners\x20will\x20support\x20countries\x20to\x20<strong>reduce\x20cholera\x20deaths\x20by\x2090\x20percent</strong>.</li>\x0a<li>Large-scale\x20use\x20of\x20<strong>Oral\x20Cholera\x20Vaccine\x20(OCV)</strong>\x20has\x20been\x20recommended\x20to\x20immediately\x20reduce\x20disease\x20burden\x20while\x20longer-term\x20cholera\x20control\x20strategies\x20are\x20put\x20in\x20place.</li>\x0a</ul>','nQjvK','<ul>\x0a<li><strong>Agratroban</strong>\x20is\x20<strong>a\x20univalent,\x20competitive,\x20direct\x20thrombin\x20inhibitor</strong>\x20that\x20reversibly\x20binds\x20to\x20thrombin\x20active\x20site.</li>\x0a<li>It\x20is\x20indicated\x20for\x20use\x20as\x20a\x20<strong>parenteral\x20anticoagulant</strong>\x20in\x20<strong>prophylaxis\x20or\x20treatment\x20of\x20patients\x20with\x20heparin-induced\x20thrombocytopenia.</strong></li>\x0a<li>It\x20is\x20also\x20indicated\x20in\x20patients\x20<strong>at\x20risk\x20for\x20or\x20with\x20heparin-induced\x20thrombocytopenia\x20undergoing\x20percutaneous\x20coronary\x20intervention\x20(PCI).</strong></li>\x0a<li>It\x20prolongs\x20the\x20aPTT,\x20PT\x20and\x20INR.\x20This\x20complicates\x20the\x20transitioning\x20of\x20patients\x20from\x20argatroban\x20to\x20warfarin.</li>\x0a<li>It\x20is\x20metabolized\x20in\x20the\x20liver\x20and\x20doesn&rsquo;t\x20undergo\x20renal\x20clearance.</li>\x0a<li>It\x20is\x20recommended\x20not\x20to\x20perform\x20spinal\x20or\x20epidural\x20anesthesia\x20on\x20patients\x20using\x20this\x20drug.</li>\x0a<li>Adverse\x20effects\x20include\x20GI\x20bleeding\x20and\x20hematuria.\x20Less\x20common\x20side\x20effects\x20are\x20headache,\x20dyspnea,\x20diarrhea,\x20etc.</li>\x0a<li>Other\x20direct\x20thrombin\x20inhibitors\x20are\x20lepirudin,\x20desirudin\x20and\x20bivalirudin.</li>\x0a<li><strong>Update:\x20</strong>It\x20was\x20approved\x20for\x20usage\x20in\x20these\x20cases\x20in\x20India,\x20in\x202017.</li>\x0a<li><strong>Fondaparinux\x20</strong>is\x20an\x20antithrombotic\x20agent\x20that\x20inhibits\x20factor\x20Xa.</li>\x0a<li><strong>Warfarin</strong>\x20is\x20a\x20vitamin\x20K\x20antagonist.</li>\x0a<li><strong>Danaparoid</strong>\x20is\x20a\x20mixture\x20of\x20glycosaminoglycans\x20with\x20anti-Xa\x20activity.</li>\x0a</ul>','tDNPu','Family\x20participation\x20for\x20improving\x20newborn\x20health','nav-btn-incorrect','Children\x20(24\x20–\x2059\x20months\x20of\x20age)','OCgVt','Ipilimumab','Warfarin','The\x20National\x20Nutrition\x20Week\x20of\x202017\x20in\x20India\x20was\x20observed\x20during\x20______','100\x20mg\x20daily\x20for\x2028\x20days','ZOkbQ','Daily\x20regimen\x20in\x20both\x20intensive\x20and\x20continuation\x20phases','reviewQuestionsContainer','ExUXS','udKOT','JAFdd','Maroteaux-Lamy\x20syndrome','Recommended\x20as\x20third\x20line\x20drugs','YgnJY','bBRig','MHhJJ','open','Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','\x22\x20data-src=\x22','Non-pregnant\x20women\x20of\x20reproductive\x20age','innerHTML','hTknj','YoTjv','yyQvj','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','wmQNB','Correct','<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-','dMFJV','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22','Catch-up\x20vaccination\x20is\x20recommended\x20in\x20the\x20age\x20group\x20below\x2015\x20years','console','oGFIb','round','prevBtn','ZDkXK','pyjka','jzcLS','75%\x20by\x20December\x202020','completed','<p><strong>Guselkumab</strong>\x20is\x20a\x20<strong>monoclonal\x20antibody</strong>\x20that\x20<strong>inhibits\x20interleukin-23</strong>\x20by\x20binding\x20to\x20its\x20p19\x20subunit.\x20By\x20this,\x20it\x20inhibits\x20the\x20pro-inflammatory\x20actions\x20of\x20IL-23,\x20decreasing\x20cytokine\x20and\x20chemokine\x20release.</p>\x0a<p>It\x20is\x20indicated\x20for\x20use\x20in\x20<strong>moderate-to-severe\x20plaque\x20psoriasis</strong>,\x20when\x20the\x20patient\x20is\x20a\x20possible\x20candidate\x20for\x20systemic\x20therapy\x20or\x20if\x20early\x20systemic\x20therapy\x20is\x20the\x20logical\x20option\x20for\x20a\x20patient.\x20It\x20is\x20given\x20as\x20a\x20<strong>subcutaneous\x20injection</strong>\x20at\x20a\x20dose\x20of\x20<strong>100mg</strong>\x20at\x20week\x200,\x20week\x204\x20and\x20every\x208\x20weeks\x20thereafter.</p>\x0a<p>Adverse\x20effects\x20of\x20guselkumab\x20include\x20the\x20<strong>risk\x20of\x20general\x20infections\x20and\x20upper\x20respiratory\x20tract\x20infections</strong>\x20(most\x20common).\x20Other\x20adverse\x20events\x20include\x20headache,\x20injection\x20site\x20reaction,\x20arthralgia,\x20diarrhea,\x20gastroenteritis,\x20and\x20tinea\x20infections.</p>\x0a<p>&nbsp;Other\x20Options:</p>\x0a<ul>\x0a<li><strong>Brodalumab</strong>\x20is\x20a\x20fully\x20human\x20<strong>IL-17RA</strong>\x20monoclonal\x20antibody\x20that\x20inhibits\x20the\x20interaction\x20of\x20IL-17\x20with\x20cytokines.\x20It\x20also\x20received\x20approval\x20for\x20usage\x20in\x20plaque\x20psoriasis.</li>\x0a<li><strong>Ixekizumab</strong>\x20is\x20also\x20indicated\x20for\x20use\x20in\x20<strong>plaque\x20psoriasis.</strong>\x20It\x20neutralizes\x20the\x20pro-inflammatory\x20effects\x20of\x20<strong>IL-17A</strong>\x20by\x20inhibition.</li>\x0a<li><strong>Etanercept</strong>\x20is\x20a&nbsp;<strong>tumor\x20necrosis\x20factor-&alpha;\x20(TNF&alpha;)\x20inhibitor</strong>.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20conditions\x20like\x20ankylosing\x20spondylitis,\x20rheumatoid\x20arthritis\x20(adult\x20and\x20juvenile),\x20psoriatic\x20arthritis\x20and\x20plaque\x20psoriasis.</li>\x0a</ul>','padStart','1st\x20June\x20–\x207th\x20June','YhCcX','fHFwp','wvqFb','90%\x20by\x20December\x202020','apjqf','In\x202017,\x20the\x20WHO\x20released\x20a\x20road\x20safety\x20technical\x20package\x20called\x20Save\x20LIVES.\x20Which\x20of\x20the\x20following\x20is\x20not\x20a\x20component\x20of\x20this\x20package?','Ebstein-Barr\x20virus','diPtv','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','Brodalumab','div','Eflornithine','fAXVh','RwHXB','uYAFc','Which\x20of\x20the\x20following\x20is\x20true\x20regarding\x20the\x20SAGE\x202017\x20recommendations\x20for\x20typhoid\x20vaccine?','name','ebfyf','<p>New\x20advice\x20on\x20which\x20antibiotics\x20to\x20use\x20for\x20common\x20infections\x20and\x20which\x20to\x20preserve\x20for\x20the\x20most\x20serious\x20circumstances\x20is\x20among\x20the\x20additions\x20to\x20the\x20<strong>WHO\x20Essential\x20Medicines\x20List\x20(EML),\x202017.</strong></p>\x0a<p>In\x20the\x20biggest\x20revision\x20of\x20the\x20antibiotics\x20section\x20in\x20the\x20EML’s\x2040-year\x20history,\x20WHO\x20experts\x20have\x20grouped\x20antibiotics\x20into\x20three\x20categories\x20–\x20<strong>ACCESS</strong>,\x20<strong>WATCH</strong>\x20and\x20<strong>RESERVE</strong>\x20–\x20with\x20recommendations\x20on\x20when\x20each\x20category\x20should\x20be\x20used.</p>\x0a<ul>\x0a<li><strong>ACCESS\x20group</strong>:\x20Antibiotics\x20that\x20are\x20meant\x20to\x20be\x20available\x20at\x20all\x20times\x20as\x20treatments\x20for\x20a\x20wide\x20range\x20of\x20common\x20infections.\x20For\x20example,\x20it\x20includes\x20<strong>amoxicillin</strong>,\x20a\x20widely-used\x20antibiotic\x20to\x20treat\x20infections\x20such\x20as\x20pneumonia.</li>\x0a<li><strong>WATCH\x20group:\x20</strong>It\x20includes\x20antibiotics\x20that\x20are\x20recommended\x20as\x20<strong>first-\x20or\x20second-choice\x20treatments</strong>\x20for\x20a\x20small\x20number\x20of\x20infections.\x20For\x20example,\x20the\x20use\x20of\x20<strong>ciprofloxacin</strong>,\x20used\x20to\x20treat\x20cystitis\x20(a\x20type\x20of\x20urinary\x20tract\x20infection)\x20and\x20upper\x20respiratory\x20tract\x20infections\x20(such\x20as\x20bacterial\x20sinusitis\x20and\x20bacterial\x20bronchitis),\x20should\x20be\x20dramatically\x20reduced\x20to\x20avoid\x20further\x20development\x20of\x20resistance.</li>\x0a<li><strong>RESERVE\x20group</strong>:\x20It\x20includes\x20antibiotics\x20such\x20as\x20<strong>colistin</strong>\x20and\x20some\x20cephalosporins\x20that\x20should\x20be\x20considered\x20last-resort\x20options,\x20and\x20used\x20only\x20in\x20the\x20most\x20severe\x20circumstances\x20when\x20all\x20other\x20alternatives\x20have\x20failed,\x20such\x20as\x20for\x20life-threatening\x20infections\x20due\x20to\x20multidrug-resistant\x20bacteria.</li>\x0a</ul>','World\x20Diabetes\x20Day,\x20which\x20is\x20conducted\x20every\x20year,\x20is\x20an\x20initiative\x20by','Dementia','GllDz','<ul>\x0a<li><strong>Mucopolysaccharidosis\x20type\x20VII</strong>\x20(MPS\x20VII)\x20is\x20also\x20called\x20<strong>Sly\x20syndrome.</strong></li>\x0a<li>It\x20is\x20a\x20rare\x20<strong>lysosomal\x20storage\x20disease</strong>\x20and\x20an\x20<strong>autosomal\x20recessive\x20disorder</strong>\x20where\x20there\x20is\x20<strong>deficiency\x20of\x20β-glucuronidase</strong>.</li>\x0a<li>Neonatal\x20form\x20of\x20Sly\x20syndrome\x20presents\x20with\x20fetal\x20hydrops.</li>\x0a<li>Infantile\x20and\x20adult\x20forms\x20of\x20this\x20disease\x20have\x20wide-ranging\x20clinical\x20features\x20which\x20include\x20skeletal\x20dysplasia,\x20corneal\x20clouding,\x20leucocytic\x20inclusions,\x20coarse\x20facies,\x20etc.\x20Mental\x20retardation\x20may\x20develop\x20in\x20the\x20infantile\x20form\x20but\x20adults\x20rarely\x20manifest\x20it.</li>\x0a<li><strong>Update:</strong>\x0a<ul>\x0a<li><strong>Vestronidase\x20alfa-vbjk</strong>\x20has\x20been\x20approved\x20by\x20the\x20American\x20regulatory\x20body\x20FDA,\x20in\x202017,\x20for\x20use\x20in\x20<strong>treatment\x20of</strong>\x20<strong>mucopolysaccharidosis\x20type\x20VII</strong>\x20(MPS\x20VII)\x20in\x20adults\x20and\x20pediatric\x20patients.</li>\x0a<li>Vestronidase\x20alfa-vjbk\x20is\x20a\x20<strong>recombinant\x20human\x20enzyme</strong>\x20that\x20is\x20intended\x20to\x20provide\x20exogenous\x20β-glucuronidase\x20for\x20uptake\x20into\x20cellular\x20lysosome.</li>\x0a<li>It\x20is\x20given\x20as\x20<strong>an\x20intravenous\x20infusion</strong>.</li>\x0a<li>Side\x20effects\x20related\x20to\x20the\x20administration\x20of\x20this\x20drug\x20<strong>are\x20infusion\x20site\x20reaction,\x20anaphylaxis,\x20diarrhea\x20and\x20rash</strong>.\x20The\x20CNS\x20effects\x20of\x20this\x20drug\x20have\x20not\x20been\x20determined.</li>\x0a</ul>\x0a</li>\x0a<li><strong>MPS\x20I\x20S</strong>\x20is\x20called\x20<strong>Scheie\x20syndrome.</strong>\x20<strong>MPS\x20II</strong>\x20is\x20called\x20<strong>Hunter\x20syndrome\x20</strong>and\x20<strong>MPS\x20VI</strong>\x20is\x20called\x20<strong>Maroteaux-Lamy\x20syndrome.</strong></li>\x0a</ul>','pRmiw','Hospital-based\x20interventions\x20are\x20recommended','lVLyj','alsYO','agGUY','cljlR','setItem','jKKNw','style','table','Which\x20of\x20the\x20following\x20statements\x20is\x20true\x20with\x20regards\x20to\x20the\x20Ending\x20Cholera—A\x20Global\x20Roadmap\x20to\x202030,\x20recently\x20released\x20by\x20the\x20WHO\x20-\x20Global\x20Task\x20Force\x20on\x20Cholera\x20Control\x20(GTFCC)?','jjnKl','YJurm','Contraindicated\x20in\x20severe\x20hepatic\x20impairment','PsayD','attachMedia','LwAoZ','includes','<p><strong>Severe\x20acute\x20malnutrition:</strong></p>\x0a<p>In\x20infants\x20and\x20children\x20under\x205\x20years\x20of\x20age,\x20refers\x20to\u00a0</p>\x0a<ul>\x0a<li><strong>Weight-for\x20length/height</strong>\x20more\x20than\x203\x20SD\x20below\x20the\x20median\x20(<strong>&lt;\x20–3SD</strong>)\x20of\x20the\x20WHO\x20child\x20growth\x20standards</li>\x0a</ul>\x0a<p>Or</p>\x0a<ul>\x0a<li><strong>Mid-upper\x20arm\x20circumference</strong>\x20&lt;115\u00a0mm</li>\x0a</ul>\x0a<p>Or</p>\x0a<ul>\x0a<li>Clinical\x20signs\x20of\x20<strong>bilateral\x20pitting\x20oedema</strong>\x20of\x20nutritional\x20origin.</li>\x0a</ul>\x0a<p>\u00a0</p>\x0a<p><strong>Update:</strong></p>\x0a<p><strong>WHO</strong>\x20in\x20october\x202017,\x20has\x20released\x20guidelines\x20for\x20Assessing\x20and\x20managing\x20children\x20at\x20primary\x20health-care\x20facilities\x20to\x20prevent\x20overweight\x20and\x20obesity\x20in\x20the\x20context\x20of\x20the\x20double\x20burden\x20of\x20malnutrition.</p>\x0a<p>Three\x20specific\x20areas\x20and\x20related\x20questions\x20were\x20prioritized\x20in\x20the\x20guidelines:</p>\x0a<p>(i)\u00a0<strong>Anthropometric\x20assessment</strong>\x20and\x20<strong>classification\x20of\x20the\x20nutritional\x20status</strong>\x20of\x20infants\x20and\x20children\x20presenting\x20to\x20primary\x20health-care\x20facilities</p>\x0a<p>(ii)\x20Management\x20of\x20infants\x20and\x20children\x20with\x20acute\x20or\x20chronic\x20malnutrition\u00a0presenting\x20to\x20primary\x20health-care\x20facilities</p>\x0a<p>(iii)\u00a0Management\x20of\x20children\x20who\x20are\x20overweight\x20or\x20obese\x20presenting\x20to\x20primary\x20health-care\x20facilities.</p>\x0a<p>\u00a0</p>','AmBNf','{}.constructor(\x22return\x20this\x22)(\x20)','Oral','custom_quiz.html','<p>The\x20principle\x20of\x20<strong>treatment\x20of\x20TB</strong>\x20has\x20been\x20shifted\x20towards<strong>\x20daily\x20regimen</strong>\x20with\x20administration\x20of\x20<strong>daily\x20fixed\x20dose\x20combination</strong>\x20of\x20<strong>first-line\x20ATD</strong>\x20as\x20per\x20appropriate\x20weight\x20bands.</p>\x0a<p>The\x20new\x20daily\x20drug\x20regimen\x20has\x20been\x20adopted\x20under\x20<strong>national\x20strategic\x20plan\x20for\x20tuberculosis\x20elimination,\x202017-2025.</strong></p>\x0a<p><strong>For\x20new\x20TB\x20cases:</strong></p>\x0a<ul>\x0a<li>Treatment\x20in\x20Intensive\x20phase\x20will\x20consist\x20of\x208\x20weeks\x20of\x20INH,\x20Rifampicin,\x20Pyrazinamide\x20and\x20Ethambutol\x20in\x20daily\x20dosages\x20as\x20per\x20four\x20weight\x20bands\x20categories</li>\x0a<li>Only\x20Pyrazinamide\x20will\x20be\x20stopped\x20in\x20CP\x20while\x20the\x20other\x20three\x20drugs\x20will\x20be\x20continued\x20for\x20another\x2016\x20weeks\x20as\x20daily\x20dosages.</li>\x0a</ul>','Bookmark','gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','fYMTP','RoBWV','NbklT','selected','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','mleDZ','hkqAu','Parathyroid\x20carcinoma','SkDlF','nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','incorrect','jigxn','The\x20newly\x20detected\x20TB\x20cases\x20throughout\x20India\x20shall\x20now\x20be\x20treated\x20with\x20which\x20of\x20the\x20following\x20regimens?','giHPD','AVpfJ','Pick\x20the\x20new\x20anti-coagulant\x20from\x20the\x20following\x20line-up\x20that\x20has\x20recently\x20been\x20approved\x20for\x20usage\x20in\x20the\x20prophylaxis\x20of\x20venous\x20thromboembolism\x20(VTE)\x20in\x20medically\x20ill\x20patients.','IvyUJ','status','Subcutaneous\x20spheroids','Which\x20of\x20the\x20following\x20statements\x20is\x20true\x20about\x20national\x20strategic\x20plan\x20for\x20malaria\x20elimination\x202017\x20–\x202022?','koOrt','apply','LvFyx','Fondaparinux','gZoaw','tMzeW','test','Quadrivalent\x20vaccine\x20for\x20elderly\x20individuals\x20more\x20than\x2065\x20years\x20of\x20age','A\x2019\x20year\x20old\x20boy,\x20weighing\x2062kgs,\x20is\x20suffering\x20from\x20visceral\x20leishmaniasis.\x20The\x20recommended\x20dosage\x20for\x20miltefosine\x20is\x20_______','cgEpY','Sgsok','VOBaV','nav-btn-answered','Farber\x20disease','Which\x20of\x20the\x20following\x20statements\x20is\x20correct\x20concerning\x20the\x20WHO\x20Baby-Friendly\x20Hospital\x20Initiative\x20for\x20small,\x20sick,\x20and\x20preterm\x20newborns\x20(2020)?','PLsJk','zSVCv','\x22\x20data-option-index=\x22','iDCZi','Used\x20only\x20in\x20HR\x20positive,\x20HER2\x20negative\x20advanced\x20breast\x20cancer','Eakit','Gastric\x20and\x20duodenal\x20ulcers','Which\x20of\x20the\x20following\x20is\x20a\x20direct\x20thrombin\x20inhibitor\x20used\x20in\x20heparin-induced\x20thrombocytopenia?','kQeve','STWZT','ctHTV','markReviewText','Primary\x20hyperparathyroidism','stringify','<p><strong>American\x20College\x20of\x20Cardiology\x20(ACC)</strong>\x20and\x20American\x20Heart\x20Association\x20(AHA)\x20have\x20released\x20a\x20new\x20set\x20of\x20<strong>performance</strong>\x20and\x20<strong>quality\x20measures</strong>\x20for\x20ST-elevation\x20MI\x20(<strong>STEMI</strong>)\x20and\x20non-ST-elevation\x20MI\x20(<strong>NSTEMI</strong>).</p>\x0a<p>The\x20key\x20suggestions\x20are\x20as\x20follows:</p>\x0a<p><strong>Performance\x20measures:</strong></p>\x0a<ul>\x0a<li>Immediate\x20angiography\x20for\x20resuscitated\x20out-of-hospital\x20cardiac\x20arrest\x20in\x20STEMI\x20patients.</li>\x0a<li>Non-invasive\x20stress\x20testing\x20before\x20discharge\x20in\x20conservatively\x20treated\x20patients.</li>\x0a<li>Early\x20cardiac\x20troponin\x20measurement,\x20within\x206\x20hours\x20of\x20arrival.</li>\x0a<li>Participation\x20in\x20a\x20regional\x20or\x20national\x20acute-MI\x20registry.</li>\x0a</ul>\x0a<p><strong>Quality\x20measures:</strong></p>\x0a<ul>\x0a<li>Risk-score\x20stratification\x20for\x20NSTEMI\x20patients.</li>\x0a<li><strong>Early\x20invasive\x20strategy,\x20within\x2024\x20hours</strong>,\x20in\x20high-risk\x20NSTEMI\x20patients.</li>\x0a<li>Therapeutic\x20hypothermia\x20for\x20comatose\x20STEMI\x20patients\x20with\x20out-of-hospital\x20cardiac\x20arrest.</li>\x0a<li>Aldosterone\x20antagonist\x20at\x20discharge.</li>\x0a<li>Inappropriate\x20in-hospital\x20use\x20of\x20NSAIDs.</li>\x0a<li>Inappropriate\x20prescription\x20of\x20prasugrel\x20at\x20discharge\x20in\x20patients\x20with\x20a\x20history\x20of\x20prior\x20stroke\x20or\x20TIA.</li>\x0a<li>Inappropriate\x20prescription\x20of\x20high-dose\x20aspirin\x20with\x20ticagrelor\x20at\x20discharge.</li>\x0a</ul>','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22','wkSGV','nav-btn-marked-review','ymrUe','<ul>\x0a<li>In\x202017,\x20the\x20WHO\x20released\x20a\x20road\x20safety\x20technical\x20package\x20called\x20<strong>Save\x20LIVES</strong>,\x20which\x20collated\x20evidence-based\x20measures\x20that\x20can\x20significantly\x20reduce\x20road\x20traffic\x20fatalities\x20or\x20injuries.</li>\x0a<li>The\x20<strong>S</strong>ave\x20<strong>LIVES</strong>\x20package\x20focuses\x20on:\x0a<ul>\x0a<li><strong>S\x20&ndash;\x20</strong>Speed\x20Management</li>\x0a<li><strong>L\x20&ndash;</strong>\x20Leadership</li>\x0a<li><strong>I\x20&ndash;</strong>\x20Infrastructure\x20design\x20and\x20improvement</li>\x0a<li><strong>V\x20&ndash;</strong>\x20Vehicle\x20safety\x20standards</li>\x0a<li><strong>E\x20&ndash;</strong>\x20Enforcement\x20of\x20traffic\x20laws</li>\x0a<li><strong>S\x20&ndash;</strong>\x20Survival,\x20post\x20crash</li>\x0a</ul>\x0a</li>\x0a<li>The\x20WHO\x20provides\x20support\x20to\x20Member\x20States\x20with\x20the\x20objective\x20of\x20aiding\x20and\x20improving\x20road\x20safety\x20and\x20standards</li>\x0a<li>The\x20<strong>Safe\x20System\x20approach</strong>\x0a<ul>\x0a<li>This\x20is\x20also\x20advocated\x20by\x20the\x20<strong>WHO</strong>\x20for\x20prevention\x20of\x20<strong>road-traffic\x20accidents</strong>\x20by\x20accommodating\x20human\x20error</li>\x0a<li>Its\x20main\x20components\x20are\x20<strong>safe\x20roads\x20and\x20roadsides,\x20safe\x20speeds,\x20safe\x20vehicles\x20and\x20safe\x20road\x20users</strong></li>\x0a</ul>\x0a</li>\x0a</ul>','ldOCx','Cervical\x20carcinoma','dZPie','Which\x20of\x20the\x20following\x20blood\x20glucose\x20levels\x20is\x20classified\x20by\x20American\x20Diabetic\x20Association\x20as\x20glucose\x20alert\x20value\x20(level\x201)\x20of\x20hypoglycemia?','currentMode','Which\x20of\x20the\x20following\x20is\x20false\x20about\x20the\x20safinamide\x20used\x20in\x20Parkinson’s\x20disease\x20(PD)?','It\x20evokes\x20an\x20impairment\x20in\x20glycemic\x20control','KmSfI','210233TIAlhH','KvBnl','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','questionMedia','Teriflunomide\x20is\x20used\x20in:','Risk-score\x20stratification\x20for\x20NSTEMI\x20patients','YYEom','QWGhu','The\x20WHO\x20recommends\x20the\x20use\x20of\x20delamanid\x20in\x20the\x20treatment\x20of\x20MDR-TB\x20in\x20all\x20of\x20the\x20following\x20situations\x20except:','Trametinib','xRZxD','dataset','stats','EXRcb','FgRvx','Cytomegalovirus','Pregnant\x20women','question_video','lghTg','The\x20chemotherapeutic\x20agent\x20sunitinib\x20is\x20effectively\x20used\x20for\x20which\x20of\x20the\x20following\x20conditions?','Can\x20cause\x20neutropenia','findIndex','MvfjX','userHistory','YcMgf','uttks','cSQdJ','Medical\x20termination\x20of\x20pregnancy','TovMZ','HLfem','button','quizFile','clZek','m15-recent-updates-e4149dd1.html','EWWJt','ZMoiP','TTPPJ','vfrQV','querySelectorAll','EvxtI','American\x20Diabetic\x20Association','application/vnd.apple.mpegurl','120/78\x20mmHg','LEbYG','OPuIy','Sly\x20syndrome','exception','solutionText','isSupported','__proto__','add','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20','\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','oVbvG','wjMpE','oAfry','All\x20of\x20the\x20above','progressBar','className','MzrsW','Non-invasive\x20stress\x20testing\x20before\x20discharge\x20in\x20conservatively\x20treated\x20patients','incorrectAnswers','selectedAnswer','tQahK','The\x20drug\x20etelcalcetide\x20sometimes\x20causes\x20serious\x20hypocalcemia\x20which\x20requires\x20medical\x20attention.\x20This\x20drug\x20has\x20been\x20approved\x20by\x20the\x20FDA\x20for\x20usage\x20in\x20which\x20of\x20the\x20following\x20conditions?','solutionImages','Colorectal\x20carcinoma','Retinoblastoma','wFxOM','hVQaD','KhhsS','Prohibition\x20of\x20discrimination\x20against\x20HIV\x20positive\x20persons','The\x202022\x20target\x20percentage\x20of\x20children\x20who\x20are\x20underweight\x20to\x20be\x20achieved\x20under\x20National\x20Nutrition\x20Strategy\x20is\x20______','APPLo','Paladai\x20feeding\x20is\x20indicated\x20in\x20very\x20preterm\x20infants\x20with\x20no\x20suck-swallow-breath\x20coordination','testModeLegend','Used\x20only\x20in\x20post-menopausal\x20women','ziegl','UryBV','VmWJv','FjRKB','gJDTj','M15\x20-\x20Recent\x20Updates','eCgEu','ldVPV','LDAwh','oTivB','90%\x20by\x20December\x202018','It\x20has\x20affinity\x20for\x20most\x20somatostatin\x20receptors','AKyUz','krEPg','150\x20mg\x20daily\x20for\x2028\x20days','TltME','zHsHO','data-option-index','(((.+)+)+)+$','hDlPT','RtVoU','ARxeg','solutionContainer','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>','hUALQ','fKbLk','szXur','Vaccine\x20is\x20not\x20recommended\x20for\x20pregnant\x20women','woCUs','aFTCH','Etanercept','eDoXA','Non-insulin\x20dependent\x20diabetes\x20mellitus','No\x20solution\x20provided','tYcjQ','incorrectResult'];_0x24e6=function(){return _0x4e0dc0;};return _0x24e6();}function previousQuestion(){const _0x4d8584=_0x2acfb5,_0xa64649={'woCUs':function(_0x472db6){return _0x472db6();},'UJYLL':function(_0x9c87b8){return _0x9c87b8();}};currentQuestionIndex>0x0&&(questionStartTime&&(questionStates[currentQuestionIndex][_0x4d8584(0x3c6)]+=Date[_0x4d8584(0x312)]()-questionStartTime),currentQuestionIndex--,_0xa64649[_0x4d8584(0x2c3)](displayQuestion),_0xa64649['UJYLL'](saveProgress));}function nextQuestion(){const _0x5256bb=_0x2acfb5,_0x51f8f6={'HQFJY':_0x5256bb(0x169),'jGcIS':_0x5256bb(0x283),'XwDUF':function(_0x2fe96f,_0x103be0){return _0x2fe96f-_0x103be0;},'ENfcT':function(_0x410a69,_0x170dbe){return _0x410a69<_0x170dbe;},'tLMaA':function(_0x2f4aca,_0x39ead3){return _0x2f4aca!==_0x39ead3;},'ratrG':_0x5256bb(0x2bb),'hENmi':'tboQA','LEVii':function(_0x5bbb10){return _0x5bbb10();},'EAiUE':function(_0x4fcec8,_0x13411e){return _0x4fcec8===_0x13411e;},'ppRme':_0x5256bb(0x235),'bFIvh':function(_0x29562d,_0x27f61c){return _0x29562d===_0x27f61c;},'cUMGd':_0x5256bb(0x342),'QlvEm':function(_0x32e8da,_0x13bfa5){return _0x32e8da===_0x13bfa5;},'ikYKb':_0x5256bb(0x1ac),'akvzw':_0x5256bb(0x150),'wreFn':function(_0x261759,_0x1d6f32){return _0x261759(_0x1d6f32);},'lGTLo':_0x5256bb(0x2cc),'wkoAB':_0x5256bb(0x144),'eAcCx':_0x5256bb(0x166),'xRfvK':_0x5256bb(0x3ca)};questionStartTime&&(questionStates[currentQuestionIndex][_0x5256bb(0x3c6)]+=_0x51f8f6[_0x5256bb(0x14f)](Date['now'](),questionStartTime));if(_0x51f8f6[_0x5256bb(0x123)](currentQuestionIndex,questionsData['length']-0x1)){if(_0x51f8f6['tLMaA'](_0x51f8f6['ratrG'],_0x51f8f6[_0x5256bb(0x39b)]))currentQuestionIndex++,_0x51f8f6['LEVii'](displayQuestion),_0x51f8f6[_0x5256bb(0x161)](saveProgress);else{const _0x2f75d0=_0x575fa6[_0x5256bb(0x19d)](_0x236fa9[_0x5256bb(0xc6)](_0x51f8f6['HQFJY']))||[];_0x2f75d0[_0x5256bb(0x136)](_0x3638fa=>{const _0x9869b5=_0x5256bb;_0x3638fa[_0x9869b5(0x279)][_0x9869b5(0x212)](_0x1012ae['toLowerCase']()[_0x9869b5(0x115)](/ /g,'-'))&&(_0x3638fa[_0x9869b5(0x346)]<_0x889ef6[_0x9869b5(0x15b)]&&(_0x3a7ed0[_0x3638fa[_0x9869b5(0x346)]]['bookmarked']=!![]));});}}else{if(_0x51f8f6[_0x5256bb(0x2de)](currentMode,_0x51f8f6[_0x5256bb(0x36c)])||_0x51f8f6[_0x5256bb(0x35a)](currentMode,_0x51f8f6[_0x5256bb(0x17d)])){if(_0x51f8f6['QlvEm'](_0x51f8f6[_0x5256bb(0x3b9)],_0x51f8f6[_0x5256bb(0x3d7)])){if(_0x49658a[_0x5256bb(0x28a)]()){const _0x19cc37=new _0x3eb039();_0x19cc37[_0x5256bb(0x31e)](_0xc76109),_0x19cc37[_0x5256bb(0x210)](_0x2e8f8c);}else _0x4504de[_0x5256bb(0x3dd)](_0x51f8f6[_0x5256bb(0x36f)])&&(_0x20ecab[_0x5256bb(0x18d)]=_0x104fd2);}else _0x51f8f6[_0x5256bb(0xda)](confirm,_0x51f8f6[_0x5256bb(0x330)])&&submitQuiz();}else{if(confirm(_0x51f8f6[_0x5256bb(0x313)])){if(_0x51f8f6[_0x5256bb(0x2f4)]!==_0x51f8f6[_0x5256bb(0xed)])currentQuestionIndex=0x0,displayQuestion(),saveProgress();else{const _0x4eea99=_0x1107a8[_0x5256bb(0xdb)][_0x5256bb(0xf1)][_0x5256bb(0x101)](_0x3e6975),_0x1a0777=_0x5da4ef[_0x2d0cf1],_0x3a8e9d=_0x31a43e[_0x1a0777]||_0x4eea99;_0x4eea99[_0x5256bb(0x28b)]=_0x1975d1[_0x5256bb(0x101)](_0x19d92d),_0x4eea99[_0x5256bb(0x38b)]=_0x3a8e9d[_0x5256bb(0x38b)][_0x5256bb(0x101)](_0x3a8e9d),_0x2596c9[_0x1a0777]=_0x4eea99;}}}}}function startTimer(){const _0x32a78b=_0x2acfb5,_0x410bac={'awcey':function(_0x14b2e9,_0x1290e2){return _0x14b2e9(_0x1290e2);},'nEHAP':function(_0x412652){return _0x412652();},'fHFwp':function(_0x234197,_0x37f1a5){return _0x234197<=_0x37f1a5;},'BPVTV':function(_0x584d20,_0x42511c){return _0x584d20(_0x42511c);},'WSCZE':function(_0x39379a,_0x11aa1b){return _0x39379a===_0x11aa1b;},'ErHBg':'timed_exam','alsYO':function(_0x32f34b){return _0x32f34b();},'sqLUZ':function(_0x283e23,_0x4e85e1){return _0x283e23!==_0x4e85e1;},'ZBGxz':_0x32a78b(0x277),'pZPiE':_0x32a78b(0x23f),'UaxNO':function(_0x529a4d){return _0x529a4d();},'OyPHc':function(_0x4d2389,_0x129805){return _0x4d2389(_0x129805);},'UQaUh':function(_0x345a5d,_0xd613fe,_0x12a436){return _0x345a5d(_0xd613fe,_0x12a436);}};if(timer)_0x410bac['OyPHc'](clearInterval,timer);timeRemaining=0x78,updateTimerDisplay(),timer=_0x410bac[_0x32a78b(0xc8)](setInterval,()=>{const _0x13c992=_0x32a78b;timeRemaining--,updateTimerDisplay(),_0x410bac[_0x13c992(0x1eb)](timeRemaining,0x0)&&(_0x410bac[_0x13c992(0x137)](clearInterval,timer),_0x410bac[_0x13c992(0x345)](currentMode,_0x410bac[_0x13c992(0x333)])?_0x410bac[_0x13c992(0x204)](submitQuiz):_0x410bac[_0x13c992(0x37c)](_0x410bac[_0x13c992(0x3bb)],_0x410bac['pZPiE'])?_0x410bac[_0x13c992(0x16b)](nextQuestion):_0x410bac['awcey'](_0x38e63b,'You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?')&&(_0x35f0e9=0x0,_0x410bac[_0x13c992(0x320)](_0x31dafe),_0x3a389b()));},0x3e8);}function updateTimerDisplay(){const _0x38e71f=_0x2acfb5,_0x42aedf={'taZFI':function(_0x1903f7,_0x48d70f){return _0x1903f7+_0x48d70f;}},_0x461bd8=Math[_0x38e71f(0x3a6)](timeRemaining/0x3c),_0x23ad46=timeRemaining%0x3c;document['getElementById'](_0x38e71f(0x139))[_0x38e71f(0x2e5)]=_0x42aedf[_0x38e71f(0x375)](_0x461bd8+':',_0x23ad46[_0x38e71f(0x38b)]()[_0x38e71f(0x1e8)](0x2,'0'));}function toggleSidebar(){const _0x3754c4=_0x2acfb5,_0x42f63e={'HMylQ':_0x3754c4(0x388),'GVQcs':_0x3754c4(0x1cf)};document[_0x3754c4(0x15a)](_0x42f63e['HMylQ'])[_0x3754c4(0x3c4)][_0x3754c4(0x19c)](_0x42f63e[_0x3754c4(0x3ab)]);}function _0x24b8(_0xe64bbc,_0x39cd70){const _0x5e35c7=_0x24e6();return _0x24b8=function(_0x4c00ed,_0x333281){_0x4c00ed=_0x4c00ed-0xba;let _0x5b79c7=_0x5e35c7[_0x4c00ed];return _0x5b79c7;},_0x24b8(_0xe64bbc,_0x39cd70);}document[_0x2acfb5(0xd5)]('DOMContentLoaded',()=>{const _0x378872=_0x2acfb5,_0x35014b={'gZoaw':function(_0x139754,_0x11656f){return _0x139754(_0x11656f);},'mleDZ':function(_0x5ee3b9,_0x14bf93){return _0x5ee3b9+_0x14bf93;},'yroFo':'return\x20(function()\x20','gwCpu':function(_0x5e8744){return _0x5e8744();},'hVQaD':_0x378872(0x18c),'HRMuW':'none','pyjka':function(_0x96e8c9,_0x5abd6c){return _0x96e8c9===_0x5abd6c;},'fKeBq':_0x378872(0x2ab),'QkBXS':_0x378872(0x1e4),'EvxtI':_0x378872(0x159),'ExUXS':_0x378872(0x217)};if(resume){if(_0x35014b[_0x378872(0x3ac)](loadProgress))document['getElementById'](_0x35014b[_0x378872(0x29f)])[_0x378872(0x209)][_0x378872(0x31f)]=_0x35014b[_0x378872(0x16c)],_0x35014b[_0x378872(0x3ac)](initializeQuiz);else{if(_0x35014b[_0x378872(0x1e3)](_0x35014b[_0x378872(0x371)],_0x35014b['QkBXS'])){let _0x586def;try{_0x586def=AyifgW[_0x378872(0x233)](_0x1da932,AyifgW[_0x378872(0x220)](AyifgW[_0x378872(0x220)](AyifgW[_0x378872(0x178)],_0x378872(0x215)),');'))();}catch(_0x309731){_0x586def=_0x1b2df7;}return _0x586def;}else clearProgress(),document[_0x378872(0x15a)](_0x378872(0x18c))[_0x378872(0x209)][_0x378872(0x31f)]=_0x35014b['EvxtI'];}}else!window['location'][_0x378872(0x30e)][_0x378872(0x3b0)](_0x35014b[_0x378872(0x1c7)])?(_0x35014b[_0x378872(0x3ac)](clearProgress),document[_0x378872(0x15a)](_0x35014b[_0x378872(0x29f)])[_0x378872(0x209)][_0x378872(0x31f)]=_0x35014b[_0x378872(0x281)]):initializeQuiz();}),document[_0x2acfb5(0xd5)](_0x2acfb5(0x374),function(_0x2c4663){const _0x4c6014=_0x2acfb5,_0x48d44c={'gfoZC':function(_0x335dc8){return _0x335dc8();},'qhVLP':function(_0x29a97e,_0x1c1046){return _0x29a97e<_0x1c1046;},'azGyr':function(_0x1e39b8,_0x2fd91f){return _0x1e39b8!==_0x2fd91f;},'fAXVh':function(_0x5c6bc3,_0x13de7a){return _0x5c6bc3===_0x13de7a;},'clZek':'performanceModal','AVpfJ':function(_0x53e576,_0x18ba3c){return _0x53e576>=_0x18ba3c;},'mBuSh':_0x4c6014(0x167),'hjgCt':function(_0x1736fa,_0x418099){return _0x1736fa-_0x418099;},'dqBwW':function(_0x4697ee,_0x340a6b){return _0x4697ee(_0x340a6b);},'TltME':'hxxef','wbfhN':function(_0x280d7c){return _0x280d7c();},'oZZFs':function(_0x74c59a,_0x46eea6){return _0x74c59a===_0x46eea6;},'YsePa':_0x4c6014(0x3e1),'pEIwA':function(_0x522629){return _0x522629();},'jjnKl':'timed_study','iUjhQ':function(_0x15e8eb){return _0x15e8eb();},'hyMfd':function(_0x33ba84,_0x1cb39d){return _0x33ba84===_0x1cb39d;},'giHPD':_0x4c6014(0x235),'qWcqA':_0x4c6014(0x342),'SzoOf':function(_0x41f587,_0x339cda){return _0x41f587===_0x339cda;},'ULQtJ':'kyBYS','rdCCU':function(_0x43e208){return _0x43e208();},'msqTt':function(_0x2d6279){return _0x2d6279();}};if(_0x48d44c['azGyr'](document['getElementById'](_0x4c6014(0x18c))['style'][_0x4c6014(0x31f)],'none'))return;if(_0x48d44c[_0x4c6014(0x1f6)](document[_0x4c6014(0x15a)](_0x48d44c[_0x4c6014(0x27a)])[_0x4c6014(0x3c4)][_0x4c6014(0x3d5)](_0x4c6014(0x39a)),![]))return;if(_0x48d44c[_0x4c6014(0x229)](_0x2c4663[_0x4c6014(0x31a)],'1')&&_0x2c4663[_0x4c6014(0x31a)]<='4'){if(_0x48d44c[_0x4c6014(0x1f6)](_0x4c6014(0x167),_0x48d44c[_0x4c6014(0x3a2)])){const _0x3958db=_0x48d44c[_0x4c6014(0x173)](_0x48d44c[_0x4c6014(0x372)](parseInt,_0x2c4663[_0x4c6014(0x31a)]),0x1),_0x43b615=document[_0x4c6014(0x280)](_0x4c6014(0x3d0));if(_0x3958db<_0x43b615[_0x4c6014(0x15b)])_0x48d44c[_0x4c6014(0x372)](selectOption,_0x3958db);}else{const _0x154200=_0x54f47e['apply'](_0x14c94a,arguments);return _0x43598a=null,_0x154200;}}else{if(_0x48d44c[_0x4c6014(0x1f6)](_0x2c4663[_0x4c6014(0x31a)],_0x4c6014(0x176))){if(_0x48d44c[_0x4c6014(0x1a1)](_0x48d44c[_0x4c6014(0x2b6)],_0x48d44c[_0x4c6014(0x2b6)])){if(_0x279ecf)_0x2e29a0+=_0x4c6014(0x3ce)+_0x17a294+_0x4c6014(0x3c5);}else _0x48d44c[_0x4c6014(0x18f)](previousQuestion);}else{if(_0x48d44c[_0x4c6014(0x17e)](_0x2c4663[_0x4c6014(0x31a)],_0x48d44c[_0x4c6014(0x351)])||_0x2c4663[_0x4c6014(0x31a)]==='\x20')_0x2c4663['preventDefault'](),_0x48d44c['pEIwA'](nextQuestion);else{if(_0x48d44c[_0x4c6014(0x1f6)](_0x2c4663['key']['toLowerCase'](),'b')&&(_0x48d44c[_0x4c6014(0x1f6)](currentMode,_0x4c6014(0x1af))||currentMode===_0x48d44c[_0x4c6014(0x20c)]))_0x48d44c[_0x4c6014(0x1f6)](_0x4c6014(0x273),'miKnw')?(_0x4219d1++,_0x48d44c[_0x4c6014(0xca)](_0x1fdaf0),_0x48d44c['gfoZC'](_0x48e2ad)):_0x48d44c['iUjhQ'](toggleBookmark);else{if(_0x48d44c[_0x4c6014(0xce)](_0x2c4663['key']['toLowerCase'](),'m')&&(_0x48d44c[_0x4c6014(0x1f6)](currentMode,_0x48d44c[_0x4c6014(0x228)])||_0x48d44c[_0x4c6014(0x1f6)](currentMode,_0x48d44c['qWcqA'])))_0x48d44c[_0x4c6014(0xe1)](_0x48d44c['ULQtJ'],_0x48d44c[_0x4c6014(0xe9)])?_0x48d44c['rdCCU'](toggleMarkForReview):_0x48d44c['qhVLP'](_0x3a4952[_0x4c6014(0x346)],_0x58f51b[_0x4c6014(0x15b)])&&(_0x1d61c1[_0x2db0c9[_0x4c6014(0x346)]]['bookmarked']=!![]);else _0x48d44c[_0x4c6014(0x1f6)](_0x2c4663[_0x4c6014(0x31a)]['toLowerCase'](),'s')&&(_0x48d44c[_0x4c6014(0x17e)](currentMode,_0x48d44c[_0x4c6014(0x228)])||_0x48d44c['oZZFs'](currentMode,_0x48d44c[_0x4c6014(0x14e)]))&&_0x48d44c['msqTt'](submitQuiz);}}}}});</script>

</body></html>